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SUMMARY  
 
Wnt-11 is a noncanonical Wnt ligand which is found upregulated in prostate cancer 
cell lines as well as in prostate tumors. It promotes cancer cell migration and invasion 
which suggest it has a role in prostate cancer progression and metastasis. Wnt ligands 
require binding to Frizzled (FZD) family of receptors in order to signal and therefore, this 
interaction provides an opportunity to inhibit Wnt signaling. However, the receptors that 
mediate Wnt-11 signaling in prostate cancer remain unknown. In this thesis, I provide 
evidence that FZD8 is a major Wnt-11 receptor in prostate cancer that integrates Wnt-
11 and TGF-β signals to promote cell invasion and epithelial to mesenchymal transition 
(EMT) and consequently, mediates prostate cancer progression. FZD8 mRNA was 
upregulated in multiple prostate cancer datasets as well as in metastatic prostate cancer 
cell lines. Moreover, analysis of patient samples revealed increased levels of FZD8 in 
prostate cancer compared to benign tissues, correlating with increased expression of 
Wnt-11. In metastatic prostate cancer cells, FZD8 co-localized and co-
immunoprecipitated with Wnt-11 and mediated Wnt-11 activation of ATF2 and AP-1 
noncanonical signaling. Functionally, FZD8 silencing reduced prostate cancer cell 
migration and invasion as well as three-dimensional (3D) organotypic cell invasion and 
expression of EMT-related genes. In addition, FZD8 was required for tumor growth in 
the chorioallantoic membrane (CAM) in vivo model. Finally, inhibition of TGF-β/Smad-
dependent signaling was observed when FZD8 was silenced in prostate cancer cells and 
FZD8 was found to be required for TGF-β-dependent cell invasion and expression of 
EMT genes. Surprisingly, FZD8 formed a TGF-β-regulated complex with TGF-β 
receptors that is mediated by the extracellular domains of both FZD8 and TGFβRI. 
Together, these observations are consistent to a model in which FZD8 integrates Wnt 
and TGF-β signaling pathways to promote cell migration, invasion and EMT, leading to 
prostate cancer metastasis. Consequently, FZD8 may constitute a useful therapeutic 
target in metastatic prostate cancer as its inhibition may block aberrant activation of both 
Wnt and TGF- signaling pathways.  
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RESUMEN 
Wnt-11 es un miembro no canónico de la familia de Wnt que se observa altamente 
expresado en líneas celulares de cáncer de próstata, así como en tumores de próstata. 
Wnt-11 promueve la migración y la invasión celular lo que sugiere que tiene un papel en 
la progresión y la metástasis del cáncer de próstata. Las proteínas Wnt necesitan unirse 
a la familia de receptores Frizzled (FZD) para activar la señalización de forma que esta 
interacción representa una oportunidad para inhibir la señalización de Wnt. Sin embargo, 
se desconocen los receptores que median la señalización de Wnt-11 en cáncer de 
próstata. En esta tesis, proporciono evidencia de que FZD8 es el principal receptor de 
Wnt-11 en cáncer de próstata y de que éste integra las señales de Wnt-11 y TGF- con 
el fin de promover la invasión celular y la transición epitelio-mesénquima (EMT) y así 
mediar la progresión del cáncer de próstata. La expresión de FZD8 a nivel de RNA 
mensajero se vio incrementada en múltiples bases de datos de cáncer de próstata, así 
como en líneas celulares de cáncer de próstata metastático. Asimismo, el análisis de 
muestras de pacientes mostró niveles aumentados de FZD8 en tejidos de próstata 
cancerosos comparados con tejido sanos de próstata, que también se relacionaron con 
niveles elevados de Wnt-11. En líneas celulares de cáncer de próstata metastático, 
FZD8 co-localizó y co-inmunoprecipitó con Wnt-11 además de mediar la activación que 
Wnt-11 produce en la señalización no-canónica de ATF2 y AP-1. Funcionalmente, el 
silenciamiento de FZD8 redujo la migración y la invasión de las células cancerosas, así 
como la invasión en cultivo organotípico tridimensional (3D) y la expresión de genes 
implicados en EMT. Además, FZD8 resultó necesario para el crecimiento tumoral en el 
modelo in vivo de la membrana corioalantoidea (CAM). Finalmente, se observó una 
inhibición de la ruta de TGF-/Smad cuando FZD8 se silenciaba en células de cáncer 
de próstata y FZD8 resultó ser necesario para la invasión celular dependiente de TGF-
así como para la expresión de genes de EMT. Inesperadamente, FZD8 resultó formar 
un complejo regulado por TGF- con los receptores de TGF-β, el cual está mediado por 
los dominios extracelulares de FZD8 y TGFβRI. Todos estos resultados son 
consistentes con un modelo en el que FZD8 integra las rutas de señalización de Wnt y 
TGF-β para promover la migración, invasión celular y el proceso de EMT, dando lugar a 
la metástasis del cáncer de próstata. Consecuentemente, FZD8 puede representar una 
óptima diana terapéutica en el cáncer de próstata metastático ya que su inhibición puede 
bloquear la activación aberrante de ambas rutas, Wnt y TGF-. 
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1. The human prostate 
1.1 Structure and function of the human prostate gland 
   The human prostate is an exocrine gland with the size of a walnut and a weight about 
10-20g that is part of the male reproductive system. The word “prostate” is taken from the 
Ancient Greek προστάτης, prostates, literally "one who stands before" which describes 
the position of the prostate gland being located below the bladder and the seminal vesicle 
and above the muscles of the pelvic floor. The rectum is behind the prostate which 
enables a clinician to feel the prostate in a rectal examination (Bhavsar & Verma 2014; 
PubMed Health 2016) (Fig. 1). 
 
Figure 1. Human prostate anatomy. The illustration shows the location of the adult prostate and 
associated tissues within the male reproductive system. Taken from Stanford Children´s Health. 
 
   The main function of the prostate is the secretion of a slightly alkaline fluid, milky or 
white in appearance, which is mixed in the urethra together with sperm cells from the 
testicles, fluid from the seminal vesicle and the secretions released by the bulbourethral 
gland to constitute the male semen (Kumar & Majumder 1995; Bhavsar & Verma 2014). 
In humans, prostate secretions usually constitute approximately 30% of the semen 
volume and they are mainly composed of simple sugars with a protein content less than 
1%, including proteolytic enzymes, prostatic acid phosphatase (PAP), beta-
microseminoprotein, spermin, cholesterol and prostate-specific antigen (PSA) among 
others (Kumar & Majumder 1995). Zinc is also present in prostate secretions with a 
concentration 500–1,000 times the concentration in blood, working as an antibacterial 
agent (Kumar & Majumder 1995). The prostatic secretion is important for the proper 
functioning and motility of the sperm cells, and therefore also for fertility in men (PubMed 
Health 2016).  
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 Apart from its secretory functions, the muscles of the prostate participate in the 
control of urine output from the bladder and ensure that the semen is forcefully pressed 
into the urethra and then expelled out during ejaculation (Kumar & Majumder 1995; 
Bhavsar & Verma 2014; PubMed Health 2016). 
The microanatomy of the prostate reveals glandular and stromal components which 
are contained within a pseudocapsule (Bhavsar & Verma 2014). Histologically, the 
prostate comprises ducts and acini (Fig. 2A) containing secretory, basal and endocrine-
paracrine cells (Fig. 2B). Secretory cells are the predominant cell type within the prostate 
gland which are mainly tall columnar cells, although there are areas of low cuboidal or 
squamous epithelium. At the molecular level, luminal cells are characterized by their 
expression of androgen receptor, as well as cytokeratins 8 and 18 and the cell surface 
marker CD57 (Abate-Shen & Shen 2000). These secretory cells, which also express 
prostatic specific antigen (PSA) and prostate-specific acid phosphatase (PSAP), are 
separated from the basal lamina and prostatic stroma by a layer of basal cells. These 
cells are generally flattened and they represent the stem cell population which gives rise 
to mature secretory cells (Kirby et al. 2004; American Urological Association 2017). 
Basal cells express cytokeratins 5 and 14 and CD44 as well as low levels of androgen 
receptor (although this is controversial), but do not produce prostatic secretory proteins 
(Abate-Shen & Shen 2000). In all zones of the prostate, the epithelium contains a small 
population of endocrine-paracrine cells which are androgen independent cells and 
contain neuron-specific enolase (NSE). However, their precise function remains 
unknown, although they are supposed to have a paracrine function supporting the growth 
of luminal cells and regulating the secretory process (Abate-Shen & Shen 2000; Kirby et 
al. 2004).  
   Structurally, although the prostate has an unlobulated appearance due to the presence 
of the pseudocapsule, this fibroelastic layer gives rise to septa which subdivide the 
prostate into different areas (Kumar & Majumder 1995). In 1912, Lowsley analyzed the 
anatomy of the fetal prostate and identified five lobes: the anterior, posterior, lateral (two), 
and medial, with the medial and the two lateral lobes the most prominent (Lowsley 1912; 
Kumar & Majumder 1995; Kirby et al. 2004). These terms, which were based on fetal 
studies and did not explain completely the morphology of the adult prostate, were 
traditionally used to describe prostate anatomy (Selman 2011). Nevertheless, later 
studies developed by McNeal using prostates obtained at autopsy divided the prostate 
gland into four different zones (McNeal 1981; Selman 2011; Reeves et al. 2016). A 
central zone (CZ), which surrounds the ejaculatory ducts and accounts approximately 
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for 2.5% of prostate cancers that tend to be more aggressive; a peripheral zone (PZ), 
surrounding the distal urethra, where 70-80% of prostate tumors originate; a transitional 
zone (TZ), which surrounds the proximal urethra, where the benign prostate hyperplasia 
(BPH) and 10-20% of cancers are initiated and a periurethral gland region. Apart from 
these glandular regions, the prostate also contains a fibromuscular zone which is also 
defined as a nonglandular region and accounts for one-third of the bulk of the prostate 
(Selman 2011; Reeves et al. 2016; Aaron et al. 2016)  (Fig. 2C). 
 
Figure 2. Histology and structure of the human prostate gland. (A) Microanatomy of prostate 
tissue by Hematosilin & Eosin staining. Taken from American Urological Association. (B) 
Illustration showing the different cellular types in a histological section of a human prostate duct. 
Adapted from Abate-Shen & Shen 2000. (C) The prostatic zones described by McNeal (1983). 
Taken from Reeves et al. 2016. 
The proper structure and function of the prostate is dependent on the presence of 
testicular hormones, mainly androgens (dihydrotestosterone (DHT) and testosterone) 
(Kumar & Majumder 1995; Aaron et al. 2016). In fact, different studies have shown that 
withdrawal of this hormonal support results in drastic metabolic changes including loss 
of secretory function and an accelerated rate of tissue involution in the prostate. 
Moreover, alterations at the subcellular levels in the nucleus, endoplasmic reticulum 
(ER), Golgi and ribosomes which result in decrease in deoxyribonucleic acid (DNA), 
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ribonucleic acid (RNA) and protein synthesis have also been described when removing 
androgens (Kumar & Majumder 1995). 
1.2 Prostate development 
    In humans, development of the prostate is absolutely dependent on androgenic 
stimulation by the biologically active androgen, 5α-DHT, which is produced by the local 
reduction of testosterone (produced in the testes) by the enzyme 5α-reductase. 
However, other hormones such as estrogen also are involved in prostate development 
(Hayward & Cunha 2000; Aaron et al. 2016). 
  In humans, the cloaca functions as the combined excretory tract until 5 weeks post 
conception, which is then divided by the urorectal septum into urinary and digestive tract 
by 6 weeks. The ventral urinary compartment is called the urogenital sinus (UGS), which 
differentiates and becomes sexually dimorphic in response to androgens. Androgens 
begin to be excreted by Leydig cells in male gonads at around 8 weeks of gestation. By 
10 weeks, the initial event in morphogenesis of the prostate is the outgrowth of solid 
epithelial buds from the urogenital sinus epithelium (UGE) into the surrounding urogenital 
sinus mesenchyme (UGM) (Meeks & Schaeffer 2011; Aaron et al. 2016). Androgens 
binds androgen receptor (AR) in the urogenital sinus mesenchyme (UGM) stimulating 
stromal cells to secrete other factors that then act on the epithelial cells and thereby, 
induce the epithelial budding, proliferation, and differentiation to form ductal structures. 
By 13 weeks, 70 primary ducts are present and have been differentiated into luminal and 
basal subtypes and exhibit secretory markers (Kirby et al. 2004; Aaron et al. 2016) (Fig. 
3). Together with epithelial differentiation the UGM proliferates and differentiates into 
prostatic smooth muscle (which expresses AR) and interfascicular fibroblasts. 
Importantly, while androgens drive the development and growth of the prostate, they also 
play a key role in maintaining a growth quiescent adult organ (Aaron et al. 2016). 
 
Figure 3. Schematic representation of phases of prostate development. A. The prostate 
develops from the urogenital sinus (UGS) which consists of both epithelium (green) and 
mesenchyme (blue). B. Androgens engage androgen receptor in the mesenchyme and induce 
epithelial budding. C. Epithelial buds elongate into solid cords of tissue that eventually canalize 
into ducts. Adapted from Meeks & Schaeffer 2011. 
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The human prostate is small in childhood, weighing around 2 g, but it undergoes a 
phase of exponential growth at puberty, increasing in size to about 20 g. This growth is 
due to the rise in serum testosterone to adult levels. Then, prostatic weight remains fairly 
constant until the end of the third decade of life when the mean prostatic weight begins 
to rise slowly. The human prostate is an extremely slow-growing organ, which is 
balanced by correspondingly low rates of apoptosis in the normal adult human prostate 
resulting in a growth-quiescent gland (Hayward & Cunha 2000). 
2. Cancer 
Cancer has been defined as the uncontrolled proliferation of cells that leads to the 
deregulation of cell homeostasis and the formation of an abnormal mass of cells named 
tumor. Although more than 100 distinct types of tumors can be found within specific 
organs, cancer is considered a complex disease involving lot of dynamic changes in the 
genome (Hanahan & Weinberg 2000). In this regard, oncogenes, tumor supressors and 
genomic stability genes have been defined as crucial genes in the tumorigenesis process 
(Lee & Muller 2010). 
During the last decades, strong efforts have been made to characterize common 
features in the cancer process. Hanahan and Weinberg defined six essential alterations 
in cell physiology that collectively dictate malignant growth. These alterations include: 
self-sufficiency in growth signals, insensitivity to growth-inhibitory (antigrowth) signals, 
evasion of programmed cell death (apoptosis), limitless replicative potential, sustained 
angiogenesis, and tissue invasion and metastasis (Hanahan & Weinberg 2000). Some 
years later, reprogramming of energy metabolism and evading immune destruction were 
also incorporated to the previously described panel of hallmarks, together with two 
enabling characteristic: genomic instability and mutation as well as tumor promoting 
inflammation (Hanahan & Weinberg 2011). Moreover, the tumor microenviroment 
constitutes another dimension of complexity which, together with these hallmarks, is 
crucial for cancer development and progression (Hanahan & Weinberg 2011; Wang et 
al. 2017) (Fig. 4). 
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Figure 4. Hallmarks of cancer. Diagram showing the acquired capabilities necessary for tumor 
growth and progression. Green: six initial hallmarks described in 2000 by Hanahan and Weinberg; 
orange, the emerging hallmarks included in 2011 and blue, the derived enabling characteristic 
incorporated also in 2011. Adapted from Hanahan & Weinberg 2011. 
2.1 Epithelial-mesenchymal transition (EMT) in cancer 
Epithelial to mesenchymal transition (EMT) is classically defined as a reversible 
process in which epithelial cells acquire mesenchymal properties by altering their 
morphology, cellular architecture, adhesion, and migration capacity (Lee et al. 2006).  
The EMT process was firstly described in 1982 when it was observed that epithelial cells 
expressed characteristics of migrating mesenchymal cells when cultured in collagen 
(Greenburg & Hay 1982). Later on, EMT was shown to be involved in embryonic 
development, wound healing, fibrosis, but importantly, it has also been implicated in 
cancer progression and metastasis (Thiery 2002). In this regard, EMT has been shown 
to trigger the dissociation of carcinoma cells from primary carcinomas, which 
subsequently migrate and disseminate to distant sites. The reverse of the EMT 
process—mesenchymal-epithelial transition (MET)—is associated with a loss of this 
migratory capacity, with cells adopting an apico-basal polarization and expressing the 
junctional complexes that are hallmarks of epithelial tissues. Significantly, it is the MET 
that is then believed to trigger the cessation of migration, inducing the same cells to 
proliferate and seed the new tumor giving rise to a metastasis (Nieto et al. 2016; Jolly et 
al. 2017)  
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The EMT/MET molecular components have been classified into three groups: 
inducers, regulators and effectors (Banyard & Bielenberg 2015) (Fig. 5). 
a) Inducers: This group includes different growth factors and receptors which 
initiate the process such as epidermal growth factor (EGF), fibroblast growth 
factor (FGF), hepatocyte growth factor (HGF), vascular endothelial growth 
factor (VEGF), insulin-like growth factor (IGF), transforming growth factor beta 
(TGF-β), Wnt and Notch.  
b) Regulators: Transcription factors (TFs) called EMT-TFs (Nieto et al. 2016) such 
as Snail, Slug, Twist or Zeb1 and 2 are included in this group. Their expression 
profiles depend on cell and tissue type and on the degree of progression 
towards mesenchymal differentiation (Lamouille et al. 2014). In addition to 
EMT-TFs, multiple miRNAs are thought to regulate EMT, including miR-34 and 
miR-200 and epigenetic and post-translational regulators (Nieto et al. 2016). 
c) Effectors: The third category is formed by the EMT-associated proteins, which 
stimulate subsequent changes in cellular shape and invasive capacities. 
Cadherin switches, such as epithelial-cadherin (E-cadherin) to neural-cadherin 
(N-cadherin) are classic representative markers of the EMT process, but also 
other cell junction-related changes, including expression of catenins, claudins 
and desmocollins or cytoeskeletal proteins, such as vimentin and keratins 
(Banyard & Bielenberg 2015).  
 
Figure 5. Classical model of reversible EMT-MET. Main inducers, regulators and effectors are 
shown. 
Although traditionally EMT has been characterized as a transformation process 
between two alternative states, mesenchymal or epithelial, recent studies have made the 
concept evolve to a more dynamic and flexible process. In this regard, EMT is now 
considered a process characterized by the presence of plasticity and transitional states 
in which cells are no longer thought to oscillate between the full epithelial and full 
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mesenchymal states, but rather, they move through a spectrum of intermediary phases, 
being able to undergo a partial EMT (Fig. 6) (Nieto et al. 2016).  
 
Figure 6. Plasticity through the transitional stages in EMT-MET. Intermediate EMT states 
have been defined having different stability. Adapted from Nieto et al. 2016. 
Recent studies that categorized cells into E (epithelial), M (mesenchymal), and 
hybrid E/M, instead of just E and M, have proposed that tumor-initiating potential might 
be maximum when cells are in a hybrid E/M state (Jolly et al. 2017). However, 
considering the heterogeneity and unstable genetic background of tumor cells, it is 
common that cellular plasticity is often accompanied by a change in a varying cohort of 
EMT markers, which can differ among tumor cell types and EMT pathways (Banyard & 
Bielenberg 2015). Consequently, the presence of a partial or a full EMT may vary with 
the cancer type, making it necessary to investigate the contribution of these phenotypic 
transitions to invasion, dissemination and metastasis (Banyard & Bielenberg 2015; Jolly 
et al. 2017). 
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3. Prostate cancer 
3.1 Epidemiology and etiology 
In 2017, prostate cancer (PCa) represents the most frequently diagnosed cancer in 
men and the third most common cause of cancer death in men in developed regions 
(Fig. 7A). An estimated 1.1 million men worldwide were diagnosed with prostate cancer 
in 2012 and 307,000 men were estimated to die in the same year (Siegel et al. 2017; 
Mottet et al. 2016).  
Prostate cancer is a disease of increasing significance worldwide with almost 70% of 
the cases appearing in more developed areas. Among these regions, incidence rates 
are higher in Australia/New Zealand and North America and in western and northern 
Europe. They are also relatively high in certain less developed regions such as the 
Caribbean, South Africa and South America, and remain low in Asian populations 
(Globocan 2012) (Fig. 7B). This wide variation in international PCa incidence rates is in 
part due to the substantial differences worldwide in the diagnosis of latent cancers 
through PSA testing of asymptomatic individuals, as well as during prostate surgery 
(Center et al. 2012).  
Although incidence rates seem to be different worldwide, factors determining the risk 
of developing PCa remain unclear. Aside from age and ethnicity, the only established 
risk factor for prostate cancer is a family history of the disease being about twice the risk 
for first-degree relatives of men with prostate cancer than for men in the general 
population (Attard et al. 2016). Genetic factors are also considered important 
determinants of the variation in risk of PCa, since higher incidence in African Americans 
as well as a 50% higher risk in monozygotic twins than in dizygotic twins has been 
reported. In fact, several genetic studies have identified co-segregation of the HOXB13 
genetic region, 77 single nucleotide polymorphisms (SNPs) (including one in the vicinity 
of the oncogene C-MYC) as well as rare mutations in genes such as BRCA2, BRCA1, 
MMR, NBS1 and CHEK2 to be associated to prostate cancer risk (Attard et al. 2016) 
(Fig. 7C). Currently, exogenous factors such as diet or alcohol consumption have been 
studied as factors involved in the progression of the disease (Mottet et al. 2016).  
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Figure 7. Prostate cancer epidemiology. (A) Estimated new cases and estimated dead in men 
per year in the United States in 2017. Adapted from Siegel, 2017. (B) Prostate cancer incidence 
worldwide. Taken from Globoscan. (C) Susceptibility variants for excess familiar risk of prostate 
cancer. Adapted from Attard, 2016. 
3.2 Histological variants of prostate cancer 
   Prostate cancer displays significant phenotypic heterogeneity but it has been 
histologically divided into different types (Shen & Abate-Shen 2010; Humphrey et al. 
2016) (Fig. 8): 
a) Benign prostatic hyperplasia (BPH) is a non-cancerous type of growth of the 
prostate that consists of histopathological abnormalities of the prostatic epithelium 
primarily found in the transitional zone, which typically include expansion of the basal 
layer and stromal hyperproliferation (Abate-Shen & Shen 2000) (Fig. 8). In BPH, the 
prostate grows larger and squeezes the urethra, preventing the normal flow of urine and 
causing lower urinary tract symptoms (LUTs). BPH is a very common problem, being 
present in more than 50% of men aged over 60 years. For some men the symptoms may 
MalesEstimated New Cases Estimated Death
Prostate 161,360 19%
Lung and bronchus 116,990 14%
Colon and rectum 71,420 9%
Urinary bladder 60,490 7%
Melanoma of the skin 52,170 6%
Kidney and renal pelvis 40,610 5%
Non-Hogdkin lymphoma 40,080 5%
Leukemia 36,290 4%
Oral cavity and pharynx 35,720 4%
Liver and intrahepatice bile duct 29,200 3%
All sites 836,150 100%
Lung and bronchus 84,590 27%
Colon and rectum 27,150 9%
Prostate 26,730 8%
Pancreas 22,300 7%
Liver and intrahepatice bile duct 19,610 6%
Leukemia 14,300 4%
Esophagus 12,720 4%
Urinary bladder 12,240 4%
Non-Hogdkin lymphoma 11,450 4%
Brain and other nervous system 9,620 3%
All sites 318,420 100%
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be severe enough to need treatment or surgery (Humphrey et al. 2016; Thorpe & Neal 
2003). 
b) Prostate intraepithelial neoplasia (PIN) is considered the primary precursor of 
human prostate cancer. It is a specific type of lesion localized in the peripheral zone 
(Abate-Shen & Shen 2000), which generally is characterized by the appearance of 
luminal epithelial hyperplasia, reduction in basal cells, enlargement of nuclei and 
nucleoli, cytoplasmic hyperchromasia, and nuclear atypia (Shen & Abate-Shen 2010) 
(Fig. 8). PIN can usually progress to high-grade PIN (HGPIN), a preneoplastic lesion 
which displays an important elevation of cellular proliferation markers and commonly 
progresses to prostate carcinoma (Abate-Shen & Shen 2000; Shen & Abate-Shen 2010). 
c) Acinar adenocarcinoma represents 90% of prostate tumors (Fig. 6). They 
originate in the secretory epithelial cells and typically are slow growing tumors. Different 
variants of acinar adenocarcinoma were defined in 2016 by the World Health 
Organization (WHO), including atrophic, pseudohyperplastic, microcystic, foamy gland, 
mucinous (colloid), signet ring-like cell, pleomorphic giant cell and sarcomatoid 
(Humphrey et al. 2016).  This last type of cancer is comprised of a mixture of both 
epithelial and mesenchymal components. It is extremely rare and accounts for less than 
0.1% of primary prostate cancer but generally occurs in younger men and is associated 
with poorer prognosis (Humphrey 2012; Humphrey et al. 2016). 
d) Non-acinar prostate carcinoma accounts for 5-10% of prostate tumors and 
include different subtypes: 
- Ductal adenocarcinoma: this is the most common histological variant of non-
acinar prostatic carcinoma with an incidence of 3.2% of all prostatic carcinomas. It 
originates in the primary and secondary prostatic ducts and is considered to be more 
aggressive than acinar adenocarcinoma (Humphrey 2012; Humphrey et al. 2016). 
- Transitional Cell carcinoma of the prostate is a carcinoma of urothelial origin that 
affects the urothelium normally lining the intraprostatic ducts (Angulo et al. 2010; 
Humphrey 2012; Humphrey et al. 2016). 
- Squamous cell carcinoma: this type of prostate tumor has an incidence lower 
than 1% (Humphrey 2012). It is typically described as an aggressive cancer, with a 
median post-diagnosis survival of 14 months. Squamous cell carcinoma developes as a 
result of adverse stimuli affecting columnar cells, causing them to lose their ability to 
produce PSA and prostatic acid phosphatase (PAP) (Malik et al. 2011). 
- Basal cell carcinoma usually arises in the transitional zone. Malignant tumors 
composed of basal cells have been designated as ‘‘adenoid cystic carcinoma’’ or 
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‘‘adenoid basal cell tumor’’ when they share histologic features of salivary gland tumors, 
and more generically as ‘‘basaloid carcinoma’’ or ‘‘basal cell carcinoma’’ when they lack 
such similarity (Ali & Epstein 2007).  
- Neuroendocrine tumors: this group includes adenocarcinoma with 
neuroendocrine differentiation, well-differentiated neuroendocrine tumors, large cell 
neuroendocrine carcinoma and small-cell neuroendocrine carcinoma, the last one being 
the most common neuroendocrine tumor in the prostate (Humphrey et al. 2016). They 
are extremely aggressive and often associated with disseminated disease being 
incidence estimates range from 0.3% to 1% of all prostatic carcinomas. They are 
significantly more common in men with castration resistant prostate cancer (CRPC) after 
androgen deprivation therapy (ADT) (Nadal et al. 2014). ERG (erythroblast 
transformation-specific) gene rearrangements are common in small-cell carcinoma of the 
prostate which can be helpful for diagnosis of this kind of prostate carcinomas 
(Humphrey 2012). 
 
Figure 8. Histology of prostate tissue. (A) Section showing the heterogeneity of prostate tissue 
where BPH, PIN and PCa can be found. (B) Higher resolution section from A where BPH and PIN 
are shown. Arrows show basal cells present in BPH and absent in the region of PIN. Adapted 
from Abate-Shen & Shen 2000. 
3.3 Prostate cancer initiation and progression 
Prostate cancer initiates with prostatic intraepithelial neoplasia (PIN) that usually 
progress to high-grade PIN (HGPIN) and later to prostate carcinoma (Abate-Shen & 
Shen 2000; Shen & Abate-Shen 2010). Importantly, PIN lesions are distinguished from 
benign prostatic hyperplasia (BPH), which is not considered the precursor state for 
prostate cancer. After PIN, the progressive accumulation of further genetic alterations 
leads to more aggressive and malignant lesions, characterized by disruption of the 
basement membrane and invasion of the surrounding stroma, leading to an invasive 
carcinoma which can stay confined in the prostate or metastasize to different organs 
(Abate-Shen & Shen 2000; Shen & Abate-Shen 2010) (Fig. 9). 
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At the molecular level, different parameters define prostate cancer initiation and 
progression, including characteristic patterns of chromosome abnormalities in prostate 
carcinoma that are indicative of stages of prostate cancer progression. Particularly, 
consistent allelic loss reflects the reduction or loss-of-function of putative tumor 
suppressor genes in prostate cancer, such as losses of heterozygosity at chromosomes 
8p, 10q, 13q, and 17p, 6q, 7q, 16q, and 18q but also gains at chromosomes 8q and 7. 
Several reasonable candidate genes, including Rb, P53, PTEN, and NKX3.1, have been 
associated to these chromosome abnormalities during prostate cancer initiation and 
progression (Abate-Shen & Shen 2000) (Fig. 9). 
 
 
Figure 9. Prostate cancer initiation and progression. Different stages of prostate cancer are 
shown together with the most frequent molecular events associated with each stage. Adapted 
from Abate-Shen & Shen 2000. 
 
3.4 Diagnosis 
In the late 1960s and early 1970s, the absence of an efficient method to diagnose 
prostate cancer prompted many researchers to search for tumor-specific antigens that 
might be useful as biomarkers or targets for cancer therapy.  
The discovery of prostate specific antigen (PSA), a kallikrein-related serine protease, 
was surrounded by high controversy, owing to its discovery in prostate tissue and semen 
by different scientists who gave it different names (Rao et al. 2008; Catalona 2014). 
Rubin Flocks in 1960 firstly identified “species-specific prostate antigens” and in 1966, 
Mitsuwo Hara reported a protein which he called “gamma-seminoprotein”. Tien Shun Li, 
Carl Beling and Richard Ablin were all involved in the discovery of PSA identifying 
different prostate antigens which later were shown to have similar sequences to PSA. In 
1979, T. Ming Chu and his research group, most notably Ming C. Wang, purified and 
characterized PSA and suggested its potential clinical applications as a biomarker for 
prostate cancer (Rao et al. 2008; Catalona 2014). A later study analyzing 2200 serum 
samples from 699 patients, 378 of whom had prostate cancer, aimed to determine the 
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use of PSA as a tumor marker (Stamey et al. 1987). In fact, they showed that levels of 
PSA in the serum of patients correlated with the stage of prostate cancer as well as with 
the estimated volume of the tumor. Moreover, this study also showed that PSA reached 
undetectable levels in the serum after radical prostatectomy, which suggested PSA could 
be a useful marker to monitor the response of prostate cancer to radiation therapy and 
to detect residual or recurrent disease (Rao et al. 2008; Catalona 2014).  Nowadays in 
many developed countries, men older than 50 years old are systematically examined 
through the analysis of PSA levels and digital rectal examination (DRE) (Mottet et al. 
2016). There is no specific normal or abnormal level of PSA in the blood because PSA 
levels are not only affected by PCa but also by prostatitis and BPH. However, PSA levels 
above 4.0 ng/mL are considered as abnormal (NIH 2016; Mottet et al. 2016). In these 
cases, other tests, such as for Prostate Cancer gene 3 (PCA3), a prostate specific 
marker highly expressed by prostate cancer cells and detected in urine, are combined 
with PSA and DRE for prostate cancer diagnosis in order to avoid over-diagnosis and 
over-treatment in screening of PCa (Mottet et al. 2016). 
   After initial screening, when DRE and PSA levels are suspicious, the diagnosis is 
confirmed by histopathological examination of a biopsy and may be supplemented with 
bone scanning and computed tomography. The classification of the diagnosed tumor is 
established based on the tumor-node-metastasis (TNM) system and the Gleason criteria 
(Mottet et al. 2016) and specific treatments are applied based on this classification.  
3.5 Classification and staging system 
   Strong efforts have been made to stratify prostate tumors into groups that could 
combine patients with similar clinical outcome. Two different criteria have been 
extensively used: 
a) Tumor stage: this system uses the size and extension of the tumor (T), the 
number of nearby lymph nodes that the tumor has (N) as well as the presence of 
metastasis (M) (Schrlsder et al. 1992) to classify prostate tumors in different stages and 
sub-stages (Fig. 10). 
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Figure 10. Classification of prostate tumors based on stage system. TNM system. Adapted 
from Mottet et al. 2016. 
b) Tumor grade: this criterion classifies tumors attending to their prognosis, which 
is evaluated upon histological examination. Since most of the tumors typically have two 
histologic patterns, a score (Gleason score) (Fig. 11) was created in 1966 that added 
the two most common grade patterns in a tumor, with scores ranging from 2 to 10, the 
higher score having the greater risk (Gleason 1992; Harnden et al. 2007).  In 2013, a 
study from Johns Hopkins Hospital and then validated in a multi-institutional study, 
includes five distinct Grade Groups based on the modified Gleason score groups. Grade 
Group 1 = Gleason score ≤ 6, Grade Group 2 = Gleason score 3 + 4 = 7, Grade Group 
3 = Gleason score 4 + 3 = 7, Grade Group 4 = Gleason score 4 + 4 = 8, Grade Group 
5 = Gleason scores 9 and 10. As this new grading system is simpler and more accurately 
reflects prostate cancer biology, it is recommended by the World Health Organization 
(WHO) to be used in conjunction with Gleason grading (Gordetsky & Epstein 2016). 
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Figure 11. Gleason score representation. Gleason score criteria for different levels of tumor 
differentiation. Adapted from Harnden et al. 2007. 
Currently, apart from tumor stage and grade, it is usual to classify PCa based on tumor 
risk which includes low-, intermediate-, and high-risk categories. These criteria were 
initially proposed by D’Amico and colleagues and are based on clinical stage, PSA and 
digital rectal examination results (Silberstein et al. 2013). According to this system, low-
risk PCa has a Gleason score of 6 on prostate biopsy, clinical stage of T1a, T1c, or T2a 
and a PSA <10 ng/mL; intermediate risk prostate cancer has a Gleason of 7, a PSA of 
10-20 ng/mL or a clinical stage of T2b or T2c and high-risk localized cancer has a 
Gleason score between 8 and 10, a PSA of >20 ng/mL or a clinical stage of T3a. Patients 
with T3b or T4 disease are classified as locally advanced (Silberstein et al. 2013). 
3.6 Treatment 
When a localized low risk tumor is diagnosed, watchful waiting and active surveillance 
are the standard of care due to the slow progression of the disease (Mottet et al. 2016) 
(Fig. 12). Upon examination of clinical progression, side-effects and potential benefit to 
survival, radical prostatectomy is the main treatment option (Fig. 12). It consists of 
removal of the entire prostate gland between the urethra and the bladder, and the 
resection of both seminal vesicles with sufficient surrounding tissue to obtain a negative 
margin. This procedure will try to preserve continence and whenever possible, potency. 
Moreover, radiotherapy is also often applied to localized prostate tumors that start 
progressing (Mottet et al. 2016). 
Androgen deprivation therapy (ADT) is universally accepted as first-line treatment of 
symptomatic metastatic prostate cancer (Fig. 12). However, ADT is also used to treat 
localized prostate cancer, biochemical (PSA) recurrence after radical prostatectomy, 
locally advanced disease, lymph node metastases and asymptomatic metastatic disease 
1 2 3 4 5
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(Perlmutter & Lepor 2007). ADT can be achieved by different means, including surgical 
castration (which leads to a reduction in testosterone levels), chemical castration with 
luteinizing hormone-releasing hormone (LHRH) agonists (which results in the down-
regulation of LHRH-receptors, suppressing luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) secretion and therefore testosterone production) and anti-
androgens (which compete with androgens blocking androgen receptor in prostate 
cancer cells) (Perlmutter & Lepor 2007). Recent studies have shown that combination of 
ADT plus docetaxel or abiraterone in newly diagnosed metastatic non-castrate prostate 
cancer offers a survival benefit as compared with ADT alone (Morris et al. 2018). 
However, after ADT, the development of castration resistant prostate cancer (CRPC) 
is very frequent and is considered as progression of the disease, despite medical or 
surgical castration, either clinical (development of metastatic disease, progression of 
pre-existing disease) or biochemical (three consecutive rises in PSA levels above nadir) 
in the presence of castrate levels of circulating testosterone (Chandrasekar et al. 2015). 
In these cases, chemotherapy (docetaxel and/or prednisone) and radiotherapy has been 
the first-line therapy. However, newer agents including antiandrogens (abitarone 
acetate, enzatulamide and apatulamide), novel chemotherapy (taxane-based), 
immunotherapy (sipuleucel-T) and bone metastasis therapy (readium-223 dichloride) are 
also applied (Nevedomskaya et al. 2018; Wang et al. 2018) (Fig. 12). However, these 
novel therapies have shown limited benefits and more trials are needed to demonstrate 
efficacy (Nevedomskaya et al. 2018). Therefore, further research on the mechanisms 
driving resistance in prostate cancer will encourage the identification of new targets to 
treat the disease. 
 
Figure 12. Different treatment options during prostate cancer progression. Adapted from  
Shen & Abate-Shen 2010. 
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4. Androgen receptor signaling in prostate cancer 
Androgens and androgen receptor (AR) play a pivotal role in the development and 
normal growth of the prostate gland but this pathway is also crucial in prostate 
carcinogenesis and progression to androgen-independent disease (Peter E Lonergan 
2011).  
The AR gene is a transcription factor located on chromosome X that encodes a 110- 
kDa protein consisting of 919 amino acids structurally divided into an N-terminal domain 
(NTD), DNA-binding domain (DBD) and a ligand-binding domain (LBD), all of which are 
essential for receptor function. Both testosterone and DHT binding to the LBD domain 
can activate AR under physiological conditions, with DHT having a significantly greater 
affinity for AR (Peter E Lonergan 2011). In the absence of ligands, AR remains in the 
cytoplasm tethered by heat shock proteins (HSPs). When testosterone or DHT are 
present, they induce conformational changes in AR that mediates dimerization of the 
receptor and its translocation to the nucleus, where it binds through the DBD domain to 
androgen response elements (AREs) on the promoters of target genes, such as PSA 
and transmembrane protease serine 2 (TMPRSS2), recruiting various coregulatory 
proteins to facilitate transcription and leading to responses such as growth and survival 
(Feldman & Feldman 2001; Peter E Lonergan 2011; Tan et al. 2015) (Fig. 13). 
Androgens and the AR control the constant growth of prostate cancer cells by 
stimulating cell proliferation and inhibiting apoptosis (Feldman & Feldman 2001; Tan et 
al. 2015). The initiation of prostate cancer can in many cases be attributed to the 
activation of distinct growth-promoting pathways, such as the androgen-dependent 
upregulation of members of the E-twenty-six (ETS) family of transcription factors by gene 
fusions between the AR-regulated TMPRSS2 gene promoter and the coding region of 
the ETS family member erythroblast transformation-specific (ERG) and ETS variant 1 
(ETV1), which have been estimated to occur in ~50% of prostate tumors. These fusions 
confer androgen responsiveness to ETS transcription factors, leading to cell-cycle 
progression (Tan et al. 2015). 
 Androgens are not the only steroid hormones involved in prostate tumorigenesis. 
Estrogens can directly and indirectly affect the development and homeostasis of the 
prostate gland and also play a pivotal role in prostate tumor initiation and progression 
(Bonkhoff & Berges 2009). Moreover, other signals are involved in prostate cancer 
initiation and progression, including those involving phosphoinositide 3-kinase (PI3K), 
RAS/RAF and Wnt signaling (Tan et al. 2015). 
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Figure 13. Androgen receptor signaling. Upon binding to dihydrotestosterone, androgen 
receptor translocates to the nucleus, binds to its target genes and regulates their expression. 
Adapted from Feldman &Feldman, 2001. 
 Since 1941, when Huggins and Hodges demonstrated the androgen dependency of 
PCa growth and progression, androgens and AR have been shown as the crucial players 
in both localized and advanced disease, as well as the major targets for therapeutic 
treatment of prostate cancer (Karen E. Livermore et al. 2016). Depriving tumors of 
androgens such as DHT and testosterone or blocking their actions has represented the 
main therapeutic option for the disease (Tan et al. 2015). Despite ADT, tumors progress 
to CRPC being then characterized by the reactivation of the AR signaling axis, which can 
take place through different mechanisms (Feldman & Feldman 2001; Chandrasekar et 
al. 2015; Watson et al. 2015): 
a) Ligand dependent mechanisms: 
 AR amplification and mutations: low levels of androgens persist despite androgen 
blockade with ADT. Amplification of the AR has been identified in a significant portion of 
CRPC cell lines, which may enable CRPC to be hypersensitive to low androgen levels 
and promote progression of the disease (hypersensitivity pathway). Also, different 
mutations in the AR gene have been identified to increase AR activity in the presence of 
T
Coregulators
T DHT
5a-reductase
AR
AR
HSP
DHT
Ligand binding
HSP
AR
DHT
AR
DHT
PP
Dimerization and 
phosphorylation
AR
DHT
AR
DHT
PP
Introduction 
46 
 
low levels of androgens and other androgen-like molecules (promiscuous pathway). 
 Co-activators and co-repressors: The AR normally recruits a series of co-
regulator complexes, which can function to either enhance (co-activators) or repress (co-
repressors) transcriptional activity, thereby modulating AR signaling. Several studies 
have found upregulation of some of these coactivators in CRPC including FKBP51, SRC 
and p300/CBP. On the other hand, co-repressors were found downregulated.  
b) Ligand independent mechanisms: 
 Aberrant activation (post-translational modification)/outlaw pathway: multiple 
growth factors, cytokines and kinases increase AR signaling, thereby promoting 
progression to castration resistance in a ligand-independent manner. PI3K, Src, NFkB 
and IGF are among these pathways. 
 Altered steroidogenesis: alternative androgen production of adrenal origin can 
lead to the production of dehydroepiandrosterone (DHEA) and its sulfated form (DHEA-
S), which are not affected by ADT and can be converted to the highly active DHT in the 
“5α-dione” pathway, promoting prostate cancer progression. 
 AR variants: recent studies have identified the presence of splice variants of AR 
(AR-Vs) that are constitutively active, typically due to the loss of the C-terminal LBD. The 
predominant variants are ARV1, ARV7 and ARV 567 with ARV7 being the most studied. 
   Since, unfortunately, most patients progress to CRPC, new drugs that have been 
approved in the last few years only extend the life of patients for months rather than 
years and resistance to these treatments is still common. Therefore, the identification of 
alternative targets not relying on AR signaling could lead to significant improvements in 
the treatment of prostate cancer.  
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5. Wnt signaling: an overview 
5.1 Wnt proteins 
Wnt proteins are a family of secreted lipoglycoproteins that play fundamental roles in 
different processes including neural patterning and organogenesis, cell proliferation, cell 
fate determination, cell polarity and migration, stem cell self-renewal and survival (Logan 
& Nusse 2004; Willert & Nusse 2012; Klaus & Birchmeier 2008; Clevers 2006; 
MacDonald et al. 2009). According to these fundamental roles, perturbation of the levels 
of Wnt ligands or altered activities of the proteins involved in Wnt signal transduction can 
result in defects in embryonic development, as well as in diseases such as cancer 
(Anastas & Moon 2013).  
The first Wnt gene, mouse Wnt-1, was discovered in 1982 (Nusse & Varmus 1982). 
Experiments conducted in mouse identified an insertion site of viral integration of mouse 
mammary tumor virus (MMTV) within the promoter of a gene called Int-1 (for 
‘integration’), which resulted in increased expression of full-length Int-1 protein leading 
to mammary tumorigenesis (Nusse & Varmus 1982). Sequence analysis showed 5 years 
later that Int-1 was orthologous to the Drosophila segment polarity gene Wingless (Wg) 
(Rijsewijk et al. 1987) and the terms were combined to produce the name ‘Wnt’ for the 
mammalian Int-1 gene and its paralogs (Nusse & Varmust 1992). 
    Later studies led to the isolation of more than 100 Wnt sequences in different species, 
all of which are highly evolutionarily conserved in metazoans (Komiya & Habas 2008). 
In mammals, 19 members of the Wnt family of proteins are present: Wnt-1, Wnt-2, Wnt-
2b/13, Wnt-3, Wnt-3a, Wnt-4, Wnt-5a, Wnt-5b, Wnt-6, Wnt-7a, Wnt-7b, Wnt-8a, Wnt-8b, 
Wnt-9a, Wnt-9b, Wnt-10a, Wnt-10b, Wnt-11 and Wnt-16 (MacDonald et al. 2009; Nusse 
2018).   
Wnt proteins are cysteine-rich proteins of about 350-400 amino acids that harbor an 
N-terminal region containing a palmitoleic acid group (PAM) crucial for their secretion, 
several highly charged amino-acid residues, many potential glycosylation sites and a 
characteristic distribution of 23-25 cysteine residues which suggest the formation of 
multiple intramolecular disulfide bonds (MacDonald et al. 2009; Mikels & Nusse 2006) 
(Fig. 14A and B).  
The tridimensional structure of X.laevis Wnt-8 in complex with the cysteine-rich 
domain (CRD) of mouse FZD8 was solved in 2012 (Janda et al. 2012) and showed that 
XWnt-8 has a distinctive donut shape which seems to resemble a hand that extends 
thumb (N-terminal) and index (C-terminal) fingers from a central “palm” domain (Fig. 
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14C). XWnt-8 comprises an N-terminal a-helical domain (NTD) from residues ~32 to 250 
that contains the lipid-modified thumb, and a C-terminal cysteine-rich domain (CTD) from 
residues 261 to 338 (Fig. 14B). The XWnt-8 NTD is composed of a seven–a-helical 
bundle palm, containing two large interhelical loop insertions that are stabilized by four 
disulfide bonds. The principal feature of the CTD is a long -strand hairpin that is also 
stabilized by an extensive network of disulfide bonds. Two asparagines (Asn104,and 
Asn263) are glycosylation sites on XWnt-8 (Janda et al. 2012) (Fig. 14B). 
 
Figure 14. Structure of Wnt proteins. (A) Schematic representation of mouse Wnt-3a. Black 
lines indicates cysteine and red lines potential glycosylation sites. Yellow region shows the N-
terminal signal sequence and purple region shows the porcupine binding area. Adapted from 
Coudreuse & Korswagen 2007. (B) Secondary-structure diagram of the XWnt-8 fold. Disulfide 
bonds are shown by red lines and glycosylation sites are shown with yellow boxes. Adapted from 
Janda et al. 2012. (C) Tridimensional structure of XWnt-8. The palmitoleic acid (PAM) group is 
shown in red. Palm, thumb and index fingers are shown. Taken from Janda et al. 2012. 
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5.2 Wnt biogenesis and secretion 
Wnt proteins are heavily modified through glycosylation (Smolich et al. 1992) and 
palmitoylation (Willert et al. 2003) prior to transport and secretion, which take place in 
the endoplasmic reticulum (ER) and are both required for proper intracellular processing 
and signaling activity (Willert & Nusse 2012). These modifications make Wnts more 
hydrophobic than they should be according to their sequence and explain the low 
solubility of active Wnt molecules (Logan & Nusse 2004; Willert & Nusse 2012; Takada 
et al. 2017). In the case of glycosylation, the oligosaccharyl transferase complex (OST) 
attaches N-linked oligosaccharide chains to the appropriate residues that can differ in 
the numbers of attachments among different Wnts (Coudreuse & Korswagen 2007; 
Willert & Nusse 2012) (Fig. 15). For palmitoylation, the acyltransferase Porcupine, a 
multipass transmembrane ER protein that is conserved across multiple species (Mikels 
& Nusse 2006), transfers acyl groups, such as a palmitoyl group, to substrates in 
cysteine and serine/threonine residues (Fig. 15). Willert et al reported a palmitic acid 
linked to a conserved cysteine residue (Cys77) and later on, Takada et al reported a 
palmitoleic acid motif (PAM) linked via an oxyester to a conserved serine residue 
(Ser209) (Willert & Nusse 2012). However, the crystal structure of Xenopus Wnt-8 in 
complex with mouse FZD8-CRD published in 2012 (Janda et al. 2012) indicates that only 
the conserved serine residue is lipidated, whereas the conserved cysteine is occupied in 
a disulfide linkage, arguing that Wnt proteins are modified by a single lipid moiety (Janda 
et al. 2012). Although glycosylation and palmitoylation occurs in all Wnt proteins, other 
post-transductional modifications may occur in specific Wnts (Willert & Nusse 2012). 
After modification of Wnts in the ER, different proteins are involved in their release 
from producing cells to the extracellular space including the multipass transmembrane 
protein Wntless (Wls)/Evenness interrupted (Evi)/Mom-3. This protein is located in the 
Golgi as well as in vesicles and in the plasma membrane and it associates and 
accompanies modified Wnts to the cell surface (Mikels & Nusse 2006; Willert & Nusse 
2012). But also other proteins such as TMEM9/p24 act as Wnt cargo proteins, promoting 
Wnts exit from the ER (Willert & Nusse 2012). After Wnt release, Wls needs to be 
retrieved back to the trans-Golgi network (TGN) to maintain Wnt secretion and this 
process is mediated through the retromer complex (Yang et al. 2008) (Fig. 15). Following 
release of Wnts, different studies have shown that they can be tethered to the plasma 
membrane via their lipid moieties but also be found in a biologically active form in the 
conditioned media. Alternatively, Wnt proteins may become incorporated into lipoprotein 
complexes (Willert & Nusse 2012). 
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Figure 15. Wnt biogenesis and secretion. Wnt proteins are palmitoylated in the ER by 
porcupine and secreted through the Golgi by Wls. After Wnt release, the retromer complex 
mediates Wls return to the trans-Golgi network (TGN). Adapted from Willert & Nusse, 2012. 
5.3 Wnt signaling pathways  
Traditionally, Wnt signals have been classified into canonical or -catenin dependent 
and noncanonical or -catenin independent pathways. However, novel branches have 
been recently characterized that increase the complexity of Wnt signaling (Fig. 16). 
A hallmark of canonical Wnt signaling is the stabilization and nuclear translocation of 
β-catenin, which in the absence of Wnt ligands is recruited and degraded by the 
destruction complex, whose components include Axin, glycogen synthase kinase-3 
(GSK-3), casein kinase 1 (CK1) and adenomatous polyposis coli (APC) (Komiya & 
Habas 2008). Wnt binding to frizzled (FZD) receptor and low density lipoprotein (LRP5/6) 
coreceptors leads to the phosphorylation of the latter by CK1 and GSK-3, which 
promotes the assembly of an intracellular signalosome driven by Disheveled (DVL) and 
Axin co-polymerization at the plasma membrane. Recent evidence suggests that FZD 
and LRP5/6 participate in the assembly of this signalosome by forming regulatory 
scaffolds which stabilize DVL and Axin adapters, thereby disrupting the destruction 
complex (DeBruine et al. 2017). This leads to the stabilization of -catenin, which 
accumulates in the cytoplasm and enters the nucleus, binding to T-cell factor 
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(TCF)/lymphoid enhancer factor (LEF) family transcription factors and co-activators, 
such as cAMP response element binding protein (CREB) binding-protein (CBP)/p300, 
B-cell CLL/lymphoma 9 (BCL9) and B Cell CLL/Lymphoma 9 Like (BCL9L) thereby 
regulating the expression of Wnt target genes (Komiya & Habas 2008). 
Noncanonical Wnt signals are less well characterized being traditionally sub-divided 
into Planar Cell Polarity (PCP) and Wnt/Ca2+ pathways (Komiya & Habas 2008). 
However, additional -catenin/TCF-independent signals have been described (van 
Amerongen 2012; Park et al. 2015). Noncanonical Wnt signals are activated upon Wnt 
binding to FZD receptors and tyrosine kinase-like co-receptors, leading to the recruitment 
and activation of DVL. The PCP pathway has two parallel branches involving small 
guanosine triphosphate hydrolase (GTPases): Rho, which activates Rho-associated 
kinase (ROCK) and Rac, which is linked to Jun-N-terminal kinase (JNK) and signaling 
by activator protein-1 (AP-1) family transcription factors. Cytoskeletal and transcriptional 
changes associated with these small GTPases regulate cell adhesion and migration 
(Komiya & Habas 2008; van Amerongen 2012; M. T. Veeman et al. 2003; Eferl & Wagner 
2003). Activation of the Wnt/Ca2+ pathway stimulates Ca2+ release from the endoplasmic 
reticulum, promoting activation of G-proteins, protein kinase C (PKC) and 
Ca2+/calmodulin-dependent kinase II (CaMKII). These events can also lead to the 
activation of transcription factors, such as nuclear factor of activated T-cells (NFAT), 
which promotes cell growth, survival, invasion and angiogenesis (van Amerongen 2012; 
M. T. Veeman et al. 2003; Kohn AD 2005; Mancini & Toker 2009). 
More recently, novel links have been identified between Wnt and Hippo signaling, 
which regulates organ size, tissue homeostasis and patterning. Hippo signals are 
transduced by YAP (Yes-associated protein), TAZ (transcriptional co-activator with Psd-
95/Disc large/ZO-1 homologous (PDZ) -binding motif) and TEADs (TEA domain family 
transcription factors) (Zanconato et al. 2016). YAP/TAZ antagonize canonical Wnt 
signaling by binding to components of the destruction complex, such as Axin (Azzolin et 
al. 2014), and regulating nuclear translocation of -catenin. In addition, a noncanonical 
Wnt-YAP/TAZ signaling axis has also been described, where Wnt binding to FZD and to 
receptor tyrosine kinase-like orphan receptor (ROR) activates Ga12/13, Rho and 
LATS1/2 (Large Tumor Suppressor Kinase) to induce YAP/TAZ and TEAD-mediated 
transcription (Park et al. 2015). 
A novel branch of Wnt signaling, Wnt-STOP (Acebron et al. 2014), has been 
described, whose signal is initiated by Wnt binding to LRP6 and whose effects are 
transcription-independent, involving Cyclin Y, rather than -catenin (Acebron et al. 2014). 
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Wnt-STOP signals promote protein stabilization at mitosis and cell growth, which suggest 
it could play an important role in cancer (Acebron & Niehrs 2016). 
 
Figure 16. Wnt signaling pathways. In the absence of Wnt ligands (WNT OFF), -catenin is 
degraded by the destruction complex (APC, Axin, GSK-3, CK1 and YAP/TAZ) and Wnt target 
genes are repressed. Binding of Wnt ligands to FZD and either LRP5/6 or ROR1/2-RYK-PTK7-
MuSK (WNT ON) activates canonical and noncanonical signaling, respectively. Canonical signals 
disrupt the destruction complex, stabilizing -catenin, which enters the nucleus and binds TCF/ 
LEF transcription factors to activate gene expression. The WNT–STOP pathway is a transcription-
independent pathway involving LRP coreceptors and cyclin Y. Noncanonical signals activate 
small GTPases and various kinases, mobilize Ca2+ and activate AP-1 family and NFAT 
transcription factors. New noncanonical signals involve activation of YAP/TAZ and tyrosine-
protein kinase Fyn (FYN)/ signal transducer and activator of transcription (STAT) signaling. Taken 
from Murillo-Garzón & Kypta 2017. 
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5.4 Wnt receptors 
After processing and secretion, Wnt proteins can enhance different signals by binding 
and activating different receptors at the cell membrane, including members of the 
Frizzled (FZD), low-density lipoprotein receptor-related protein (LRP) 4 to LRP6, receptor 
tyrosine kinase-like orphan receptor (ROR), protein tyrosine kinase 7 (PTK7), receptor 
tyrosine kinase (RYK), muscle skeletal receptor tyrosine kinase (MUSK) and 
proteoglycan families (glypican 4-6, GPC4-6) (Niehrs 2012) (Fig. 17) 
 
Figure 17. Wnt receptors and coreceptors. Variety of Wnt receptors and coreceptors. Adapted 
from Niehrs, 2012. 
5.4.1 FZD receptors 
The seven-pass transmembrane family of Frizzled (FZD) receptors were firstly 
discovered in Drosophila (Vinson & Adler 1987; Vinson et al. 1989) being later 
characterized their homologues in mammals (Bhanot et al. 1996). According to the 
International Union of Basic and Clinical Pharmacology (IUPHAR) classification, Frizzled 
receptors have been defined as a separate family, the Class Frizzled receptors, although 
some studies have shown similarity between them and G-protein-coupled receptors 
(GPCR) (Schulte & Bryja 2007; Schulte 2010). Mammalian Frizzled receptors contains 
10 members, FZD1-10, as well as the Hedgehog pathway protein Smoothened (SMO). 
Phylogenetic analysis of FZD proteins identifies different clusters based on their identity, 
which can vary from 20 to 40% being even higher between different clusters. Five main 
clusters group FZD proteins as follows: FZD1/2/7 (75% identity), FZD3/6 (50%), FZD5/8 
(70%) and FZD4/9/10 (65%) (Fig. 18A) (Schulte & Bryja 2007; MacDonald, B.T & He 
2012; Schenkelaars et al. 2015). Several FZD genes appear to lack introns including 
FZD1, FZD2, and FZD7 to FZD10, but others such as FZD5 contain one intron, although 
the entire open reading frame is encoded by a single exon (Huang & Klein 2004).   
FZD receptors range in length from about 500 to 700 amino acids (Huang & Klein 
2004). The N-terminal region is extracellular and contains a cysteine rich domain (CRD) 
that is connected to the transmembrane domain (TMD) through a variable 70-120 amino 
acid linker region (MacDonald, B.T & He 2012; Niehrs 2012) (Fig. 18B). The seven 
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transmembrane region contains three intracellular loops (ICL) and three extracellular 
loops (ECL) ending with a C terminal domain of variable length. Although the CRD within 
all members is remarkably conserved, each cluster shares a hallmark characteristic: 
FZD5 and FZD8 receptors have exceptionally long CRD-to-TMD linkers; FZD3 and FZD6 
receptors have long cytoplasmic tails with many regulatory elements; FZD4, FZD9 and 
FZD10 have very short C-terminal tails and the shortest CRD-to-TMD linkers; and FZD1, 
FZD2 and FZD7 seem to possess a CRD most different in sequence and structure from 
other FZD receptors (DeBruine et al. 2017). Apart from cysteines in the CRD, FZD 
receptors contain conserved cysteines in the ECL 1 and 2, which could engage in 
stabilizing disulfide bonds (Schulte 2010; MacDonald, B.T & He 2012) (Fig. 18B). The 
intracellular loops of FZD receptors contain essential sites for post-translational 
modifications such as phosphorylation, ubiquitination and proteolysis, which are known 
to regulate their function (Schulte 2010; Niehrs 2012). The C-terminal domain of FZD 
proteins contains the conserved KTxxxW domain which is essential for FZD signaling 
through its interaction with the Disheveled (DVL) PDZ domain. However, other residues 
in intracellular loops 1 and 3 are also required for DVL interaction and FZD signaling 
(Schulte & Bryja 2007; Schulte 2010; MacDonald, B.T & He 2012) (Fig. 18B). 
The FZD CRD is a highly conserved domain in FZD that mediates high affinity 
interactions with Wnt proteins (Niehrs 2012). The resolution of the structure of Xenopus 
Wnt-8 in complex with the CRD of mouse FZD8 (Janda et al. 2012) led to important new 
insights into Wnt biochemistry. In the complex structure, XWnt-8 appears to grasp the 
FZD8-CRD at two opposing sites in FZD-CRD: “site 1” and “site 2” respectively, which 
resembles a hand that extends thumb (N-terminal) and index (C-terminal) fingers from a 
central “palm” domain. The N-terminal domain of Wnt-8 is dominated by the palmitoleic 
lipid projecting into a groove in the FZD8-CRD. This interaction is mediated by amino 
acid residues that are conserved among Wnt and FZD family members, which may 
explain the promiscuous interactions among many Wnt and FZD proteins. Wnt-FZD CRD 
interactions in the C-terminal domain of Wnt-8 are mediated between amino acid 
residues that are highly conserved in all Wnts and a small depression in the FZD8-CRD 
structure that harbors some residues that are not conserved among other FZD CRDs. 
Therefore, it is possible that the specificity in Wnt–FZD binding arises from the interaction 
of the Wnt index finger with this surface domain in FZD (Janda et al. 2012) (Fig. 18C). 
The crystal structure also provides knowledge about Wnt formation of ternary 
complexes with coreceptors necessary for both canonical and noncanonical signaling 
(Janda et al. 2012) (Fig. 18C). Through conservation analysis of 20 Wnt sequences, four 
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main regions of conserved residues were identified in XWnt-8, including the thumb and 
index finger, the core of the N-terminal domain helical bundle and a large continuous 
patch composed of 10 residues.  The location of this patch at the opposite end of XWnt-
8 from  the FZD CRD domain and its solvent exposure suggest a potential binding site 
for interaction with Wnt coreceptors such as LRP5/6, ROR1/2, PTK7 and RYK (Niehrs 
2012; Janda et al. 2012). 
A       B
 
C 
 
Figure 18. FZD receptors. (A) Phylogenetic tree of the family of FZD receptors. Adapted from 
Schulte, 2007. (B) Structure of FZD receptors showing the CRD domain with cysteines (C) 
forming 5 disulphide bonds. ECL and ICL: extracellular and intracellular loops * represents 
potential phosphorylation sites and # potential glycosylation sites. The transmembrane domain 
and the C-terminal domain with the conserved KTxxxW* sequence and the less conserved VTTE 
sequences are also shown. Adapted from Schulte, 2007 and MacDonald, 2012. (C) Crystal 
structure of XWnt-8 in complex with FZD8 CRD. Sites of interaction between Wnt and FZD are 
shown as well as the patch residues involved in the formation of ternary complexes. Taken from 
Murillo-Garzón & Kypta 2017. 
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During the last year, two independent structural studies of FZD CRDs revealed novel 
insight into Wnt-FZD interactions (Nile et al. 2017; Debruine et al. 2017). The structures 
of FZD7 and FZD5 CRD (Nile et al. 2017) and the FZD4-CRD (Debruine et al. 2017) 
suggest that the Wnt acyl group is required for FZD CRD dimerization, supporting a 1:2 
stoichiometry model for Wnt-FZD complexes (Nile et al. 2017; Debruine et al. 2017). 
Moreover, palmitoylated Wnt-5a and Wnt-8a were found to stabilize the FZD4 CRD-CRD 
interaction, suggesting that FZD receptors form signalosomes upon Wnt binding and that 
the Wnt palmitoyl group is crucial for this interaction (Debruine et al. 2017). However, 
although hypothetical models have been created, further studies will be required to 
determine how these interactions orchestrate Wnt signalosome assembly (Fig. 19). 
 
Figure 19. Hypothetical model of Wnt signalosome assembly. (1) LRP5/6 and FZD receptors 
exist as inactive dimers; (2) Wnt stabilizes LRP5/6 and FZD receptors and allows DVL 
dimerization; (3) Multiple Wnts may drive assembly of large receptor signalosomes. Adapted from 
DeBruine et al, 2017. 
The two most prominent intracellular binding partners for FZD receptors are the 
scaffold protein DVL and GPCRs (Dijksterhuis et al. 2014). In humans, there are three 
variants of DVL (DVL1, DVL2 and DVL3) all of which contain three functional domains: 
the N-terminal domain, which contains the DIX (Disheveled and Axin) polymerization 
domain; the C-terminal region, where the DEP (Disheveled, Egl-10 and Pleckstrin) 
domain is located and which is functionally involved in the regulation of small GTPases 
and in addition, a central PDZ (Psd-95/Disc large/ZO-1 homologous) binding domain, 
which enables interactions with other proteins. DVL-FZD interaction is mainly based on 
three mechanisms involving the KTxxxW–DVL interaction, the DEP domain interaction 
with a bipartite motif in the ICL3 of FZD and DEP-domain-mediated electrostatic 
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interactions with the negatively charged head groups of membrane lipids. In this regard, 
DVL plays not only an important role in the β-catenin-dependent but also in the 
independent signaling pathways (Dijksterhuis et al. 2014).  
Although FZD receptors share features with GPCRs (seven transmembrane 
segments, an extracellular N-terminal domain, and a cytoplasmic C-terminal tail), they 
lack hallmarks of prototypical GPCRs and they are classified as nonconventional 
GPCRs. However, other studies have shown that FZDs can directly interact with GPCRs 
and signal through them to activate Wnt/Ca2+ and Wnt/cAMP signaling (Nichols et al. 
2013; Dijksterhuis et al. 2014).  
Apart from being Wnt receptors, FZD proteins have been described to bind to 
Clostridium difficile toxin B (TcdB) through the CRD of FZD which therefore, can result 
on competition with Wnt for binding to FZDs, blocking Wnt signaling (Tao et al. 2016; 
Chen et al. 2018). 
5.4.1.1 FZD8 
FZD8 is one of the best characterized FZD family members since the structure of 
mouse FZD8 CRD was solved in complex with Xenopus Wnt-8. FZD8 is located on 
chromosome 10 and encodes for a protein of 694 amino acids with a molecular mass of 
69 kDa (Saitoh et al. 2001). As shown before, the homology between FZD receptors is 
extremely high with FZD5 the closest family member (Fig. 18) (Schulte & Bryja 2007; 
MacDonald, B.T & He 2012). FZD8 is expressed in fetal kidney and brain as well as in 
adult kidney, heart, pancreas and skeletal muscle (Saitoh et al. 2001). Like other FZD 
receptors, FZD8 is regulated through ubiquitination by Zinc and Ring Finger 3 (ZNRF3) 
which leads to its degradation by the proteasome. Moreover, it is glycosylated at 
Asparagines 49, 152 and 475. Independent studies have shown the involvement of FZD8 
in the canonical pathway (Wang et al. 2012; Albers et al. 2013; Yin et al. 2013; Bravo et 
al. 2013; Q. Jiang et al. 2015; Fu et al. 2016; Yang et al. 2017; Li et al. 2017; Kramer et 
al. 2017). However, FZD8 has also been implicated in noncanonical signaling (Gregory 
et al. 2010; Kumawat et al. 2013; Wang et al. 2015; A. I. R. Spanjer et al. 2016; Murillo-
Garzón et al. 2018), which again highlights the promiscuity of FZD receptors to activate 
different pathways in different contexts. 
Most of the alterations described for FZD8 have been related to different cancer types, 
such as renal cell carcinoma (Janssens et al. 2004; Yang et al. 2017), acute 
lymphoblastic leukemia (Khan et al. 2007; Gregory et al. 2010) and lung cancer (Wang 
et al. 2012; Bravo et al. 2013), where it was found upregulated. It has also been 
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implicated in triple negative breast cancer, where it mediates drug resistance (Yin et al. 
2013), in head and neck squamous carcinoma, where FZD8 was found to be a target for 
elimination of cancer stem cells (Sun et al. 2014), and in colon cancer progression, where 
it mediates Wnt-2 signaling (Kramer et al. 2017). Particularly in prostate cancer, FZD8 
has been found upregulated in prostate tumors (Pascal et al. 2009; Li et al. 2017) but 
genetic alterations of FZD8 are not very frequent (Fig. 20). 
 
Figure 20. FZD8 genetic alterations in prostate cancer datasets. Taken from cBioPortal.org. 
Last but not least, FZD8 alterations have also been linked to other diseases, such as 
rheumatoid arthritis (Miao et al. 2015), asthma pathogenesis (Kumawat et al. 2013; A. I. 
R. Spanjer et al. 2016), chronic bronchitis (Anita I.R. Spanjer et al. 2016), high glucose 
stress (Pang et al. 2016), corneal defects (Benson et al. 2017) and psoriasis (Shen et al. 
2017). Moreover, a human-accelerated regulatory enhancer (HARE5) of FZD8 has been 
implicated in brain development and size (Boyd et al. 2015). 
5.4.2 LRP5/6 coreceptors 
LRP5 and LRP6 are members of the low-density lipoprotein receptor family, which act 
as coreceptors in Wnt- β-catenin dependent signaling. Both have more than 1600 amino 
acids, sharing around 70% sequence identity (MacDonald, B.T & He 2012). Their single 
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pass transmembrane structure contains an extracellular domain (ECD) that mediates the 
interaction with Wnt and FZD, leading to ternary complexes, and an intracellular domain 
(ICD) that contains five Pro-Pro-Pro-Ser/Thr-Pro (PPPSP) repeats whose 
phosphorylation by GSK3 and CK1 is required for β-catenin-dependent signaling (Niehrs 
2012). Once LRP6 is fully phosphorylated at PPPSPXS sites, it binds Axin and GSK3, 
leading to recruitment of the β-catenin destruction complex and inhibition of GSK3 
through its sequestration in multivesicular bodies (MVBs). These events protect β-
catenin from phosphorylation, escaping ubiquitination and proteasomal degradation and 
promoting its accumulation in the cytoplasm and nucleus (Niehrs 2012). The role of 
LRP5/6 coreceptors promoting canonical Wnt signaling can be regulated by the secreted 
protein SOST or sclerostin, which binds LRP5/6 coreceptors and consequently, disrupts 
the formation of the Wnt-FZD-LRP complex and inhibit canonical Wnt signaling 
(Semënov et al. 2005). 
5.4.3 ROR1/2 coreceptors 
The receptor tyrosine kinase-like orphan receptors (RORs) are transmembrane 
proteins included within the receptor tyrosine kinase (RTK) family. Both ROR1 and ROR2 
have about 940 amino acids and share about 58% identity (Masiakowski & Carroll 1992). 
They contain an extracellular domain consisting of an immunoglobulin-like motif, a 
cysteine-rich frizzled domain, which harbors high homology to the FZD CRD and 
mediates ligand binding and a Kringle domain involved in protein-protein and protein-
ligand interactions. The intracellular region includes a tyrosine kinase domain whose 
functionality has been extensively debated, and a proline-rich domain flanked by two 
serine-threonine–rich regions (Green & Nusse 2014; Borcherding et al. 2014). They were 
named orphan receptors because their ligands had not been discovered. However, 
different studies have shown that they can associate with different Wnt ligands, such as 
Wnt-5a, transducing mostly PCP signaling (Niehrs 2012; van Amerongen 2012; 
Rebagay et al. 2012; Green & Nusse 2014; Borcherding et al. 2014).  
5.4.4 Receptor tyrosine kinases (RYK, PTK7 and MuSK) and others 
RYK (receptor-like tyrosine kinase) is a single pass transmembrane receptor that 
binds Wnt ligands. It contains an extracellular domain resembling the Wnt inhibitory 
factor (WIF) protein, which has been proposed to interact directly with the lipid 
modification on the Wnt protein (Green & Nusse 2014). The cytoplasmic portion of RYK 
has a tyrosine kinase motif that is not considered to be active (Green & Nusse 2014). 
Hence, RYK may act as a coreceptor rather than as a primary signal transducing 
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receptor and has been implicated in β-catenin-dependent, PCP and WNT–Ca2+ 
signaling (van Amerongen 2012; Niehrs 2012; Green & Nusse 2014). 
Protein Tyrosine Kinase 7 (PTK7) is a single pass transmembrane receptor with 
seven extracellular immunoglobulin-like domains, a transmembrane region, a 
juxtamembrane region and a catalytically inactive cytoplasmic tyrosine kinase domain 
(Niehrs 2012; Peradziryi et al. 2012). PTK7 is mainly involved in the PCP pathway 
(Peradziryi et al. 2012; Hayes et al. 2013; Martinez et al. 2015) but some reports also 
showed its involvement in -catenin dependent signaling in X.laevis (Puppo et al. 2011). 
Therefore, it may activate both canonical and noncanonical pathways (Niehrs 2012). 
Muscle Specific Kinase (MuSK) is a type I, single-pass transmembrane glycoprotein 
that acts as Wnt receptor specifically in muscle and that has been linked to PCP signaling 
(Niehrs 2012). Its extracellular region contains three immunoglobulin-like domains (Ig1-
3) and a cysteine-rich domain (CRD) that is similar to the FZD CRD. A single 
transmembrane helix connects the extracellular domain to the cytoplasmic region, which 
contains the tyrosine kinase domain that can be auto-phosphorylated on three tyrosine 
residues (Gnanasambandan 2013).  
Even though they are less well characterized, other proteins have also been reported 
as Wnt receptors or coreceptors, including VANG like proteins 1 and 2 (VANGL1/2), 
which are mainly involved in the PCP pathway (Hatakeyama et al. 2014) and 
proteoglycans such as glypican-4 (GPC4), which regulates the signaling at the level of 
the interaction between the ligand and receptor (Capurro et al. 2014). Some other 
receptors including CD146, have also been reporter to bind Wnt ligands, such as Wnt-
5a, to activate JNK and regulate cell migration (Ye et al. 2013). 
5.5 Regulation of Wnt signaling 
Regulation of Wnt signaling is very complex and is mediated through different 
effectors that can function as agonists or antagonists (Fig. 21). Antagonists can be 
classified depending on their mechanism of action. Some of them are secreted regulators 
that bind Wnt proteins, for example sFRPs (secreted Frizzled-Related Proteins), WIF-1 
(Wnt inhibitory factor 1) and Cerberus (Kawano & Kypta 2003; Malinauskas & Jones 
2014; Cruciat & Niehrs 2013). Other antagonists such as Dickkopf (DKK) proteins  
(Kawano & Kypta 2003; Malinauskas & Jones 2014; Cruciat & Niehrs 2013) and SOST 
(Semënov et al. 2005) associate with Wnt co-receptors LRP5/6, or Shisa (Cruciat & 
Niehrs 2013) which binds to FZD receptors in the ER, preventing its translocation to the 
membrane (Yamamoto et al. 2005). Among Wnt agonists, Norrin directly activates Wnt 
Introduction 
61 
 
signaling by binding to FZD4 (Cruciat & Niehrs 2013). Adding further complexity, sFRPs 
can also bind to FZD receptors and activate or inhibit Wnt signaling in different contexts 
(Kawano & Kypta 2003; Bovolenta et al. 2008).  
 
Figure 21. Wnt signaling regulation. Schematic overview of the different antagonist and agonist 
of the Wnt signaling.  
Recent studies have revealed additional mechanisms of regulation of Wnt signaling 
at the membrane (Cruciat & Niehrs 2013; Malinauskas & Jones 2014; Hao et al. 2016). 
The transmembrane E3 ubiquitin ligases ZNRF3 (Zinc and Ring Finger 3) and RNF43 
(Ring Finger Protein 43) inhibit Wnt signaling by targeting FZD receptors for 
ubiquitination and degradation. ZNRF3 and RNF43, in turn, are regulated by R-Spondins 
(RSPO1-4), secreted proteins that enhance Wnt signaling by simultaneously binding 
ZNRF3/RNF43 and leucine-rich repeat-containing G protein-coupled receptors (LGR4-
6) to promote ubiquitination and membrane clearance of ZNRF3/RNF43, thus facilitating 
FZD receptor stabilization (Hao et al. 2012; Hao et al. 2016) (Fig. 22). 
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Figure 22. Wnt signaling regulation by RNF43/ZNRF3/RSPO. RNF43 and ZNRF3 ubiquitin 
ligases inhibit Wnt signaling by ubiquitinating FZD receptors, promoting their degradation. R-
Spondin (RSPO) binds RNF43/ZNRF3 and LGR5, resulting in membrane clearance of RNF43 
and ZNRF3 and increased FZD stability. Mutations in RNF43 and ZNRF3 or overexpression of 
RSPO as a result of a RSPO gene fusion activate Wnt signaling. Taken from Murillo-Garzón & 
Kypta, 2017. 
 
6. Wnt signaling in cancer 
A role for Wnts in cancer was first described three decades ago in mouse models of 
mammary cancer and in human and mouse colon cancer (Nusse & Varmus 1982; 
Korinek et al. 1997; Morin et al. 1997). Since then, alterations in Wnt signaling have been 
described in different types of cancer, including colon, breast, lung and prostate (Polakis 
2000; Clevers 2006; Polakis 2012; Anastas & Moon 2013) among others. Different roles 
have been defined for Wnt signaling in a cancer-stage-specific and a cancer-type-
specific manner. In this regard, Wnt signaling is able to either promote or inhibit tumor 
initiation, growth and metastases and is also involved in drug resistance (Anastas & 
Moon 2013). 
6.1 Wnt alterations in prostate cancer 
Activating mutations in the gene encoding β-catenin (CTNNB1) and inactivating 
mutations in the genes that encode proteins in the destruction complex (APC and AXIN1) 
increase Wnt–β-catenin signaling in many types of cancer, particularly colorectal cancer, 
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but are infrequent in prostate cancer (Murillo-Garzón & Kypta 2017). Nevertheless, 
recent studies analyzing 150 CRPC tumors revealed genomic alterations affecting APC 
and CTNNB1 in 18% of samples (Robinson et al. 2015). Moreover, high expression of 
-catenin and -catenin partners such as AR have been found to be associated with high 
Gleason grade, disease progression and PSA levels (Murillo-Garzón & Kypta 2017) 
(Table 1).  
The low frequency of Wnt signaling pathway gene mutations in the majority of prostate 
tumors has encouraged the study of upstream components of the pathway. In this 
respect, alterations in Wnt ligands such as Wnt-5a, Wnt-7b or Wnt-11 and Wnt regulators 
including sFRP and DKK have been reported  (Murillo-Garzón & Kypta 2017). 
Particularly, mutations in the ubiquitin ligases RNF43 and ZNRF3 and gene fusions that 
increase expression of RSPO2 were detected at an overall frequency of 6% in a panel 
of 150 metastatic CRPC tumors (Robinson et al. 2015), suggesting novel therapeutic 
options might be a possibility for some patients with prostate cancer (Table 1).   
Perturbations in the levels of Wnt receptors have also been described in prostate 
cancer. FZD2 was found as a Wnt-5a receptor involved in the activation of PKC and JNK 
(Yamamoto et al. 2010). Moreover, FZD2 was required for prostate cancer cell invasion 
and expression of metalloproteinase-1 (MMP-1), thereby promoting aggressiveness of 
prostate cancer (Yamamoto et al. 2010). Increased expression of FZD2 as a Wnt-5a 
receptor has also been reported in prostate tumors and their expression is associated 
with EMT and higher Gleason score (Sandsmark et al. 2017). The oncogene ERG, 
expressed in prostate tumors with TMPRSS2-ERG rearrangements, has been found to 
increase the expression of several FZD receptors, including FZD3, FZD5 and FZD7 
(Brase et al. 2011) and FZD8 (Brase et al. 2011; Chakravarthi et al. 2018), and also 
FZD4, which has a role in EMT (Gupta et al. 2010). Independent studies reported 
increased expression of FZD8 (Pascal et al. 2009) and its closest relative protein, FZD5, 
in advanced prostate cancer (Thiele et al. 2011). Among the coreceptors, ROR1 protein 
was shown to be expressed at high levels in 19 of 21 prostate tumors (S. Zhang et al. 
2012) (Table 1). 
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WNT 
pathway 
component 
Alteration Disease stage Effect on  WNT signaling, on 
prostate cancer cells and on 
patients if known 
-catenin 
(CTNNB1) 
Activating 
mutations 
CRPC Disease progression (mice) 
APC Inactivating 
mutations 
SNPs 
CRPC 
Advanced prostate 
cancer 
Disease progression (mice) 
Decreased PSA-free survival  
Ligands       
 WNT5A Upregulation CTCs from CRPC and 
ADT patients with 
tumors and metastases 
Localized cancer 
Noncanonical; increased CRPC 
growth, bone metastasis; 
metastasis and recurrence 
Increased survival, improved 
outcome  
 WNT7B Upregulation Tumor 
CTCs from patients 
receiving ADT 
Noncanonical; induces 
osteoblastic response in bone 
 WNT11 Upregulation  ADT, metastases Noncanonical; promotes 
invasion and neuroendocrine-
like differentiation 
 WNT16B Upregulation Tumor stroma Canonical; therapy resistance 
Receptors       
FZD2 Upregulation CRPC Recurrence 
FZD4 Upregulation ERG positive tumors Canonical and noncanonical: 
EMT  
FZD5 Upregulation Tumors  Noncanonical 
FZD8 Upregulation Tumors  Canonical and noncanonical 
ROR1 Upregulation Tumors  Not canonical; not known 
Regulators       
SFRP1 Downregulation Tumors Reduced survival 
SFRP2 Upregulation Tumor stroma Potentiation of  WNT-16B; 
therapy resistance 
DKK1 Upregulation Serum, tumors Increased tumor growth, bone 
metastases
 
and osteolytic 
lesions in mice; poor prognosis 
in patients 
DKK3 Downregulation Tumors   
Inhibits tumor growth and 
metastasis 
ZNRF3/  
RNF43 
Inactivating 
mutations 
CRPC Potentiation of  WNT signals 
RSPO2 Upregulation 
(gene fusion) 
CRPC Potentiation of  WNT signals 
Table 1. Key changes in Wnt signaling pathways components in prostate cancer. Adapted 
from Murillo-Garzón & Kypta 2017. 
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6.2 Targeting Wnt signaling 
   Specific Wnt pathway inhibitors has been developed that can be classified into 
functional groups (Murillo-Garzón & Kypta 2017) (Fig. 23): 
a) Inhibition of Wnt secretion: this strategy has relied on targeting porcupine which 
is responsible for Wnt palmitoylation. Drugs in this group include IWPs (Chen et 
al. 2009), Wnt-C59 (Proffitt et al. 2013), LGK974 (Liu et al. 2013), and ETC-159 
(Madan et al. 2016). 
b) Regulation of Wnt antagonists or agonists: in this approach are included for 
example the use of recombinant SFRP1 protein (Ghoshal et al. 2015), as well as 
an adenoviral vector expressing DKK3 (Veeck & Dahl 2012) and RSPO blocking 
antibodies such as OMP-131R10 (Storm et al. 2015). 
c) Preventing DVL activation: since DVL is crucial for signal transduction different 
inhibitors have been developed, for example 3289-8625 (Grandy et al. 2009). 
d) Stabilizing the destruction complex: this strategy is based on tankyrase inhibitors 
that target Axin for proteasomal degradation. This group include inhibitors such 
as IWR (Haikarainen et al. 2014), XAV-939 or NVP-TNKS656 (Shultz et al. 2013) 
e) Targeting nuclear -catenin partners: drugs such as iCRTs (Gonsalves et al. 
2011), which prevent -catenin/TCF interaction or ICG-001 (Emami et al. 2004) 
or PRI-724 (El-Khoueiry et al. 2013), both preventing -catenin interaction with 
CBP coactivator, might provide new therapies. 
f) Blocking Wnt-receptor interactions: approaches focused on specific Wnts, FZD 
receptors or other signaling components at the cell membrane might, in principle, 
be more selective than manipulating the pathway at the level of its cytosolic or 
nuclear components and hence, better positioned to lead to clinically viable 
strategies.  These inhibitors include drugs such as Wnt-5a antibodies (Hanaki et 
al. 2012) or a peptide targeting Wnt-5a (Foxy5) (Säfholm et al. 2006; Säfholm et 
al. 2008); OMP-54F28 (Le et al. 2015), a decoy Wnt receptor which competes 
with the native FZD8 for its ligand; OMP-18R5 (Gurney et al. 2012), which target 
FZD1,2,5,7 and 8; OTSA10 (Fukukawa et al. 2008), targeting FZD10 or UC-961 
(Kolb et al. 2016), which targets ROR1. 
   Several drugs that target Wnt signaling are currently in clinical trials, but very few of 
them are being tested for the treatment of prostate cancer. However, the increased 
frequency of APC mutations, identification of novel mutations in CRPC, and the growing 
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evidence that noncanonical Wnt signals are active in prostate cancer, are anticipated to 
stimulate further interest in this area of drug development (Murillo-Garzón & Kypta 2017). 
 
Figure 23. Drugs that target Wnt signaling. Many drugs have been developed that act on 
different targets at different levels in the Wnt signaling pathway. The therapeutics are inhibitors 
of Wnt secretion (red), regulators of Wnt antagonist and antagonist function (blue), drugs that 
target Wnt receptor interactions (green), drugs that prevent disheveled (DVL) activation (pink), 
drugs that stabilize the destruction complex (grey), and drugs that target β-catenin (β-cat) partners 
in the nucleus (purple). Taken from Murillo-Garzón & Kypta, 2017. 
  
7. Wnt signaling crosstalk with other pathways: TGF- signaling 
The Transforming Growth Factor beta (TGF-β) family of cytokines, characterized by 
six conserved cysteine residues, contains two subfamilies, the TGF-β/Activin/Nodal 
subfamily and the BMP (bone morphogenetic protein)/GDF (Growth and Differentiation 
Factor)/MIS (Mullerian Inhibiting Substance) subfamily (Shi & Massagué 2003). Most 
members of this family exist in different forms, with the TGF-β cytokine consisting of 
three isoforms: TGF-β1, TGF-β2, and TGF-β3. 
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TGF-β ligands are synthesized within the cell as 75-kDa homodimers that are then 
cleaved in the Golgi to produce mature 25-kDa TGF-β homodimers. TGF-β homodimers 
bind latency-associated proteins (LAPs) through a disulphide bond, generating a large 
latent complex in the ER. These complexes are secreted to the extracellular matrix to 
interact with fibronectin fibrils and heparan sulfate proteoglycans at the cell membrane 
and are stored in fibrillin-rich microfibrils in the extracellular matrix (Cao & Kyprianou 
2015). Latent TGF-β is activated and released from the latent complex by proteases, 
reactive oxygen species, integrins and thrombospondin 1 to form active signaling 
molecules (Padua & Massagué 2009; Cao & Kyprianou 2015). 
TGF-β uses a simple mechanism to signal from the cell membrane to the nucleus that 
involves binding to specific kinase receptors at the surface of target cells and the 
activation of Smad family transcription factors. However, non-Smad pathways have also 
been described (Shi & Massagué 2003; Kubiczkova et al. 2012) 
7.1 TGF- signal transduction 
For initiation of TGF-β signaling, active TGF-β homodimers bind to two pairs of type I 
and type II serine/threonine kinases receptors forming a heterotetrameric receptor 
complex. The constitutively active type II receptor comes in close contact with the type I 
receptors whose interaction can be negatively regulated by the pseudo-receptor BAMBI 
by intercalating in the receptor complex (Massagué et al. 2005). TGFRII binding to 
TGFRI causes the phosphorylation of a 30-amino-acid regulatory segment called the 
GS region, located immediately upstream of the kinase domain. Phosphorylation of the 
type I receptor disrupts the interaction between the kinase domain and a TGF- signaling 
inhibitor, FKBP12 (FK506 binding protein-12). With the release of FKBP12 from the 
active site, the Smad transcription factors are then able to form a heteromeric complex 
with the receptors and be phosphorylated by them at their C-terminal domains 
(Massagué 2000; Padua & Massagué 2009). Smad phosphorylation by receptors causes 
their activation and translocation to the nucleus, where they assemble complexes with 
other nuclear cofactors to directly control target gene expression (Massagué 2000; Shi 
& Massagué 2003) (Fig. 24). Members of many other DNA-binding protein families 
participate as Smad cofactors, including FOX, HOX, RUNX, E2F, AP-1, CREB/ATF, 
Zinc-finger and other families and these interaction facilitates target gene specificity 
(Kubiczkova et al. 2012). 
However, the diversity of TGF-β signaling in cells is determined not only by various 
ligands, receptors, Smad mediators and Smad-interacting partners, but also by the ability 
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of TGF-β to activate other signaling pathways. These Smad-independent pathways 
include various branches of mitogen-activated protein kinase (MAPK) pathways, Rho-
like GTPase signaling pathways, and PI3K/AKT pathways (Zhang 2009; Kubiczkova et 
al. 2012) (Fig. 24). 
 
Figure 24. Smad-dependent and Smad-independent pathways. In the inactive state, TGF- 
remains latent bound to latency associated proteins (LAPs) and FKBP21 blocks the 
phosphorylation site of TGFRI. When TGF- is active, a heteromeric complex is formed with 
TGFRII and I and the latter is phosphorylated by TGFRII. This phosphorylation allows Smad 
phosphorylation and its translocation to the nucleus where it binds to other cofactors to regulate 
gene expression. The TGF- complex can also activate non-Smad pathways involving 
ERK/JNK/PI3K or Rho GTPases. Adapted from Padua & Masagué, 2009 and Zhang, 2009. 
7.2 TGF- receptors 
This family of receptors have structural characteristics similar to both serine/threonine 
and tyrosine kinases although they are more often referred to as serine/threonine kinase 
receptors (Heldin & Moustakas 2016). The human genome encodes seven type I 
receptors (ALKs 1-7) and five type II receptors (ActR-IIa, ActR-IIB, BMPRII, AMHRII, and 
TGFRII) that function as receptor complexes for various members of the TGF-β family. 
The type II receptors range from 85 to 110 kDa, while the type I receptors are smaller 
ranging from 65 to 70 kDa (Kubiczkova et al. 2012). The TGF-β1 ligand, which is the 
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most abundant isoform, preferentially signals through the TGFRII receptor and the 
ALK5 type I receptor, TGFRI. In addition to these two classes of receptors, type III 
receptors such as betaglycan, help TGF- ligands bind more efficiently to their receptors 
(Padua & Massagué 2009). The structural motifs of the receptors include small cysteine-
rich extracellular domains, a transmembrane domain and a kinase domain that harbors 
a very short C-terminal tail (Heldin & Moustakas 2016). The type I, but not type II, 
receptors contain a characteristic SGSGSG sequence, termed the GS domain, 
immediately N-terminal to the kinase domain (Shi & Massagué 2003) (Fig. 25). 
The activities of both TGFβRI and TGFβRII are regulated by several phosphorylation 
events. After ligand-induced assembly of the heterotetrameric TGF-β receptor complex, 
the constitutively active TGFβRII phosphorylates TGFβRI in the GS domain, located just 
upstream of the kinase domain. Moreover, TGFβRI can be phosphorylated at Ser165 in 
the juxtamembrane domain and auto-phosphorylated on serine/threonine residues, as 
well as on tyrosine residues. The kinase activity of TGFβRII is regulated positively by 
auto-phosphorylation at Ser213 and Ser409, and negatively by auto-phosphorylation at 
Ser416. In addition, TGFβRII can be auto-phosphorylated on tyrosine residues, including 
Tyr259, Tyr336, Tyr424 and Tyr470, which may also contribute to the regulation of the 
kinase activity of TGFβRII, and by Src at Tyr284 and Tyr470 (Heldin & Moustakas 2016). 
But apart from phosphorylation, TGF-β receptor activity and stability are also regulated 
by ubiquitination, neddylation and sumoylation (Heldin & Moustakas 2016). Not only that, 
localization of TGF-β receptors has been shown to be regulated by endocytosis and 
microRNAS have been shown to negatively regulate the expression level of TGF-β 
receptors (Heldin & Moustakas 2016). 
 
Figure 25. Schematic illustration of the motifs of TGF-β receptors. Adapted from Heldin & 
Moustakas, 2016. 
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7.3 Smad proteins 
Smad proteins are key elements in the transduction of TGF-β signaling. In humans, 
the Smad family includes eight members, but only five of them (Smad1, Smad2, Smad3, 
Smad5, and Smad8) act as substrates for TGF-β family receptors, being commonly 
named as receptor-regulated Smads, or RSmads.  Smad1, 5, and 8 serve principally as 
substrates for the BMP and anti-Mullerian hormone receptors, and Smad2 and 3 for the 
TGF-β, activin, and Nodal receptors. Apart from RSmads, Smad4, serves as a common 
partner for all RSmads, and Smad6 and Smad7 are inhibitory Smads (Massagué et al. 
2005). 
Smad proteins are ∼500 amino acids in length consisting of two globular domains 
coupled by a linker region. The N-terminal domain, or “Mad-homology 1” (MH1) domain, 
is highly conserved in all RSmads and Smad4 but not in Smad6 and 7. The linker region 
is quite divergent between the various subgroups, whereas the C-terminal or MH2 
domain is conserved in all Smad proteins. The MH1 domain is a DNA-binding module 
stabilized by a tightly bound zinc atom. The MH2 domain is one of the most versatile 
protein-interacting modules in signal transduction. RSmads have a conserved C-terminal 
motif, Ser–X–Ser, that is phosphorylated by the activated receptor (Massagué et al. 
2005). 
Smad proteins undergo a constant process of nucleo-cytoplasmic shuttling where the 
nuclear translocation is mediated through Smad interaction with nucleoporins. Smad 
nuclear accumulation results from receptor-mediated phosphorylation events that 
decrease the affinity of RSmads for cytoplasmic anchors and increase their affinity for 
nuclear factors. Subsequent de-phosphorylation of RSmads causes their return to the 
cytoplasm for another round of receptor-mediated phosphorylation and nuclear 
translocation (Massagué et al. 2005).  
7.4 Dual role of TGF-β 
All members of the TGF-β family play important roles during development, as well as 
in normal physiological and disease processes, by regulating an extensive range of 
cellular processes, including cell growth, differentiation, migration, apoptosis, and 
extracellular matrix production 
In cancer, a dual role of TGF-β has been described, in which it is able to act either as 
a proto-oncogene or as a tumor suppressor, depending on cell context and tumor stage 
(Kubiczkova et al. 2012). TGF-β is a potent anti-tumor agent because it strongly inhibits 
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the growth of epithelial cells. However, in a different cellular context, TGF-β can also 
promote tumor progression because it is able to induce changes in transcriptional 
activities that re-program epithelial cells into mesenchymal cells, thereby facilitating 
tumor metastasis and invasion (Zhang 2009). 
In the case of prostate cancer, TGF-β plays a positive role as a tumor suppressor in 
normal prostate epithelial cells and premalignant lesions (high-grade intraepithelial 
neoplasia). However, elevation of TGF-β expression will quickly drive tumor progression, 
invasion and metastasis; thus the characterization of the temporal events responsible for 
the transition from growth suppressor to growth promoter are key to use TGF-β as a 
therapeutic target in prostate cancer (Jones et al. 2009).   
7.5 Wnt and TGF-β signaling crosstalk 
Aberrations in Wnt signaling pathways usually drive tumorigenesis in cooperation with 
other signaling pathways, oncogenes and tumor suppressors. Some of these pathways 
include PI3K/AKT, Ras, mTOR, Notch, Hedgehog as well as EGF, FGF, VEGF or TGF-
 (Thompson et al. 2011). Among them, crosstalk between Wnt and TGF- signaling has 
been extensively studied during the last years (Guo & Wang 2009; Attisano & Wrana 
2013). 
There is a remarkable synchronization between Wnt and TGF- signaling pathways 
during an animal development, in which the levels of both ligands reciprocally regulated 
each other. Nevertheless, this synchronization takes place not only during development 
but also in tumor progression (Guo & Wang 2009). The best-characterized scenario of 
this crosstalk is the nucleus, where Smad proteins have been found to associate with β-
catenin/Tcf/LEF complexes to regulate the expression of shared target genes (Guo & 
Wang 2009). However, Smads not only interact with β-catenin/Tcf/LEF complexes but 
have also been found to associate with AP-1 family transcription factors, which mediate 
-catenin-independent Wnt signals (Padua & Massagué 2009) (Fig. 26) 
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Figure 26. Crosstalk between Wnt and TGF- signaling pathways. TGF-β communicates with 
Wnt signaling at several levels. Physical interactions between pathway components can occur 
leading to changes in target gene expression.  
In prostate cancer, different studies have shown the contribution of both pathways 
to the progression of the disease. A paracrine TGF-/Wnt-3a signaling was observed to 
promote prostate cancer progression since it was observed that in mouse models, 
secretion of stromal Wnt-3a activates canonical Wnt signaling in the epithelium, 
facilitating progression of PIN lesions to adenocarcinoma and resistance to androgen 
deprivation (X. Li et al. 2008). Moreover,  studies from Brase et al in 2011 showed an 
upregulation of target genes from Wnt and TGF- pathways in TMPRSS-ERG fusion 
positive tumors, which are present in approximately 50% of prostate cancer patients 
(Brase et al. 2011). Furthermore, some years ago Wnt signaling was found to promote 
progression to prostate adenocarcinoma leading to increased reactive stroma and TGF-
 signaling in mouse models of prostate cancer (Carstens et al. 2014). All these studies 
support the potential of combined strategies that target both TGF- and Wnt signaling 
pathways in order to improve prostate cancer treatment. 
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8. Wnt-11 signaling 
Among the large family of Wnt ligands, Wnt-11 is traditionally defined as a 
noncanonical Wnt (Uysal-Onganer & Kypta 2012). Although its downstream effectors 
have not been fully characterized, Wnt-11 can activate PKC and JNK (Flaherty et al. 
2008) and CREB family members (Zhou et al. 2007) and inhibit β-catenin dependent 
signaling (Railo et al. 2008; Maye et al. 2004). 
8.1 Wnt-11 in development 
Wnt-11 is best known for its role during embryonic development (Lako et al. 1998; 
Majumdar et al. 2003). In fact, Wnt-11 was shown to promote convergent extension 
movements during zebrafish gastrulation (Heisenberg et al. 2000) as well as to increase 
cell contact persistence to coordinate cell movements during gastrulation through 
accumulation of FZD7 on adjacent sites of cell contacts (Witzel et al. 2006). The 
involvement of Wnt-11 in convergence and extension movements has been reported to 
implicate its binding to ROR2 (Bai et al. 2014). 
Wnt-11 was also involved in axis formation in Xenopus embryos (Tao et al. 2005). As 
previously described in zebrafish, later studies in Xenopus also showed that Wnt-11 
induces accumulation of FZD7 at apical adherens junctions, together with polarized 
accumulation of Disheveled (Yamanaka & Nishida 2007). Furthermore, RYK was found 
to cooperate with FZD7 to mediate Wnt11-stimulated endocytosis of Disheveled and 
activation of the noncanonical Wnt pathway to regulate convergent extension 
movements (Kim et al. 2008). 
In mouse kidney development, Wnt11 mutation results in ureteric branching 
morphogenesis defects and consequent kidney hypoplasia in newborn mice. In this 
study, Wnt-11 cooperates in a positive autoregulatory feedback loop with Ret/Gdnf, a 
mesenchymally produced ligand that is crucial for normal ureteric branching, (Majumdar 
et al. 2003). Moreover, FZD4 and FZD8 act as Wnt-11 receptors during this process (Ye 
et al. 2011). 
The role of Wnt-11 in cardiomyocyte differentiation has also extensively described 
(Pandur et al. 2002; Flaherty et al. 2008; He et al. 2011; Abdul-Ghani et al. 2011), where 
the effects of Wnt-11 involve activation of noncanonical pathway in all cases. 
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8.2 Wnt-11 in cancer: implication in prostate cancer 
Apart from its role in development, Wnt-11 has also been linked to different types of 
cancer such as colon (Dwyer et al. 2010; Ouko et al. 2004; Nishioka et al. 2013), lung 
(Bartis et al. 2013) and prostate (Zhu et al. 2004; Dwyer et al. 2010; Uysal-Onganer et 
al. 2010), where it promotes cancer cell migration, adhesion and survival, all hallmarks 
of advanced disease. However, some controversy exists since a tumor suppressor role 
for Wnt-11 has been described in hepatocellular carcinoma, where it reduces cell 
migration by activating Rho and inhibiting Rac (Toyama et al. 2010), and in ovarian 
cancer where Wnt-11 overexpression reduces cell migration and invasion as well as 
tumor growth and metastasis in vivo (Azimian-Zavareh et al. 2018). 
Particularly, in prostate cancer, WNT11 messenger RNA (mRNA) levels are elevated 
in a subset of high-grade prostatic tumors, in CRPC xenografts and in tumor metastases 
(Zhu et al. 2004; Uysal-Onganer et al. 2010). Inhibition of AR signaling increases 
expression of WNT11, and Wnt-11, in turn, inhibits AR-dependent transcriptional activity 
and AR-dependent proliferation (Zhu et al. 2004) and promotes prostate tumor cell 
survival, migration and invasion and neuroendocrine-like differentiation (NED) (Uysal-
Onganer et al. 2010). Moreover, Wnt-11 has been reported to be a direct target of ERG 
transcription factor (Mochmann et al. 2011; Sreenath et al. 2011; Wu et al. 2013). WNT11 
expression was also found elevated in tumors from patients receiving ADT, which 
supports its involvement in prostate cancer progression (Volante et al. 2016).    
Different FZD family receptors can interact with Wnt-11, including FZD7 in Xenopus 
(Djiane et al. 2000; Penzo-Mendèz et al. 2003; Yamanaka & Nishida 2007), FZD5 
(Cavodeassi et al. 2005) and FZD7 (Witzel et al. 2006) in zebrafish, FZD4 in 
differentiating cardiomyocytes (Abdul-Ghani et al. 2011; Ye et al. 2011) and FZD4 and 
FZD8 in the developing kidney (Ye et al. 2011). Given the known complexity of Wnt 
signaling, it is likely that the Wnt-11-receptor signaling will be determined not only by the 
specific member(s) of the FZD family involved, but also by cell context and the pool of 
other receptors expressed (Grumolato et al. 2010; Niehrs 2012).  
Even though some Wnt receptors have been implicated in prostate cancer 
progression (see 6.1 Wnt alterations in prostate cancer), the specific receptors that 
transduce Wnt-11 signals in prostate cancer still remain unknown and their identification 
may provide novel therapeutic targets for this disease. 
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Previous results from Dr.Kypta´s group demonstrated that Wnt-11 was elevated in a 
subset of high-grade prostatic tumors, in CRPC xenografts and in tumor metastases (Zhu 
et al. 2004; Uysal-Onganer et al. 2010). Moreover, Wnt-11 was found to promote 
prostate cancer cell migration and invasion (Uysal-Onganer et al. 2010), both hallmarks 
of advance disease. Independent studies also reported that WNT11 was highly 
expressed in tumors from patients receiving ADT which supports its involvement in 
prostate cancer progression (Volante et al. 2016). 
Since Wnt-11 receptors in prostate cancer are not known, we hypothesize that 
identifying and characterizing the receptors that mediate Wnt-11 migration and invasion 
in prostate cancer cells could represent potential therapeutic target to treat this disease.  
Based on this knowledge, the main aims of the project are to identify Wnt-11 receptors 
in metastatic prostate cancer and characterize their requirement for the pathway and 
their functional effects on prostate cancer progression. 
The specific aims of the project are: 
a) To identify highly expressed Wnt receptors in metastatic prostate cancer through 
screening analysis in a panel of prostate cancer cell lines as well as through in 
silico profiling in prostate tumors. 
b) To characterize the Wnt-11/receptor signaling pathway through evaluation of 
canonical/noncanonical reporters, study of target genes as well as the analysis 
of Wnt-11/receptor interaction and localization. 
c) To evaluate the functional effects of Wnt-11 receptors driving prostate cancer cell 
invasion and metastasis through in vitro and in vivo models. 
d) To characterize the molecular mechanism underlying Wnt-11/receptor signaling 
in prostate cancer cells. 
e) To analyze the potential relevance of Wnt-11 receptors as biomarkers for 
prostate cancer progression as well as their potential use as therapeutic targets. 
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1. Cell culture  
The prostate cancer cell lines LNCaP, PC-3 and VCaP were from the American Type 
Culture Collection (ATCC) as were human embryonic kidney HEK293T cells. PC-3M 
cells were provided by Scott Fraser and Mustafa Djamgoz (Imperial College London), 
LNCaP and C4-2B cells were from Charlotte Bevan (Imperial College London) and 
DU145 cells were from John Masters (University College London) and Magali Williamson 
(Kings College London). Cell lines were authenticated by DNA profiling (Eurofins 
Genomics, Germany) and cells were routinely tested for mycoplasma. Low passage cell 
stocks were cultured for up to six months after thawing. LNCaP, C4-2B, PC3, PC-3M 
and DU145 cells were cultured at 37˚C, 5% CO2 in RPMI-1640 with GlutaMAX™ 
(Invitrogen) supplemented with 10% fetal bovine serum (FBS; First Link, UK) and 
antibiotics (100 units/mL penicillin, 100 μg/mL streptomycin, Invitrogen, UK). For some 
experiments LNCaP cells were cultured in medium containing 5% charcoal-stripped 
serum (CSS, First Link, UK) for 3 or 6 days. VCaP cells were cultured in DMEM/Ham´s 
F12, 10% FBS, antibiotics, 0.5% sodium pyruvate and 1.5 mM glutamine. HEK293T cells 
were cultured in DMEM, 10% FBS and antibiotics. For transfections, cells were cultured 
in OptiMEM (Gibco). The main features of the used prostate cancer cell lines are 
summarized in Table 2.  
Cell line First isolation Hormone 
status 
AR PSA Other markers 
LNCaP Lymph node 
metastatic 
prostate 
adenocarcinoma 
(1980) 
Androgen 
dependent 
Positive Positive p53 wild type/PTEN 
negative 
LNCaP 
C4-2B 
Subline of 
LNCaP mouse 
xenografts (1994) 
Androgen 
independent 
Positive Positive Low levels of p53 
/PTEN negative 
VCaP Vertebral 
metastatic lesion 
(2001) 
Androgen 
dependent 
Positive Positive p53 mutation/ PTEN 
positive/TMPRSS2-
ERG gene 
rearrangement 
PC-3 Vertebral 
metastatic 
prostate tumor  
(1979) 
Androgen 
independent 
Negative Negative p53 deletion/PTEN 
negative 
PC-3M Subline of PC-3 
mouse 
xenografts 
Androgen 
independent 
Negative Negative p53 deletion/PTEN 
negative 
DU145 Brain metastatic 
prostate tumor 
(1975) 
Androgen 
independent 
Negative Negative p53 mutation 
P53/PTEN positive 
Table 2. Characteristics of the prostate cancer cell lines.  
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2. Compounds 
TGF-β1 (R&D Systems) was added in gene reporter assays at a concentration of 0.1 
or 1 ng/mL 4 h after transfection of reporter and incubated for 24 h. For q-RT-PCR 
analysis, cells were treated with 1 ng/mL TGF-β for 24 h. For evaluation of TGF-β-
induced Smad phosphorylation, 1 ng/mL TGF-β was added to cells 48 h after silencing 
for 30 min. Inhibitor 1 (3235-0367) and 2 (2124-0331) from the ChemDiv library (Lee et 
al. 2015) were used in migration experiments at 10 μM for 24 h. For miniaturized 
tridimensional (3D) cultures and the chicken chorioallantoic membrane (CAM) assays, 
phenol red free matrigel (BD Biosciences, Vantaa, Finland) was used at a concentration 
of 8 ng/mL. 
3. Plasmids and siRNAs 
Different plasmids were used in this work which are described in Table 3.  
Plasmid Source Reference 
pcDNA Wnt-11  (Uysal-Onganer et al. 
2010) 
PA-Wnt11 Junichi Takagi (Mihara et al. 2016) 
pRL-Tk Promega  
Super8XTOP/FOPFlash Randall Moon (Addgene Plasmid 
#12456) 
(M. Veeman et al. 2003) 
AP-1-luc  (Vivanco et al. 1995) 
CAGA12-luc  (Dennler et al. 1998) 
ATF2-luc Christof Niehrs  (van der Sanden et al. 
2004) 
pRK5 mFzd1-10-1D4 Chris Garcia and Jeremy Nathans 
(Addgene #42263-42272).  
(Yu H, Ye X, Guo N 
2012) 
CMV500  Charles Vinson (Addgene #33348) (Rishi et al. 2004) 
CMV500 Δ-ATF2  Charles Vinson (Addgene #33362) (Rishi et al. 2004) 
3TP-lux Joan Massagué and Jeff Wrana 
(Addgene #11767) 
(Wrana et al. 1992) 
HA-FZD8  Jeffrey Rubin   
pRK5 TGFRI-Flag Rik Derynck (Addgene #14831) (Feng & Derynck 1996) 
pCMV5B TGFRII wild-type 
(N-term HA) 
Jeff Wrana (Addgene #24801)  
pRK5 mFz8CRD IgG  Xi He (Addgene #16689) (Semenov et al. 2001) 
pCS2 LRP6N-IgG Xi He (Addgene #27279)  (Tamai et al. 2000) 
pRK5-Flag-ALK5-HA (ecto)  Rik Derynck (Addgene #31720)  
Flag-SMAD3 Wei Cui  
HA-ATF2 Pedro Lazo  
Table 3. List of plasmids used in this study. 
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SMARTpool siRNAs were purchased from Dharmacon, ThermoFisher and dsiRNA 
from Integrative DNA Technologies (IDT, Leuven Belgium). The siRNAs and dsiRNA 
used are listed in Table 4. 
Distributor siRNA 
/dsiRNA 
Sequence 5´3 siRNA /dsiRNA 
Concentration (nM) 
SMARTpool 
(Dharmacon, Thermo 
Fisher) 
FZD2 CCACGUACUUGGUAGACAU 25-50 
    GAACUGCGCUUCUUCCUGU  
    GGAGGAAGUUCUACACUCG  
    GCUACAAGUUUCUGGGCGA  
SMARTpool 
(Dharmacon, Thermo 
Fisher) 
FZD3 CCAAAUACUCCUAUCAUAA 25-50 
    ACAGAUCACUCCAGGCAUA  
    GUUCGAAGCUCAUGGAGAU  
    UGAUUGAUGUCACAAGAUU  
SMARTpool 
(Dharmacon, Thermo 
Fisher) 
FZD4 GAUCGAUUCUUCUAGGUUU 25-50 
    UCACACCGCUCAUCCAGUA  
    GGACAAAGACAGACAAGUU  
    CCAAGGAGUUCACUGAUAU  
SMARTpool 
(Dharmacon, Thermo 
Fisher) 
FZD5 GCAUUGUGGUGGCCUGCUA 25-50 
    GCACAUGCCCAACCAGUUC  
    AAAUCACGGUGCCCAUGUG   
    GAUCCGCAUCGGCAUCUUC  
SMARTpool 
(Dharmacon, Thermo 
Fisher) 
FZD8 AGACAGGCCAGAUCGCUAA 25-50 
    ACACCUACAUGCCCAAUCA  
    UCACCGUGCCGCUGUGUAA  
    CGGCGAGCUCCGUGUCUUA  
Integrated DNA 
Techonologies (IDT) 
dsiFZD8 rArGrCrUrCrCrGrUrGrUrCrUr
UrArUrCrCrArArArGrCrAGA 
25-50 
  rUrCrUrGrCrUrUrUrGrGrArUr
ArArGrArCrArCrGrGrArGrCrU
CG 
 
Table 4. Table summarizing the siRNAs and dsiRNA used in this study. 
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4. RNA analysis 
4.1 RNA extraction and cDNA synthesis 
  Total cellular RNA from prostate cancer cells was extracted using TRIzol (Invitrogen 
Life Technologies, Burlington, ON) according to the manufacturer’s protocol. For the 
silencing experiments, RNA was extracted using illustra™ RNAspin Mini Isolation Kit 
(GE Healthcare). DNAse treatment was performed on columns, as instructed by 
manufacturer. In both cases, the concentration and purity of RNA samples was 
determined by the spectrophotometric measurement of the absorbance at 260nm and 
280nm using ND-1000 spectrophotometer (NanoDrop Technologies). In general, 2 μg of 
total RNA was used for cDNA synthesis using M-MLV Reverse Transcriptase and RNase 
OUT Ribonuclease Inhibitor (Invitrogen), according to manufacturer’s instructions. 
Amounts of reagents for cDNA synthesis of one sample are described in Table 5 and 
they were scaled up as necessary. 
Reagent Stock concentration Final concentration Volume 
(ul) 
Ramdon primers (Life 
technologies) 
100ng/μL 5 ng/μL 2 
dNTP mix (Bioline) 10mM (2,5mM each) 1 mM (250 uM/each) 4 
5X First Strand Buffer 
(Invitrogen) 
5X 1X 8 
DTT (Invitrogen) 0,1M 5mM 2 
M-MLV-Reverse transcriptase 
(Life Technologies) 
200U/μL 5,U/μL 1 
RNAse OUT (Life 
Technologies) 
40UμL 1U/μL 1 
RNA+ H20 (Sigma) Variable Variable 22 
Table 5. Protocol for the retro-transcription procedure. Original and final concentrations are 
described. 
4.2 Primer design and setup 
Primers were designed using the Primer-BLAST tool 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/) aiming to detect as many genetic 
isoforms as possible targeting a unique sequence for each gene of 80-150bp. When 
possible, primers were separated by an intron to avoid genomic DNA amplification. 
Melting temperature about 61-63ºC, minimum self-complementarity, GC content 
between 30-55% and minimum differences between forward and reverse melting 
temperature were stablished as optimal parameters in order to obtain high efficient 
primers.  
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The USC Genome Browser (https://genome.ucsc.edu/) was used to double-check 
that the designed primers were amplifying the target genes. After that, primer 
amplification efficiency was tested by serial dilution of cDNA (1X, 0.5X, 0.2X, 0.1X, 
0.05X) and standard Curve analysis using the ∆∆CT method. Amplicons were run on 
agarose gels to confirm their correct size. 
4.3 Quantitative Real-Time PCR  
   Quantitative-PCR was performed using PerfeCTa SYBR® Green Supermix, Low 
Rox (Quanta, Barcelona, Spain) in a Viia7 Real-Time PCR System (Applied Biosystems, 
Madrid, Spain) with the following conditions: Taq polymerase activation 95°C 3 min, 
denaturation 95°C 15 sec, annealing/extension 62°C 1 min, melting curve 95ºC 15 sec, 
60˚C 1 min, 95˚C 15 sec, 40 cycles. All reactions were done in a final volume of 6μL (5μL 
of mix and 1μL cDNA). Relative levels of mRNA were determined according to the ∆∆CT 
quantification method, relative to the housekeeping gene 36B4. The primers used are 
listed in Table 6.  
Primer Sequence 5-->3´ Primer concentration (nM) 
FZD1 F CATTCTCTAGTGTCTAAAACCT 300 
FZD1 R TAACATTTTATAACCCATATCTTC 300 
FZD2 F ATTCGCTGCACCAAGTGCTTC 300 
FZD2 R CGAATGCTTCCCCTAGACATGA 300 
FZD3 F TGATGGCTCTCATAGTTGGCA  300 
FZD3 R ACCTGTCGGCTCTCATTCAC  300 
FZD4 F GACAACTTTCACACCGCTCA 900 
FZD4 R TCTTCTCTGTGCACATTGGC 900 
FZD5 F GTACCCAGCCTGTCGCTAAA 300 
FZD5 R CCGAGAAGAGCAGACAGTCC 300 
FZD6 F TCCCAGATGTATGAAAATGGC 900 
FZD6 R CCAGATTTGCGAGAGGAAGA 900 
FZD7 F GCCTCTGTTCGTCTACCTC 300 
FZD7 R GTCGTGTTTCATGATGGTGC 300 
FZD8 F GCTCTACAACCGCGTCAAGA 900 
FZD8 R GCTGAAAAAGGGGTTGTGGC 900 
FZD9 F TGGCGGTCTTCATGCTCAAA 300 
FZD9 R TATCTTGCGGTAGCACAGGC 300 
FZD10 F CCGCCTCACACCCCAGTGGAT 300 
FZD10 R TTCTGTCTTGCAGAGAGACTATT 300 
VANGL1 F GCTTCTACAGCCTGGGACAC 300 
VANGL1 R GCTCGGAATTTGGAGGCTGT 300 
VANGL2 F AAGTCGGGCCACTCCCGCAG 300 
VANGL2 R CCCATCTCGACTCTTAGAGC 300 
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ROR1 F AAAGAGCTACCTCTTTCTGCTGTACG 300 
ROR1 R CTTCTTGTTGAAATTCCGTCCATTG 900 
ROR2 F GGCAGAACCCATCCTCGTG 300 
ROR2 R CGACTGCGAATCCAGGACC 300 
RYK F TCTCTACCTGAGCGAGGACG 300 
RYK R CCAGGTGAAGTGCAGGAAAT 300 
PTK7 F GTTGCCTCTGCTCAGCGT 300 
PTK7 R CCCTGCAGTGCATCCTG 300 
LGR4 F GGCCTTGTCTGGGTTGAAAG  300 
LGR4 R CAAAGCACTCAGCCCTCGAA  300 
LGR5 F GGGAGCATTCACTGGCCTTTA 300 
LGR5 R TCCAGACGCAGGGATTGAAG 300 
LRP4 F GGTCTTGGTCAGCCATGTGT 300 
LRP4 R ACACGCTGGATTGACTTGGT 300 
LRP5 F AAGAGGAAGGAGATCCTGAGTG 300 
LRP5 R ATTGTCCTCCTCACAGCGAGT 300 
LRP6 F TGAGGGTCTGCGTGAAATCC 300 
LRP6 R TGGGAACAACCCCCATTGTC 300 
GPC4 F TCGTGACTGTGAAGCCATGT 300 
GPC4 R TCTAGCCTCTCTGCCACCAT 300 
MuSK F CCCACCATCACCTGGATTGAA 300 
MuSK R TGTGTAGAGTCCTGGCTTGG 300 
WNT11 F AGACCGGCGTGTGCTATG 900 
WNT11 R CACCTGTGCAGACACCAGAC 900 
ATF2 F AGTCCTTTACCTCACCCAGAGT 300 
ATF2 R GATGTGGGCTGTGCAGTTTG 300 
JUN F TGAGTGACCGCGACTTTTCA 300 
JUN R TTAAGATGCCTCCCGCACTC 300 
CREB F AGCCCAGCCACAGATTGCCAC 300 
CREB R  GTTACGGTGGGAGCAGATGAT 300 
AXIN2 F AAGTGCAAACTTTCGCCAAC 300 
AXIN2 R ACAGGATCGCTCCTCTTGAA 300 
CDH1 F AGCAGAACTAACACACGGGG 600 
CDH1 R ACCCACCTCTAAGGCCATCT 600 
CLDN1 F CTGTCATTGGGGGTGCGATA 600 
CLDN1 R CTGGCATTGACTGGGGTCAT 600 
CDH2 F CATGAAGGACAGCCTCTTCTCAA 300 
CDH2 R GCTTCTCACGGCATACACCAT 300 
VIM F GCTTCAGAGAGAGGAAGCCG 600 
VIM R AAGGTCAAGACGTGCCAGAG 600 
SNAI F CCCTGGCTGCTACAAGGC 600 
SNAI R TGAGTGGGTCTGGAGGTGG 600 
SNAI2 F GCCAAACTACAGCGAACTGG 300 
SNAI2 R AGTGATGGGGCTGTATGCTC 300 
TWIST1 F GCCACTGAAAGGAAAGGCATC 600 
TWIST1 R TGGTTTTGCAGGCCAGTTTG 600 
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ZEB1 F AAGAATTCACAGTGGAGAGAAGCCA 300 
ZEB1 R CGTTTCTTGCAGTTTGGGCATT 300 
MMP9 F TTGGTCCACCTGGTTCAACT 300 
MMP9 R TCAACTTGGTCCACCTGGTT 300 
PAI1 F CAATCGCAAGGCACCTCTGA 600 
PAI1 R TTCACCAAAGACAAGGGCCA 600 
TGF1 F TGTCACCGGAGTTGTGCGGC 300 
TGF1 R GCAGTGGGCGCTAAGGCGAA 300 
TGFRI F GAAAGTGGCGGGGAGAAGAA 600 
TGFRI R AATCTCTGCCTCACGGAACC 600 
TGFRII F TCCTGAAGACGGCTCCCTAA 600 
TGFRII R GTTCTTTGGTGAGAGGGGCA 600 
SMAD2 F AACCGAAATGCCACGGTAGA 600 
SMAD2 R GCACTCAGCAAAAACTTCCCC 600 
SMAD3 F GAAACTCAAGAAGACGGGGCAG 900 
SMAD3 R CGATGGGACACCTGCAACC 900 
36B4 F GTGTTCGACAATGGCAGCAT 300 
36B4 R AGACACTGGCAACATTGCGGA 300 
Table 6. List of primers used in this study. Sequences and concentrations are described. 
5. Cell transfection and silencing 
  Cells were plated 24 h before transfection to be 70-80% confluent at the moment of 
transfection. Lipofectamine LTX with PLUS reagents (LifeTechnologies), were used for 
cell transfection as instructed by the manufacturer. Briefly, OptiMEM was added to the 
cells after a previous OptiMEM wash to remove antibiotics. After that, the required 
plasmids and Plus reagent were incubated in OptiMEM for 15 min and Lipofectamine 
LTX was also individually incubated in OptiMEM for 5 min. Mixing of both DNA/lipid mixes 
was done in 1:1 ratio and further incubated together for 15 min. DNA-lipid mix was then 
added to the cells and transfection analyzed after 24 h. DNA/LTX/Plus amounts are 
summarized in Table 7.  
Plate Experiment DNA/well (ng) LTX/well (μL) Plus/well (μL) 
24 well Immunofluorescence 250 0,75 0,25 
12 well Gene Reporter 500 1,5 0,5 
6 cm Immunoprecipitation 2500 4,5 1,5 
Table 7. Protocol for cell transfection. The reagent amounts used in cell transfections in 
different types of experiments are indicated. 
 For silencing experiments, 24 h before transfection, cells were plated to be 60% 
confluent at transfection. RNAimax (Invitrogen) was used for cell silencing as instructed 
by the manufacturer. Briefly, OptiMEM was added to the cells after a previous OptiMEM 
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wash to remove antibiotics. After that, siRNA or dsiRNAs (Table 3) were incubated in 
OptiMEM to be at a final concentration in the well of 25 or 50 nM, depending of the gene. 
RNAimax was mixed with OptiMEM and then the RNA/lipid was mixed in a 1:1 ratio and 
incubated for 5 min. DNA-lipid complexes were then added to the cells and silencing was 
evaluated after 48 h.  
 In both cases, cell transfection and silencing, fresh media were added to the cells 4h 
after transfection.  
6. Generation of stable knockdown cells 
For stable knockdown of FZD8, lentiviral pLKO and shFZD8 constructs (TRC 
Lentiviral Human shRNA, RHS4533, Dharmacon) were used. For generation of 
lentiviruses, two cell cell lines were used: a packaging cell line (HEK293T) and the target 
cell line in which the transgene wants to be knocked down (PC-3M).  
The general protocol for lentivirus infection is performed in different steps (Fig. 27): 
 Day 1: 
- Morning: Packaging cells were seeded at high density (2x106 cells/100mm 
plate) 
- Afternoon: Packaging cells were transfected. 
 Day 2: Packaging cells media was changed to fresh culture media and the target 
cell line was seeded. 
 Day 3: Target cells were first infected with virus containing supernatant from 
packaging cells. For this, 7 mL of supernatant from packaging cells was filtered 
with 0.45 μm filters and 3 mL of fresh media were added to a total of 10 mL. 
Protamine sulfate was added to the mixture (1:1000 dilution) to increase infection 
efficiency. After infection, fresh media was added to packaging cells for further 
virus production. 
 Day 4: A second infection of target cells was performed with virus containing 
supernatant and the packaging cells were discarded.  
 Day 5: Target cells were subjected to selection with puromycin at 2 μg/mL and 
the efficiency of FZD8 knockdown was evaluated by q-RT-PCR.  
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Figure 27. Schematic process for the generation of stable knockdown cells. 
HEK293T cell transfections were performed using 5 ug of pLKO and shFZD8 
constructs together with 2.5 μg of psPAX2 (provides integrase, reverse transcriptase and 
structural proteins) and 2.5 μg of VSV-G (provides the envelope proteins) (Fig. 28). 50 
μL of calcium chloride (CaCl2) per condition were added in a final volume of 500 μL. The 
DNA solution was mixed with 500 μL of HEPES-buffered solution (HBS) (50 mM HEPES, 
280 mM NaCl, 10 mM KCl,1.5mM Na2HPO4.2H2O, 12 mM dextrose, pH=7.05) in the 
presence of oxygen by making bubbles to favor the formation of calcium phosphate 
crystals. 
 
Figure 28. Schematic of lentivirus generation in HEK293T cell. 
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7. Gene reporter assays 
Gene reporter assays have been widely used in order to measure the expression of 
genes of interest at the transcriptional level. They are based on the direct fusion between 
the promoter of the gene of interest with specific firefly reporters. Luciferase reporter 
(firefly) from Photinus pyralis is one of the most widely used reporters due to the rapid 
production of light when combined with the substrate luciferin, which can be measured 
through luminescence (Yun & DasGupta 2015). This assay is complemented with the 
use of the renilla reporter from Renilla reniformis, which is expressed under the control 
of a constitutive promoter working as an internal control for normalization of transfected 
cell number (Yun & DasGupta 2015) (Fig. 29). 
 
Figure 29. Basis of gene reporter assays. (A) Chemical reactions of Luciferase and Renilla. 
(B) Schematic illustration of gene reporter assays.  
In our gene reporter assays, 100,000 (C4-2B) or 80,000 (PC-3M and DU145) cells 
per well were plated in 12-well plates. Transfections were normally carried in triplicate 
wells 24 h after plating. Cells were transfected with 250 ng of ATF2/AP-1/TOP/FOP 
luciferase reporters, 50 ng of Renilla (pRL-tk) and 200 ng empty vector or Wnt-11 
plasmid. For CAGA luciferase analysis, cells were transfected with 450 ng of CAGA 
reporter and 50 ng pRL-tk. When FZD plasmids were co-transfected, 150 ng of ATF2 
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luciferase reporter was used together with 50/100 ng of FZD plasmid.  In experiments 
involving gene silencing, reporters and other plasmids were transfected 24 h after 
siRNAs.  
24 h after transfection of reporters, cells were washed twice with PBS (Phosphate 
buffered saline) and lysed in 150 μL per well of Passive Lysis Buffer (Promega). Lysates 
were shaken at room temperature (RT) for 10 min and then frozen at -80ºC for 20 min to 
facilitate lysis. After that, lysates were collected and centrifuged at 15,000 g for 5 min. 
Two different Luciferase Assay System were used. When the Dual Glo Luciferase Assay 
Systems (Promega) was used, 50 μL of lysate was added to white luminometer plates 
(PerkinElmer) and 50 μL of luciferase reagent was added on top. After 10 min of 
incubation, luciferase activity was measured using a Veritas microplate luminometer 
(Turner biosystems). After this measurement, 50 μL of renilla reagent (substrate: buffer; 
1:100) was added on top. After 10 min incubation, Renilla activity was measured. When 
the Luciferase Assay Kit (PJK, Germany) was used, 30 μl of lysate was added to white 
luminometer plates and 80 μL of luciferase PJK was added on top. In different wells, 25 
μL of lysate was also plated and 25 μL of Renilla (substrate: buffer; 1:50) was added. 
After 5 min of incubation at RT, luciferase activity was measured. In both cases, gene 
reporter activities were calculated as luciferase/renilla and TOP/FOP ratios when 
required.  
8. Cell migration and invasion assays 
For migration and invasion assays, 250,000 PC-3M or DU145 cells per well were 
plated in 6-well plates and transfected with control and FZD8 siRNA for 48 h. Afterwards, 
cells were trypsinized and resuspended in RPMI with 1% FBS and 50,000 cells/well were 
added to duplicate uncoated or Matrigel-coated 8 µm pore transwell filters with a 
polycarbonate membrane (BD Biosciences) for migration and invasion assays, 
respectively (Fig. 30). When the effects of inhibitors 1 and 2 (I1, I2) were tested, DMSO 
or inhibitors were added at 10 µM to 50,000 cells/well on uncoated 8 µm pore transwell 
filters for migration assays. For TGF--dependent invasion assays, siRNA-transfected 
cells were cultured overnight in media with 0.2% FBS and then treated with 5 ng/mL 
TGF-1 for 24 h. Cells were then trypsinized and resuspended in media containing 0.2% 
FBS and 5 ng/mL TGF-1. 50,000 cells/well were added to Matrigel-coated 8 µm pore 
transwell filters. In all cases, inserts were set in 24-well plates with media containing 20% 
FBS in the lower chamber. As a control for cell viability, cells were plated in parallel at 
the same density in 24-well plates. 
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 Migration and invasion were evaluated after 24 and 48 h, respectively. Non-
migrating/invading cells were removed using a cotton swab and migrating/invading cells 
retained in the polycarbonate membrane of the insert were stained using 0.1% crystal 
violet, 20% methanol, 0.36% para-formaldehyde (PFA) in PBS (Fig. 30). After that, 
pictures were taken of 5 different fields of the insert and the average numbers of 
migrating/invading cells per insert was determined by counting stained cells. The control 
plate was also stained using crystal violet and absorbance measured at 595 nm after 
solubilizing in methanol. These data were then used to normalize the numbers of 
migrating/invading cells to the numbers of viable cells. Results were shown as relative 
cell migration/invasion. 
 
Figure 30. Schematic diagram for migration and invasion assays. 
9. Protein analysis 
9.1 Protein extraction  
For total cell extracts, cells were lysed for 10 min in radioimmunoprecipitation assay 
(RIPA) lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 1% 
NP-40, 1 mM EDTA (Millipore)) with cOmplete™ Mini EDTA-free Protease Inhibitor 
Cocktail (Roche), PhosSTOP Phosphatase Inhibitor Cocktail Tablets (Roche) and 0.1% 
sodium dodecyl sulfate (SDS) (LifeTechnologies) and then centrifuged for 12 min at 
15,000 g. Supernatants were combined with 2X Laemmli buffer (Sigma) and heated at 
37ºC or 95ºC for 10 or 5 min, respectively, depending on the assay. Remaining extracts 
were store at -80ºC. 
9.2 Western blotting (WB) 
   After protein sample preparation, extracts were separated on SDS polyacrylamide gels 
using a Mini Protean System (BioRad). Gels were prepared as shown in Table 8, 
adjusting for gel percentage according to target protein size. 
Cells
Media 20%FBS
Media 0,2-1%FBSPolycarbonate 8 μm
membrane (+/- matrigel) Crystal violet (CV) solution
24-48h
Cells in upper 
chamber
Migrating cells pass 
through the membrane
Non migrating cells 
are removed
Migrating cells are 
stained with CV
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Reagent Volume (ml) 8% 
resolving gel 
Volume (ml) 
stacking gel 
H20 2.3 0.68 
30% Acrylamide (Sigma) 1.3 0.17 
1.5M Tris (pH 8,8) 1.3  
1.5M Tris (pH 6,8)  0.13 
10% Sodium dodecyl sulphate (SDS) (Gibco) 0.05 0.01 
10% Ammonium persulfate (APS) (Sigma) 0.05 0.01 
TEMED (Sigma) 0.003 0.002 
Table 8. Protocol for the preparation of acrylamide gels for WB. 
Gels were run at 15 mA/gel for 1,5-2h and transferred to nitrocellulose 0.2 μm pore 
size (Millipore) at 10-12V for 30-40 min using a semi-dry transfer cell (BioRad). 
PageRulerTM Plus Prestained Protein Ladder (Thermo Scientific) was used as protein 
size marker with a range of 250-10 kDa. Membranes were washed with TBST (Tris-
buffered saline 0.05% Tween (Sigma)) and incubated in blocking buffer containing 3% 
BSA (Bovine serum albumin, Sigma) in TBST for 1h. 
Primary antibodies (Table 9) were incubated with blots at 4º C overnight. After 3-4 
TBST washes, blots were incubated for 1h at RT in blocking buffer with HRP-conjugated 
secondary antibodies (1: 20,000, Jackson ImmunoResearch). Membranes were washed 
again 3-4 times with TBST and then developed using chemiluminescence (Amersham 
ECL western blotting detection reagents, GE Healthcare). 
Antigen Company Catalog number Species Concentration 
pSMAD2 Cell Signaling 138D4 Rabbit 1:1000 
pSMAD3 Abcam ab52903 Rabbit 1:2000 
SMAD2/3 Santa Cruz sc-133098 Rabbit 1:1000 
PA tag  Novus Biological NBP-03952 Rat 1:1000 
1D4 tag Santa Cruz sc-57432 Mouse 1:2000 
HA tag Santa Cruz sc-805 Rabbit 1:1000 
Flag tag Sigma-Aldrich F1804 Mouse 1:1000 
FZD8 LS Bio LS-C120599 Rabbit 1:2000 
IgG GenScript A00166 Human 1:5000 
Wnt-11 RyD AF2647 Goat 1:2000 
N-cadherin Santa Cruz sc-393933 Mouse 1:500 
Vimentin Santa Cruz sc-373717 Mouse 1:500 
Claudin-1 Santa Cruz sc-166338 Mouse 1:500 
-Tubulin Sigma-Aldrich T5293 Mouse 1:5000 
GAPDH SIGMA G8795 Mouse 1:2000 
Table 9. List of antibodies used in WB assays. 
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9.3 Immunoprecipitation (IP) 
For immunoprecipitation (IP) assays, 500,000 PC-3M cells were plated in 6 cm plates 
and transfected with 2.5 ug of total DNA (1:2 ratio for FZD8-1D4: Wnt-11-PA, FZD8-1D4: 
TGFRI-Flag/HA-TGFRII, FZD8-CRD-IgG: TGFRI-Flag/HA-TGFRII and FZD8-CRD-
IgG: Flag-ALK5-HA(ecto)). After 24 h, cells were washed twice with PBS and lysed in 1 
mL of IP lysis buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA 
with cOmplete™ EDTA-free Protease Inhibitor Cocktail and PhosSTOP Phosphatase 
Inhibitor Cocktail Tablets) for 5 min on ice. Samples were then centrifuged at 4ºC for 12 
min at 15,000 g. For inputs, 50 μL of supernatant was combined with 2x Laemmli Buffer 
and heated for 10 min at 37 °C (this temperature was used to reduce FZD aggregation) 
or stored at -80 °C. For IPs, supernatants were incubated for 90 min on ice with 1 μg of 
antibody (anti-PA or anti-1D4). Protein A/G PLUS-Agarose (Santa Cruz) was add to each 
sample and incubated for 1 h on a rotating wheel at 4 °C. For fusion proteins, 
immunoprecipitation was performed without antibody incubation. IPs were then collected 
by centrifugation at 500 g for 30 sec. Pellets were washed three times with IP buffer and 
once with ice-cold TBS. After washes, samples were resuspended in 15 μL of 2X 
Laemmli Buffer and heated for 10 min at 37 °C. Western blotting was performed as 
described above. Primary antibodies used for blotting are listed in Table 9.  
10. Immunofluorescence 
   For immunofluorescence assays, PC-3M cells were plated on coverslips at 40,000 
cells per well in a 24-well plate. 24 h after plating, cells were transfected with 170 ng 
Wnt-11 and 80/40 ng FZDs plasmids depending on the FZD construct. The following 
day, cells were fixed in 4% PFA in PBS (Santa Cruz) for 20 min at RT and permeabilized 
using 0.1% Triton X-100 in PBS for 10 min at RT. Blocking was performed using 2% 
BSA, 50 mM glycine, 0.01% NaN3 in PBS for 40 min to 1 h. Primary antibodies (Table 
10) were added overnight at 4˚C. Coverslips were washed three times with PBS and 
secondary antibodies were prepared in blocking buffer at 1:500 (AlexaFluor488, 
AlexaFluor594, AlexaFluor647, Life Technologies) and incubated for 1h at RT. After 
three washes with PBS, coverslips were mounted using Vectashield mounting medium 
with DAPI (Vector Labs). Stained cells were visualized using a confocal microscope 
(Leica TCS SP2) with a 63x oil immersion objective. For analysis of colocalization, 10 
cells from two independent experiments were quantified using Image J and the Coloc 2 
plug-in and Pearson's correlation coefficient determined. 
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   When immunofluorescence was performed on miniaturized 3D cultures the 
corresponding wells from the 96 well Angiogenesis μ-slides plate (Ibidi GmbH, 
Martinsried, Germany) were fixed in 4% PFA in PBS for 30 min and washed three times 
with cold PBS. Permeabilization was performed with 1% Triton X-100 (Sigma-Aldrich) 
and blocking in 20% horse serum for 45 min at RT. Primary antibodies (Table 10) were 
also added overnight at 4ºC. Vimentin staining was used to visualize invasive and 
mesenchymal structures and anti-laminin-a1 was used to stain the basal membrane of 
non-differentiated structures.  Secondary antibodies (AlexaFluor® 488 and 568 (Life 
Technologies)) were added at 1:500 for 1h at RT. Nuclei were stained with Draq5 
(Thermo Fisher Scientific). Images were taken with a Zeiss LSM780 laser scanning 
confocal microscope, using a 20x objective.  
Antigen Company Catalog 
number 
Species Application Concentration 
1D4 tag Santa Cruz sc-57432 Mouse IF 1:200 
HA tag Santa Cruz sc-805 Rabbit IF 1:200 
Flag tag Sigma-Aldrich F1804 Mouse IF 1:200 
Wnt-11 RyD AF2647 Goat IF 1:50 
FZD8 LS Bio LS-
C120599 
Rabbit IF 1:50 
Vimentin Abcam Ab16700 Rabbit IF 1:100 
Laminin-a1 Santa Cruz Sc-59849 Mouse IF 1:100 
Table 10. List of antibodies used for immunofluorescence experiments. 
11. Clinical samples 
Tissue arrays (TMAs) were generated at the Imperial College Experimental Cancer 
Medicine Centre (ECMC) using tissue from surgical resections from 99 prostate cancer 
patients provided by the Imperial College Healthcare NHS Trust Tissue Bank (ICHTB; 
project R15043), which is supported by the National Institute for Health Research (NIHR) 
Biomedical Research Centre, based at Imperial College Healthcare NHS Trust and 
Imperial College London. The clinical characteristics of the patients are summarized in 
Table 11. Other investigators may have received samples from these same tissues. 
TMAs contained two cores from regions containing cancer and two cores from regions 
without cancer from each patient. A histopathologist (James Carton) examined 
representative haematoxylin and eosin-stained sections to evaluate their pathology. Nine 
cores did not contain cancer and three showed low quality staining or loss of sample and 
were not analyzed further. The staining intensities of FZD8 and Wnt-11 were scored 
independently by two people (Virginia Murillo and Robert Kypta) and divergences in 
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scores were re-evaluated until consent was found. Each core was scored based on the 
staining intensity as 0 (no staining), 1 (weak staining), 2 (moderate staining) or 3 (strong 
staining). 
Characteristic 
Number of 
patients 
Gleason (patients)   
3 + 3 6 
3 + 4 59 
4 + 3 27 
4 + 4 0 
4 + 5 7 
Stage  
pT2a 1 
pT2b 1 
pT2c 48 
pT3a 29 
pT3b 11 
Lymph node metastasis  
Yes 1 
No 89 
Perineural invasion  
Yes 37 
No 53 
Lymphovascular invasion  
Yes 7 
No 83 
Inflammation  
Yes 27 
No 72 
Gleason (sections analyzed)  
3 + 3 47 
3 + 4 21 
4 + 3 14 
4 + 4 7 
4 + 5 1 
No cancer 9 
Table 11. Clinical features of patients included in the TMA.  
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12. Immunohistochemistry 
Paraffin blocks containing lymph node metastases surgically removed from mice 31 
days after orthotopic implantation of 2 x 106 PC-3M-luc cells were provided by Genscript 
(Piscataway, NJ, USA). Sections from these blocks, from TMAs and from CAM sections 
were de-paraffinized with Histo-Clear II (National Diagnosis, USA) and then transferred 
through four changes of 100%, 96%, 70% ethanol and water. Antigen retrieval was 
performed in a pressure cooker filled with sodium citrate buffer at pH 6.0. Endogenous 
peroxidase activity was quenched for 10 min with 3% hydrogen peroxide. Blocking was 
performed for 15 min with Avidin followed by 15 min with Biotin (Avidin/Biotin blocking kit 
(Vector Labs). Samples were washed with PBS and blocked with 5% horse serum for 30 
min at RT to reduce nonspecific staining. After washing, primary antibodies to FZD8 (LS 
Bio, Rabbit, 1:100) and Wnt-11 (R&D, Goat, 1:100) were applied overnight at 4˚C. 
Sections were incubated with biotinylated secondary antibody (Vector Labs) for 30 min 
followed by Vectastain® Elite ABC reagent (Vector Labs) for 30 min. Liquid 3,3’- 
diaminobenzidine (DAB) (DAKO) was used as a chromogenic agent for 1-2 min and 
sections were counterstained with Mayer's haematoxylin. Images were taken on an 
AxioImager D1 light microscope. 
13. Miniaturized tridimensional (3D) assays 
Tridimensional cell cultures have emerged as a technique that allows the researcher 
to work with a cellular model that mimics the functions of living tissues (Pampaloni et al. 
2007). In this model, organotypic acinar structures named organoids are formed that 
display physiologically relevant cell-cell and cell-matrix interactions, epithelial 
polarization and differentiation, recapitulating human cancer histology in vivo (Pampaloni 
et al. 2007; Härma et al. 2010). Specifically, prostate cancer cells such as PC-3 or PC-
3M initially differentiate into hollow organoids (days 4-5) and later spontaneously de-
differentiate into invasive stellate structures (days 8-12) (Härma et al. 2010) (Fig. 31).  In 
this regard, 3D cultures represent a very useful model to study cell invasion in more 
physiological conditions. 
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Figure 31. Schematic illustration of prostate cancer cells cultured in 3D and 2D. The former 
allows organotypic organoid formation, acinar differentiation and invasion. The basement 
membrane is depicted in blue. (Adapted from Björk et al., 2016). 
13.1 Tridimensional (3D) culture and live-cell imaging 
For miniaturized 3D cultures, PC-3 and PC-3M cells were plated on 6 well plates at a 
cell density of 150,000 cells/well and the following day they were silenced with Ctrl and 
FZD8 siRNAs. 48 h after silencing, 3D cultures were set up by embedding silenced cells 
between two layers of Matrigel and culturing them for 8-9 days on uncoated 96 well 
Angiogenesis μ-slides (Ibidi GmbH, Martinsried, Germany). Wells were filled with 10 μL 
of Matrigel/culture medium (1:1) and kept at 37°C for 1 h until polymerization. Cells were 
then trypsinized and counted and 20 μL of a second layer of Matrigel (1:4) containing 
650 PC-3 and PC-3M cells per well were added on top of the well and kept at 37°C for 4 
h until polymerization. Wells were then filled up with 60 μL of medium and humidity was 
maintained by adding sterile PBS between the wells. Media were changed every second 
day.  
Live cell imaging was performed using Incucyte (Essen BioScience, Hertfordshire, 
UK), which is a flexible platform that allows real time monitoring of cell cultures through 
automatic acquisition and analysis of images around the clock. In our case, images were 
captured every two hours for 8-9 days (Fig. 32). 
For monitoring silencing efficiency during the 3D culture, silenced cells were replated 
onto 12-well plates and RNA was extracted at day 4 and day 8. Gene expression was 
analyzed by q-RT-PCR. 
Day 0 Day 9
3D 
culture
2D 
culture
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Figure 32. Schematic representation of the 3D culture technique. The different tools needed 
for the imaging and analysis are shown. Adapted from Härma et al. 2014. 
13.2 Tridimensional (3D) image acquisition, pre-processing and 
morphometric analyses 
At the experimental endpoints multicellular structures were double stained with 1 μM 
of calcein 488 and ethidium homodimer 647 in media at 37ºC for 30 min. Calcein allows 
to stain for live cells through the conversion of nonfluorescent calcein to fluorescent 
calcein. This reaction is mediated by the removal of the acetomethoxy group by 
esterases, which are only present in live but not in dead cells. On the contrary, ethidium 
homodimer allows the detection of apoptotic cells due to its ability to bind DNA of dead 
cells passing through their broken membrane.  
Confocal images were taken of 4 different fields per well with a Zeiss spinning disk 
confocal unit using a 5x objective. Intensity projections were created with SlideBook 
(Intelligent Imaging Innovations Inc, Denver, CO, USA) and background noise was 
removed by normalization, also using SlideBook. Finally, confocal images were analyzed 
with VTT’s AMIDA software (Härma et al. 2014) and raw numerical data were statistically 
processed and visualized with R/Bioconductor (Fig. 32). Morphometric parameters used 
in the analysis can be found in Table 12.  
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Parameter  Explanation  Unit  
Area  Area of the segmented structure  pixels  
AreaR Area of apoptotic cells pixels 
Roundness  Roundness of the segmented structure  %  
Roughness  Roughness of the surface of the segmented structure  %  
AppIndex Indexes the severity of the invasiveness by utilizing Roundness 
and Roughness parameters 
ratio 
MaxApp Estimate for the maximum length of appendages of the 
segmented structure  
pixels 
Table 12. Morphometric parameters used for the analysis of miniaturized 3D culture. For 
an extended explanation of the parameters see Härma et al. 2014. 
14. Tumor growth assay on the chorioallantoic membrane (CAM) 
Fertilized white Leghorn chicken eggs were cleaned with water and 70% ethanol to 
remove bacteria. Afterwards, eggs were placed into the eggs incubator with the pointed 
end in the bottom (embryo development day 0, EDD0). Incubation is performed at 37 °C 
under constant humidity (60%) and rotation of 100 degrees every 20 min. No method of 
randomization was used. Separation of the developing CAM was induced on EDD4 by 
drilling a hole of approximately 2 mm of diameter in the pointed end of the eggs. After 
covering holes with tape, eggs were placed again in the incubator. On EDD7, egg holes 
were enlarged to a final size of approximately 1 cm of diameter and a plastic ring was 
set above blood vessels of the CAM membrane. After that, 500,000 PC3 cells/egg 
silenced for 48 h for Ctrl and FZD8 siRNAs were suspended in PBS and Matrigel (1:1) 
and 20 μL/egg of the mix were implanted in the middle of the ring on the CAM. On 
EDD10, eggs were placed on ice for 1 h to anesthetized embryos. Holes were enlarged 
and tumors were photographed in ovo and excised. Tumor area was measured blind 
using photographs from three independent experiments, each with 15 eggs per 
condition, using ImageJ (NIH, Bethesda, MD, USA). Tumor specimens were excised 
from the CAM and placed in 4% PFA, paraffin embedded and cut in 5 μm sections for 
immunohistochemical analysis (Fig. 33). 
Materials and Methods 
101 
 
 
Figure 33. Schematic representation of the CAM assay. Adapted from Crespo & Casar, 2016. 
15. Bioinformatics analysis 
The Oncomine database (www.oncomine.org) was used to examine the expression 
of Wnt receptors in prostate cancer datasets. Cancer versus Normal comparison with p-
value < 0.05 and fold change > 1.5 were considered significant. The cBioPortal database 
(www.cbioportal.org) was used to obtain correlation levels between FZD8 and ERG as 
well as FZD8 and WNT11 and EMT markers. This database was also used to analyze 
the correlation between FZD8 and WNT11 expression levels with freedom from 
biochemical recurrence. Analysis of the MSKCC dataset was performed through 
R/bioconductor in order to stratify samples into normal, cancer and metastasis as well 
as to differentiate Gleason score, stage and lymph node invasion status. The CamcAPP 
database (http://bioinformatics.cruk.cam.ac.uk/apps/camcAPP/) was used to determine 
the disease free status based on FZD8 and WNT11 expression levels. 
16. Statistical analysis 
Results are presented as the mean ± standard deviation (SD). All experiments were 
repeated at least three times. Statistical evaluations were performed with GraphPad 
Prism 5.0 (GraphPad, La Jolla, CA, USA) using Student's t test for single comparisons 
or one-way analysis of variance (ANOVA) with post-hoc Tukey for multiple group 
comparisons. A two-tailed p value ≤ 0.05 was considered to indicate statistical 
significance. For TMA analysis, patients were divided into low (0, 1) and high (2, 3) FZD8 
and Wnt-11 expression and Gleason scores > 4+3 and < 3+4 and analyzed by one-way 
v2 test, Chi-squared test with Yates correction or Fisher’s exact test, two-sided. 
Correlation analysis was calculated using Phi-correlations to test association between 
expression of FZD8 and Wnt-11. All TMA analyses were performed using SPSS v16 
(IBM Corp., Somers, NY, USA).
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Chapter 1. Identification and characterization of Wnt-11 
receptors in metastatic prostate cancer 
The involvement of Wnt-11 in prostate cancer was previously reported by our group 
showing that Wnt-11 expression is elevated in prostate tumors and particularly in patient 
metastases (Uysal-Onganer et al. 2010). WNT11 expression was also found upregulated 
in hormone-depleted LNCaP cells as well as in castration-resistant LNCaP cell tumor 
xenografts (Zhu et al. 2004).  
All members of the Wnt family of proteins mediate their signaling through binding and 
activation of different receptors and coreceptors at the cell membrane, which then 
promotes the consequent activation of the intracellular canonical or noncanonical 
signaling cascades, and the regulation of target genes expression (M. T. Veeman et al. 
2003; Komiya & Habas 2008; Niehrs 2012; Zhan et al. 2017)  
Based on previous studies showing the involvement of Wnt-11 in prostate cancer 
metastasis and on the well-known requirement of Wnt receptors for activation of all 
branches of Wnt pathways, we first aimed to identify which of the Wnt receptors show 
an increased expression in prostate cancer and therefore could play a role in prostate 
cancer progression and metastasis. A variety of receptors and co-receptors are able to 
bind Wnt ligands in different types of cancer, including the frizzled family members 
(FZD1-10), VANGL1 and 2, tyrosine kinase-like receptors (ROR1, ROR2, RYK, PTK7 
and MuSK), LRP4-6, LGR4 and 5 and GPC4 (Niehrs 2012). The strategy to elucidate 
the implication of Wnt receptors in prostate cancer was divided into two screening 
approaches, based on in vitro experiments using different prostate cancer cell lines and 
on in silico analysis of prostate tumor databases. 
1.1 Screening of Wnt receptors with increased expression in 
prostate cancer cell lines 
In order to identify candidate receptors involved in prostate cancer progression we 
characterized the expression pattern of a panel of 23 Wnt receptors by q-RT-PCR in 
different prostate cancer cell lines representing a range of prostate tumor types. These 
cell lines included LNCaP cells and a castrate-resistant derivative, C4-2B, both of which 
express high levels of AR and low levels of WNT11; VCaP cells, which harbor a 
TMPRSS2-ERG gene fusion and express high levels of AR and WNT11, and PC-3M, a 
metastatic AR-negative cell line that expresses moderate levels of WNT11. We also 
examined Wnt receptor gene expression in LNCaP cells cultured in hormone-depleted 
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medium, which is known to reduce proliferation and induce neuroendocrine-like 
differentiation, concomitant with an increase in WNT11 expression.  
As a way to mimic prostate cancer progression, the different prostate cancer cell lines 
used in the q-RT-PCR analysis were arranged from lower to higher malignant potential; 
expression in C4-2B cells was used for normalization in all experiments. When receptors 
were undetectable (UND) in C4-2B cells, values from PC-3M or VCaP cells were used 
instead (Table 13).  
  
Ct C4-2B 
 
Ct PC-3M 
 
Ct VCaP 
FZD1 UND UND  UND 
FZD2 26     
FZD3 23     
FZD4 21     
FZD5 21     
FZD6 22     
FZD7 25     
FZD8 26     
FZD9 26     
FZD10 UND UND 27 
VANGL1 21     
VANGL2 28     
ROR1 24     
ROR2 30     
RYK 20     
PTK7 25     
LGR4 21     
LGR5 UND 27   
LRP4 31     
LRP5 20     
LRP6 21     
GPC4 23     
MuSK UND 28   
WNT11 30     
Table 13. Wnt receptor Ct values in prostate cancer cell lines used for normalization. Q-
RT-PCR Ct values for listed genes in C4-2B cells used for normalization in Figure 15; PC-3M or 
VCaP were used for normalization in cases where a gene was undetectable (UND) in C4-2B cells, 
except for FZD1, which was not expressed in any prostate cancer cell line. 
At first glance, examination of expression patterns in the different prostate cancer cell 
lines revealed that genes encoding several Wnt receptors (FZD2-5, FZD8, VANGL1, 
ROR1, RYK, LGR4, LRP5 and LRP6 and GPC4) were highly expressed in at least three 
prostate cancer cell lines, suggesting a role for them in prostate cancer (Fig. 34). Of 
note, FZD1 expression was undetectable in any of the prostate cancer cell lines, 
suggesting this receptor is unlikely to be involved in prostate cancer. 
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Figure 34. Expression levels of WNT11 and Wnt receptor genes in prostate cancer cell 
lines. Q-RT-PCR analysis showing expression levels of the indicated genes, normalized to 36B4, 
in LNCaP cells, CSS (LNCaP cells that were hormone-depleted by culture in medium containing 
5% charcoal-stripped serum for 3 or 6 days), C4-2B, PC-3M and VCaP cells. PC-3M or VCaP 
were used for normalization in cases where a gene was undetectable (UND) in C4-2B cells (see 
Table 13); error bars show SD for three independent experiments.  
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Trying to simplify the large amount of data obtained after this q-RT-PCR analysis (Fig. 
34), the different prostate cancer cell lines were classified according to the features of 
prostate cancer that they represent and grouped the expression of the different Wnt 
receptors into these categories (Table 14). These groups included: neuroendocrine-like 
differentiation (NED), when receptor expression was increased upon CSS treatment; 
androgen independence (AI), when receptor expression was increased in C4-2B cells, 
compared to parental LNCaP cells; metastatic prostate cancer (mPCa), when there was 
an increased expression in the prostate cancer cell lines derived from patient metastasis 
(VCaP and PC-3M); and restricted expression, when the receptor expression was limited 
to a single cell line.  
Receptor 
UP in 
NED 
UP in  
AI PCa 
UP in 
mPCa 
Restricted 
expression 
     
FZD2 X X X  
FZD3     
FZD4  X X  
FZD5  X   
FZD6     
FZD7 X    
FZD8   X  
FZD9  X   
FZD10    X 
VANGL1  X   
VANGL2 X    
ROR1   X  
ROR2 X    
RYK  X X  
PTK7 X    
LGR4   X  
LGR5    X 
LRP4 X  X  
LRP5 X    
LRP6     
GPC4   X  
MuSK    X 
WNT11 X X X  
 
Table 14. Summary of Wnt receptor genes and WNT11 expression in prostate cancer. Wnt 
receptor and WNT11 mRNA expression in prostate cancer cell lines with neuroendocrine-like 
differentiation (NED), androgen-independence (AI PCa), capacity for metastasis (mPCa) and 
restricted expression to one cell line (for details see Figure 34); FZD2, FZD4 and FZD8 (grey 
highlight) were highly expressed in cells with the most aggressive features. 
 
Results 
109 
 
The reorganization and categorization of the q-RT-PCR data allowed us to further 
analyze which of these Wnt receptors might mediate Wnt-11 signaling in prostate cancer 
through a deeper comparison of Wnt receptors and WNT11 expression profiles. 
Interestingly, although many other FZD receptors were highly expressed in the more 
aggressive prostate cancer cell lines, only some of them showed a pattern of expression 
similar to that of WNT11. Among them, FZD2 correlated best with WNT11, as it was 
more highly expressed in PC-3M and VCaP cells than in LNCaP and C4-2B cells and it 
was also upregulated in hormone-depleted LNCaP cells, where WNT11 expression was 
increased (Fig. 34, Table 14). FZD4 and FZD8 expression also showed a partial 
correlation with that of WNT11. In fact, FZD4 and FZD8 expression were higher in the 
more aggressive prostate cancer cells, VCaP and PC-3M, as was WNT11 expression, 
suggesting a possible role for these receptors in prostate cancer progression and 
metastasis. However, FZD4 also showed increased expression in the androgen-
independent C4-2B cell line, in contrast to WNT11, and FZD8 showed lower mRNA 
levels in hormone-depleted LNCaP cells, where WNT11 is upregulated (Fig. 34, Table 
14).  
In conclusion, the results from these initial screens highlight the upregulation of 
several Wnt receptors in prostate cancer cell lines as well as the similar expression 
patterns of some of them with WNT11, suggesting that these candidates may be 
implicated in prostate cancer progression through mediation of Wnt-11 signaling.  
1.2  In silico screening of Wnt receptors with increased expression 
in prostate tumors  
It is complicated to determine which of the previously identified candidate Wnt 
receptors is crucial for prostate cancer progression and could function as a Wnt-11 
receptor. To complete the initial profiling in prostate cancer cell lines, we used a second 
approach based on in silico analysis of prostate cancer databases, in order to evaluate 
the expression of Wnt receptors in prostate tumors.  
Thus, we examined the expression levels of the 23 Wnt receptors in the OncomineTM 
database. Oncomine is a cancer microarray database and web-based data-mining 
platform which facilitates discovery from genome-wide expression analyses. Oncomine 
contains more than 65 gene expression datasets comprising nearly 48 million gene 
expression measurements from over 4700 microarray experiments and allows the 
analysis of gene expression in most of the major types of cancer in comparison with the 
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respective normal tissues, as well as a variety of cancer subtypes and clinical-based and 
pathology-based analyses (Rhodes et al. 2004). 
In this screen, we focused on datasets with p-values smaller than 0.05 (p<0.05) and 
fold changes higher than 1.5 (FC>1.5). At a first glance, when analyzing the data, we 
could observe that, consistent with our previous results in prostate cancer cell lines, 
among all the Wnt receptors examined only FZD4, FZD8 and the coreceptor, PTK7 were 
clearly upregulated in prostate cancer compared to normal tissue (Table 15). However, 
in contrast to what observed in our screen using prostate cancer cell lines, FZD2 
expression was only found upregulated in a single dataset being also downregulated in 
one dataset (Table 15), which reduces its potential as receptor involved in prostate 
cancer progression and as a mediator of Wnt-11 signaling. 
Receptor UP in PCa DOWN in PCa 
   
FZD1 1 6 
FZD2 1 1 
FZD3 1 1 
FZD4 4   
FZD5   1 
FZD6     
FZD7 1 6 
FZD8 6   
FZD9     
FZD10   2 
VANGL1     
VANGL2   1 
ROR1   1 
ROR2   6 
RYK   1 
PTK7 2   
LGR4   1 
LGR5   2 
LRP4   2 
LRP5     
LRP6 1 1 
GPC4   1 
MUSK   1 
Table 15. Profiling of Wnt receptors genes in prostate tumors. Analysis of Wnt receptor 
expression profiles using datasets from OncomineTM; FZD4, FZD8 and PTK7 (grey highlight) were 
found to be most frequently upregulated; only datasets with p < 0.05 and fold-change > 1.5 were 
considered. 
 
Results 
111 
 
A deeper analysis of the Oncomine datasets revealed that FZD4, FZD8 and PTK7 
were not only upregulated in prostate cancer compared to benign prostate tissue in 
multiple datasets but also in PIN lesions compared to benign prostate, which are thought 
to be the precursor of prostate cancer (Table 16).  Therefore, these results implicate 
these receptors in disease progression. It is important to take into account that not all 
the analyzed datasets have a large enough sample size for considering the observed 
differences as biologically significant, but the consistency of the results in all of them 
support the involvement of FZD4, FZD8 and PTK7 in prostate cancer. 
 Dataset Comparison 
Sample 
number P-value Fold change 
FZD4 Lapointe Carcinoma vs Normal 112 1.61E-11 1,724 
  Varambally Carcinoma vs Normal 13 1.03E-04 1,761 
  Tomlins PIN vs Normal 36 1.63E-04 3,917 
  Luo Carcinoma vs Normal 30 0.023 1,523 
FZD8 Tomlins Carcinoma vs Normal 52 3.67E-06 5,057 
    PIN vs Normal 35 2.26E-04 2,462 
  Varambally Carcinoma vs Normal 13 0.002 2,803 
  Arredouani Carcinoma vs Normal 21 0.001 1,811 
  Grasso Carcinoma vs Normal 85 1.47E-05 1,717 
PTK7 Tomlins Carcinoma vs Normal 47 0.001 2,208 
    PIN vs Normal 29 4.02E-04 3,466 
Table 16. FZD4, FZD8 and PTK7 expression in prostate cancer datasets. Only datasets with 
p < 0.05 and fold-change > 1.5 were considered. 
Since analysis of Oncomine datasets is only based on gene expression, we also used 
the Protein Atlas database (www.proteinatlas.org) to examine the expression of Wnt 
receptors at the protein level. The Human Protein Atlas is a Swedish-based program 
initiated in 2003 with the aim of mapping all the human proteins in cells, tissues and 
organs using integration of various omics technologies, including antibody-based 
imaging, mass spectrometry-based proteomics, transcriptomics and systems biology. All 
the data in the knowledge resource is open access to allow to free exploration of human 
proteome data. Consistent with the analysis from the Oncomine database, FZD8 protein 
expression levels were low in normal prostate and moderately high in prostate cancer, 
suggesting a possible role for FZD8 in prostate cancer. In contrast, FZD4 and PTK7 
protein levels were similar (low and high, respectively) in normal prostate and prostate 
cancer tissues (Fig. 35), which did not support their possible involvement of these 
receptors in prostate cancer. 
 
Results 
112 
 
 
Figure 35. Immunohistochemistry of Wnt receptors and coreceptors. Detection of FZD4, 
FZD8 and PTK7 in sections of normal prostate and prostate cancer; images were collected from 
www.ProteinAtlas.org. Scale bar 100 µm.  
In summary, the analysis of Wnt receptor expression in prostate tumors allowed us to 
identify potential candidates that are upregulated in prostate cancer and therefore may 
play a role in the pathogenesis of prostate cancer. Although PTK7 was also found 
upregulated in prostate cancer and coreceptors are important for Wnt signaling, we will 
focus our efforts on FZD receptors, since they are essential in all branches of Wnt 
signaling.    
1.3 Identification of FZD receptors involved in Wnt-11 signaling 
The analysis from both screening approaches in prostate cancer cell lines and in 
prostate tumors led us to conclude that FZD2, FZD4 and FZD8 may be involved in 
prostate cancer pathogenesis. However, clarifying their roles as potential Wnt-11 
receptors in metastatic prostate cancer required further investigation. Although some 
FZD receptors have been reported to bind Wnt-11 in different models, such as FZD7 in 
Xenopus (Djiane et al. 2000; Penzo-Mendèz et al. 2003; Yamanaka & Nishida 2007), 
FZD5 (Cavodeassi et al. 2005) and FZD7 (Witzel et al. 2006) in zebrafish, FZD4 in 
differentiating cardiomyocytes (Abdul-Ghani et al. 2011; Ye et al. 2011) and FZD4 and 
FZD8 in the developing kidney (Ye et al. 2011), to date there was no evidence for which 
FZDs transduce Wnt-11 signals in prostate cancer. 
 
Normal
Tumor
FZD4 FZD8 PTK7
Results 
113 
 
1.3.1 Colocalization of Wnt-11 with FZD family members 
The analysis of the cell line data led us to hypothesize that FZD2, FZD4 and FZD8 
may be involved in prostate cancer pathogenesis, and as they show similar expression 
patterns to that of Wnt-11, they may also mediate Wnt-11 signaling in prostate cancer 
cells. However, the high expression of some other FZD family members in PCa cells 
meant that we could not rule them out.  
To further explore this possibility, immunofluorescence was used to examine which of 
the FZD family members is capable of co-localizing with Wnt-11 in prostate cancer cells. 
PC-3M prostate cancer cells were co-transfected with Wnt-11 and epitope-tagged forms 
of each of the members of the FZD family (FZD1-10). Subsequent staining for FZD-tag 
and Wnt-11 revealed very different patterns of expression and Wnt-11 colocalization 
among the FZD members. A deeper analysis of the staining showed a strong 
colocalization between Wnt-11 and FZD8, as shown by a Pearson coefficient of 
correlation of 0.686 (Table 17 and Fig. 36). Of note, moderate colocalization was also 
found between Wnt-11 and FZD6 (Pearson of 0.459) and Wnt-11 and FZD10 (Pearson 
of 0.529) (Table 17 and Fig. 36). However, no or weak colocalization was observed for 
the other FZD family members (Table 17 and Fig. 36).  
 
Table 17. Quantification of Wnt-11 and FZD receptor colocalizaton. ImageJ analysis of 
colocalization for 10 cells per experiment (see Methods). FZD6, FZD8 or FZD10 (grey highlight) 
showed strong colocalization. 
 
 
 
Pearson (-1< x <1)
FZD1 -0.016 ± 0.009
FZD2 0.062 ± 0.025
FZD3 0.181 ± 0.063
FZD4 0.125 ± 0.082
FZD5 0.224 ± 0.102
FZD6 0.459 ± 0.068
FZD7 -0.002 ± 0.014
FZD8 0.686 ± 0.030
FZD9 -0.037 ± 0.026
FZD10 0.529 ± 0.050
Results 
114 
 
Since our q-RT-PCR analysis showed that FZD6 was not highly expressed in 
metastatic prostate cancer cell lines and that FZD10 expression was restricted to a single 
cell line, this colocalization analysis supports a role of FZD8 as the FZD receptor that 
mediates Wnt-11 signaling in metastatic prostate cancer.    
 
 
Figure 36. Wnt-11 and FZD receptor localization. Immunofluorescence analysis of PC-3M cells 
transfected with 1D4-tagged FZD1-10 (red) and Wnt-11 (green) for 24 h; images are 
representative of three independent experiments, blue staining shows cell nuclei (DAPI), scale 
bar 20 µm.  
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Figure 36. Wnt-11 and FZD receptor localization (continuation). Immunofluorescence 
analysis of PC-3M cells transfected with 1D4-tagged FZD1-10 (red) and Wnt-11 (green) for 24 h; 
images are representative of three independent experiments, blue staining shows cell nuclei 
(DAPI), scale bar 20 µm.  
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1.3.2  Evaluation of Wnt-11-FZD signaling  
The results from our initial screen and the colocalization assays indicate that FZD8 
satisfies several criteria to be a Wnt-11 receptor in metastatic prostate cancer. However, 
since other FZD family members were also highlighted in our studies, we decided to 
explore the potential role of all of them as Wnt-11 receptors through further analysis. 
Since Wnt proteins mediate signaling by activating different transcription factors, gene 
reporter assays are widely used tool to monitor the activation of this pathway.  
In a variety of cell contexts, including cardiac tissue morphogenesis (Zhou et al. 2007), 
Xenopus embryo development (Ohkawara & Niehrs 2011) and avian facial 
morphogenesis (Geetha-Loganathan et al. 2014), Wnt-11 has been found to activate 
ATF2 dependent gene reporter activity, which is considered a reporter of the 
noncanonical pathway. In this regard, our first goal was to determine whether Wnt-11 
was also able to activate an ATF2-dependent luciferase reporter (Ohkawara & Niehrs 
2011) in prostate cancer cells. With this purpose, we used two different prostate cancer 
cell lines, C4-2B and PC-3M, which harbor low and relatively high levels of endogenous 
Wnt-11, respectively and performed gene reporter assays. Consistent with observations 
in other models, transfection of Wnt-11 in both prostate cancer cell lines showed a 
significant activation of the reporter (Fig. 37) supporting the activation of this 
noncanonical signal by Wnt-11 in prostate cancer cells. 
 
Figure 37. Wnt-11 activates the ATF2-dependent gene reporter. Relative ATF2 
luciferase/renilla activity in C4-2B and PC-3M cells transfected with empty vector (V) or Wnt-11. 
 Aiming to determine which FZD family members might be capable of transducing 
Wnt-11 signals in prostate cancer, we co-transfect Wnt-11 together with the ten members 
of the FZD family. The gene reporter assay revealed that ATF2-dependent transcriptional 
activity in PC-3M cells was significantly enhanced upon transfection of seven members 
of the FZD family (Fig. 38A). Among them, FZD8 and FZD10 showed the strongest 
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increases and their effects were further boosted by Wnt-11 (Fig. 38A), suggesting that 
these receptors can mediate Wnt-11 signaling in prostate cancer. Importantly, the 
amount of each receptor plasmid used (Fig. 38A) was adjusted based on the level of 
protein expression when cotransfected with Wnt-11 (Fig. 38B) in order to reduce the 
possibility of effects on ATF2 reporter activity resulting from different protein expression 
levels. Of note, expression of FZD3 and FZD10 was substantially lower than other FZD 
family members even though higher amounts of plasmid were transfected, which 
suggests that FZD3 and FZD10 are less stable. Despite its low expression, FZD10 was 
able to activate ATF2 luciferase, suggesting the lack of effect of FZD3 is not related to 
its lower expression. 
 
 
Figure 38. Involvement of FZD receptors in Wnt-11/ATF2 signaling in prostate cancer.  (A) 
Relative ATF2 luciferase/renilla activity in C4-2B cells transfected with empty vector (pcDNA) or 
Wnt-11 and FZD1-10; results are normalized to pRK5. (B) Western blot of C4-2B cells transfected 
with and without Wnt-11 and the same amounts of FZD1-10 as in (A). 
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1.3.3  FZD8 as a major Wnt-11 receptor  
All the previous results are consistent with FZD8 mediating the Wnt-11 response. 
However, it was still unclear if endogenous FZD8 transduces Wnt-11 signals in prostate 
cancer, as several other FZD family members are also highly expressed.  
To address this issue, gene reporter assays were carried out in PC-3M cells silenced 
with siRNAs targeting the highly expressed FZD family members. According to our data 
from the initial profiling in prostate cancer cell lines, FZD2-5 and FZD8 were highly 
expressed in the more metastatic cell lines, showing Ct values between 20 to 22 by q-
RT-PCR (Table 13,14 and Fig. 34). Gene reporter assays after silencing of these 
receptors and transfection of Wnt-11 revealed that, FZD8 silencing reduced Wnt-11 
activation of ATF2-dependent transcription by approximately 40% (Fig. 39A). This 
analysis also showed that FZD2 silencing reduced it by 20%, while silencing of FZD3, 
FZD4 and FZD5 had no effect (Fig. 39A). Of note, FZD8 silencing also mildly reduced 
FZD5 expression (Fig. 39B), which is related in sequence to FZD8. However, FZD5 was 
not highly expressed in the more aggressive prostate cancer cell lines (Table 14 and 
Fig. 34) and FZD5 silencing did not affect Wnt-11 activation of ATF2-dependent 
transcription (Fig. 39A), consistent with endogenous FZD8, rather than FZD5, mediating 
the Wnt-11 response.  
To confirm this results, an unrelated Dicer-substrate siRNA (dsiRNA) was used to 
silence FZD8. In fact, this dsiRNA also inhibited Wnt-11 activation of ATF2-dependent 
transcription (Fig. 39C), supporting the role of FZD8 in transducing the Wnt-11 signal. 
Importantly, the effect of FZD8 siRNA on ATF2 transcriptional activity could be rescued 
by transfection of mouse FZD8, which is not recognized by the FZD8 siRNA (Fig. 39D). 
Together, these findings indicate that endogenous FZD8 is a major mediator of Wnt-11 
signaling in prostate cancer.  
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Figure 39. Requirement for FZD8 in the response to Wnt-11 in prostate cancer cells.  (A) 
Relative ATF2 luciferase/renilla activity in PC-3M cells silenced for the indicated FZDs and then 
transfected with Wnt-11; results are normalized to siCtrl. (B) Relative expression levels of the 
indicated genes, normalized to 36B4, in PC-3M cells silenced for FZD8. (C) Relative ATF2 
luciferase/renilla activity in PC-3M cells silenced for FZD8 with dsiRNAs and then transfected with 
Wnt-11. (D) Relative ATF2 luciferase/renilla activity in PC-3M cells silenced for FZD8 siRNAs and 
transfected with empty vector pRK5 (V) or FZD8 plasmid. Error bars in (A) to (D) show SD for 
three independent experiments; * p < 0.05, ** p < 0.001 by Student´s t test or ANOVA with Tukey 
post-hoc test where appropiate  
ATF2 is a component of the AP-1 complex, in which it forms homo- or hetero-dimers 
with JUN, FOS and MAF (musculoaponeurotic fibrosarcoma) transcription factors (Eferl 
& Wagner 2003; Lopez-bergami 2011). Since Wnt-11 is also known to regulate AP-1 
signaling (Y. Li et al. 2008) and we have previously shown that FZD8 is involved in ATF2 
signaling, we decided to corroborate the implication of FZD8 in transducing Wnt-11/AP-
1 noncanonical signaling using an AP-1-dependent gene reporter (Vivanco et al. 1995). 
Analysis of these data showed that FZD8 silencing also reduced Wnt-11 activation of 
AP-1-dependent transcription (Fig. 40A), which supports our previous results involving 
FZD8 in noncanonical Wnt signaling.  
Although Wnt-11 usually inhibits Wnt/-catenin signaling due to its activation of 
noncanonical pathways (Uysal-Onganer & Kypta 2012), FZD8 has been reported to be 
involved in Wnt/-catenin signaling in some cell types (Miao et al. 2015; Sun et al. 2014; 
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Yin et al. 2013; Albers et al. 2013). However, FZD8 silencing in PC-3M prostate cancer 
cells did not inhibit -catenin/Tcf-dependent transcriptional activity, as measured using 
the Super8xTOPFlash reporter and its nonresponsive control Super8xFOPFlash (Fig. 
40B). In agreement with these results, FZD8 silencing reduced expression of ATF2 
mRNA but not expression of the -catenin/Tcf target gene AXIN2, which actually 
increased (Fig. 40C). Together, these data corroborate the role of FZD8 in -catenin-
independent Wnt signaling in prostate cancer. 
 
 
Figure 40. FZD8 mediates Wnt-11 noncanonical signaling. (A) Relative AP-1 luciferase/renilla 
activity in PC-3M cells transfected with siCtrl or siFZD8 and then with Wnt-11. (B) Relative -
catenin/TCF activity (TOPFlash/FOPFlash) in PC-3M cells transfected with siCtrl or siFZD8 and 
then with Wnt-11. (C) Q-RT-PCR analysis showing mRNA expression of the indicated genes, 
relative to 36B4, in PC-3M cells transfected with control (Ctrl) and FZD8 siRNAs. Error bars in (A) 
– (C) show SD from at least three independent experiments; * p < 0.05, ** p < 0.001 by Student´s 
t test or ANOVA with Tukey post-hoc test.  
 
Interaction of Wnt proteins with FZD receptors is an essential step in activation of both 
canonical and noncanonical Wnt signals (Mikels & Nusse 2006). Since our results 
support the role of FZD8 as major Wnt-11 receptor in metastatic prostate cancer and we 
also found that Wnt-11 and FZD8 strongly colocalize in prostate cancer cells, we 
hypothesized that Wnt-11 and FZD8 should be able to form a stable complex, which 
mediates activation of signaling. In order to corroborate our hypothesis, 
immunoprecipitation analyses were carried out using PC-3M cells transfected with 
tagged forms of Wnt-11 and FZD8. As expected, the results indicated that Wnt-11 and 
FZD8 can form a stable complex (Fig. 41) in prostate cancer cells, further supporting a 
role for Wnt-11- FZD8 signaling in prostate cancer.  
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Figure 41. FZD8 binds Wnt-11 in vitro. Western blots of anti-1D4 and anti-PA 
immunoprecipitates (IP) and extracts (Input) from PC-3M cells transfected with plasmids encoding 
1D4-tagged FZD8 and PA-tagged Wnt-11 were probed for Wnt-11 (PA) or FZD8 (1D4); blots are 
representative of three independent experiments and the positions of molecular mass markers 
are indicated.  
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Chapter 2. Implication of FZD8 in prostate cancer pathogenesis 
Prostate cancer, as any other type of cancer, is a complex disease involving a lot of 
dynamic changes in the genome which together lead to cancer development and 
progression. Different alterations such as self-sufficiency in growth signals, insensitivity 
to growth-inhibitory signals, evasion of apoptosis, limitless replicative potential, 
sustained angiogenesis, genomic instability and mutation, tumor promoting inflammation 
and tissue invasion and metastasis have been identified as drivers of tumorigenesis 
(Hanahan & Weinberg 2000; Hanahan & Weinberg 2011).  
Due to our previous results showing the increased expression of FZD8 as well as its 
role as a Wnt-11 receptor in metastatic prostate cancer cell lines, we hypothesized that 
FZD8 could have a role in prostate cancer progression driving the metastatic process. 
We therefore decided to explore our hypothesis using three different strategies 
combining in vitro and in vivo assays, as well as samples from prostate cancer patients. 
2.1 Role of FZD8 in prostate tumorigenesis: in vitro analysis  
In order to study the implication of FZD8 in tumor progression and metastasis, we 
firstly aimed to evaluate different features of tumor cells that have been described as 
essential during the metastatic process, such as the acquisition of cell motility and the 
regulation of the epithelial to mesenchymal transition (EMT). 
2.1.1   Contribution of FZD8 to capacity for prostate cancer cell 
migration and invasion 
The loss of cell-cell adhesion capacity allows malignant tumor cells to dissociate from 
the primary tumor mass and the changes in cell-matrix interaction enable the cells to 
invade the surrounding stroma. This process involves the secretion of substances to 
degrade the basement membrane and extracellular matrix and also the expression/ 
suppression of proteins involved in the control of motility and migration. After acquiring 
these properties, the motile cells then journey through the circulatory system invading 
the vascular basement membrane and the extracellular matrix in the process of 
extravasation. Later, these cells will attach at a new location and proliferate to produce 
the secondary tumor (Martin et al. 2000). Since migration and invasion are among the 
key events leading the course of tumor progression and metastasis and it was previously 
reported that Wnt-11 is required for prostate cancer cell migration and invasion (Uysal-
Onganer et al. 2010), we hypothesized that FZD8 could be required for these functions 
in prostate cancer cells. 
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2.1.1.1 Cell migration and invasion in conventional two-
dimensional (2D) cell cultures 
    As a first approach, we performed migration and invasion assays using conventional 
2D cell culture. In order to do that, two independent metastatic prostate cancer cell lines: 
PC-3M (which metastasizes to the bone) and DU145 (which is derived from a metastasis 
in the brain) were transiently silenced for FZD8 for 48 h and then subjected to migration 
and invasion assays.  Analysis of both assays revealed that FZD8 silencing significantly 
reduced cell migration (Fig. 42A and B) and invasion through Matrigel (Fig. 42C and D) 
in both cell lines. Of note, FZD8 silencing also had a small effect on cell number, reducing 
it by up to 20% (Fig. 43A and B). However, this effect was already accounted for when 
measuring the effects of FZD8 silencing on cell migration and invasion. Taken together, 
these results indicate that FZD8 contributes to the migratory and invasive capacities of 
metastatic prostate cancer cells. 
 
Figure 42. FZD8 is required for prostate cancer cell migration and invasion. (A) Migration 
assays for PC-3M and DU145 cells silenced with control (siCtrl) and FZD8 siRNAs, values are 
relative to siCtrl and normalized to viable cell number of silenced cells plated in parallel; error bars 
show SD for at least four independent experiments. (B) Representative images of migrated cells, 
scale bar 100 μm. (C) Invasion assays for PC-3M and DU145 cells silenced with control (siCtrl) 
and FZD8 siRNAs, values are relative to siCtrl and normalized to viable cell number; error bars 
show SD for at least three independent experiments. (D) Representative images of invaded cells, 
scale bar 100 μm. * p < 0.05 by Student´s t test. 
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Figure 43. Effects of FZD8 silencing on cell proliferation. (A) and (B) Cell number analysis of 
PC-3M and DU145 cells transfected with control of FZD8 siRNAs used to normalize numbers of 
migrating (Fig. 42A) and invading (Fig. 42C) cells; error bars show SD of at least three 
independent experiments. * p < 0.05 by Student´s t test. 
To corroborate the requirement for FZD8 in cell invasion, PC-3M cell lines in which 
FZD8 was stably silenced were generated using two independent lentiviral shFZD8 
constructs. The analysis of invasion assays showed that, in agreement with the results 
obtained by transient silencing, stable FZD8 knockdown significantly reduced prostate 
cancer cell invasion (Fig. 44A and B). The extent of FZD8 silencing was confirmed by 
q-RT-PCR (Fig. 44C) and its effect on cell number (Fig. 44D) was taken into account 
when analyzing the effect on cell invasion. Taken together, these results indicate that, 
as for Wnt-11, FZD8 contributes to the migratory and invasive activities of metastatic 
prostate cancer cells. 
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Figure 44. Stable knockdown of FZD8 reduces prostate cancer cell invasion. (A) Invasion 
assays using PC-3M cells stably silenced for FZD8 using lentiviruses expressing two different 
FZD8 shRNAs (shFZD8.1 and shFZD8.2), values are relative to pLKO and normalized to numbers 
of viable cells plated in parallel (Figure 44D); error bars show SD for three independent 
experiments. (B) Representative images of invaded cells, scale bar 100 μm. (C) Relative mRNA 
expression levels of FDZ8 measured by q-RT-PCR in shFZD8 PC-3M cells; error bars represent 
SD of three independent experiments. (D) Cell number of stable PC-3M cells expressing the 
indicated shRNAs; error bars show SD of three independent experiments. This data was used to 
normalize numbers of invading cells. * p < 0.05 by ANOVA with Tukey post-hoc test 
A recent study reported small molecule inhibitors of Wnt signaling that target the Wnt 
binding site on FZD8 (Lee et al. 2015). Structure-based virtual screening and cell-based 
assays were used to identify five small molecules that have low IC50 values in the 
micromolar range. Their binding to the FZD8 CRD was confirmed by NMR experiments 
and their ability to inhibit canonical Wnt signaling was shown with TOP/FOP reporter 
assays and analysis of LRP6 phosphorylation (Lee et al. 2015). Based on these studies, 
we selected two of these compounds: inhibitor 1 (3235-0367) and 2 (2124-0331) and 
tested their effects on prostate cancer cell migration. Consistent with our FZD8 silencing 
studies, both compounds significantly reduced PC-3M cell migration (Fig. 45A and B) 
without affecting cell number (Fig. 45C), providing further support for FZD8 as a 
therapeutic target in metastatic prostate cancer.  
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Figure 45. Wnt/FZD inhibitors reduce prostate cancer cell migration. (A) Migration assays 
for PC-3M cells treated with DMSO or inhibitors 1 (I1) and 2 (I2) at 10 μM for 24 h; values are 
relative to DMSO and normalized to viable cell number; error bars show SD for four independent 
experiments. (B) Representative images of migrated cells, scale bar 100 μm. (C) Cell proliferation 
analysis of PC-3M cells treated with DMSO, inhibitor 1 (I1) and inhibitor 2 (I2); error bars show 
SD for four independent experiments. These data were used for normalization the migration 
experiments in (A). * p < 0.05 by ANOVA with Tukey post-hoc test 
2.1.1.2 Cell invasion in organotypic tridimensional (3D) cultures 
Our results highlight a role for FZD8 in prostate cancer cell motility through regulation 
of migration and invasion of prostate cancer cells. In order to perform a better 
examination of the role of FZD8 in this context, we took advantage of a three-dimensional 
(3D) organotypic cell culture model that includes Matrigel to mimic the tissue extracellular 
matrix (ECM). Previous studies have shown that in this assay, PC-3 and PC-3M 
metastatic prostate cancer cells initially differentiate into hollow organoids (days 4-5) and 
later spontaneously de-differentiate into invasive stellate structures (days 8-12) (Härma 
et al. 2010). 
   To determine the effects of FZD8 silencing using this assay, FZD8 was silenced in both 
PC-3 and PC-3M cells and they were cultured as organoids, monitoring morphology, 
polarization and growth for up to 9 days using the IncuCyteTM system. Evaluation of the 
3D assay revealed that cells transfected with control siRNA initially matured into well-
differentiated organoids and then formed invasive and multicellular structures at days 8-
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9 (Fig. 46A and B). In contrast, as anticipated based on the results from the 2D 
experiments, FZD8-silenced cells matured into well-differentiated organoids but did not 
form invasive structures by the end of the assay (Fig. 46A and B). Of note, these effects 
were completely evident at the endpoint of the assay, despite recovery of basal FZD8 
mRNA expression levels by day 8, which suggests that phenotypical changes occur early 
in the process (Fig. 46C and D). 
 
Figure 46. FZD8 silencing reduces prostate cancer cell invasion in organotypic 3D 
cultures. (A) Representative images from Incucyte live-cell imaging of 3D cultures of control and 
FZD8-silenced in PC-3M (upper panel) and PC-3 (lower panel) cells at days 1 to 9; scale bar 100 
μm. (C) and (D) FZD8 expression levels in FZD8-silenced cells at days 0, 4 and 8 of 3D culture 
in PC-3M (C) and PC-3 (D); error bars show SD for three independent experiments. * p < 0.05 ** 
p< 0.001 by ANOVA with Tukey post-hoc test. 
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    In order to quantify the phenotypic changes observed during the 3D culture, at least 
1,000 organoids were examined using high-content, automated morphometric image 
data analysis (AMIDA) software, which allows the segmentation and quantitative 
measurement of large numbers of images with different shapes, sizes and textures 
(Härma et al. 2014). For this purpose, organoids were live-stained with calcein and 
ethidium homodimer at the endpoint of the 3D culture and visualized by confocal 
microscopy. After imaging, all the pictures were segmented (Fig. 47) and analyzed using 
AMIDA. This analysis revealed that FZD8 silencing significantly reduced the severity 
(AppIndex) and length (MaxApp) of invasive multicellular structures, accompanied by 
reductions in the numbers of small filopodia-like cellular extensions (Roughness) and 
organoid size (Area), as well as by a rounder shape (Roundness) (Fig. 48 and 49). Of 
note, FZD8 silencing in PC-3M cells significantly reduced the frequency of cell death 
(AreaRatioR), which in theory could promote the subsequent formation of invasive 
structures. However, this is not the case for FZD8 silencing, which significantly reduced 
parameters involved in cell invasion (Fig. 48A). 
 
Figure 47. Representative segmentation of live-cell confocal images by AMIDA. FZD8-
silenced PC-3M (upper panel) and PC-3 (lower panel) cell organoids cultured in 3D for 9 days 
were stained with ethidium homodimer-1 (red) to detect apoptotic cells and with calcein (green) 
to detect live cells. Confocal images were segmentated with AMIDA for posterior quantification of 
effects. 
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Figure 48. Quantification of phenotypic effects of FZD8 silencing in organotypic 3D 
cultures. Heatmaps and graphical p-value matrix of morphometric parameters measured by 
AMIDA and altered by FZD8 silencing in PC-3M (A) and PC-3 (B) cell organoids (red, increased 
and blue decreased). P values are Bonferroni-corrected from t-tests, comparing siFZD8 and 
siCtrl. 
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Figure 49. Boxplots for the main parameters affected by FZD8 silencing in organotypic 3D 
cultures. Box and whisker plots of selected parameters from heatmaps in Fig. 48 in PC-3M (A) 
and PC-3 (B) cells; p=0 indicates p-value <0.001.  
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2.1.2   Role of FZD8 in the epithelial to mesenchymal transition 
(EMT)  
The epithelial-mesenchymal transition (EMT) is a reversible and flexible process in 
which epithelial cells acquire mesenchymal properties moving through a spectrum of 
intermediate phases in which they alter their morphology, cellular architecture, adhesion 
and migratory capacities (Lee et al. 2006; Nieto et al. 2016). EMT has been reported to 
drive the dissociation of carcinoma cells from primary carcinomas, which as a result, 
migrate and disseminate to distant sites. Later, the reverse of EMT (MET) is proposed 
to cause cessation of migration, inducing the same cells to proliferate and giving rise to 
a new tumor mass (Nieto et al. 2016). 
Given that Wnt signaling is one of the pleiotropic factors that induce the EMT program 
(Banyard & Bielenberg 2015) and our previous results support the role of FZD8 in 
prostate cancer progression through regulation of cell migration and invasion, we 
hypothesized that FZD8 could be also involved in the regulation of EMT.  
2.1.2.1 EMT in standard 2D culture 
In order to corroborate the idea of FZD8 involvement in EMT in prostate cancer, we 
first used conventional 2D culture techniques. To do this, the levels of EMT-associated 
genes were analyzed by q-RT-PCR in PC-3M and DU145 cells, in which FZD8 was 
transiently silenced for 48 h. FZD8 silencing in PC-3M cells (Fig. 50A) significantly 
reduced the expression of the mesenchymal genes encoding N-cadherin (CDH2) and 
Vimentin (VIM), as well as the mesenchymal transcription factors Snail (SNA1), TWIST1 
and ZEB1, but not the expression of Slug (SNAI2). In addition, FZD8 silencing increased 
expression of the epithelial cell marker Claudin 1 (CLDN1). The effects of FZD8 silencing 
in DU145 cells were, on the whole, similar (Fig. 50B), reducing the expression of 
Vimentin (VIM), Snail (SNAI1), Slug (SNAI2) and ZEB1. However, FZD8 silencing did 
not affect TWIST1 nor CLDN1 in DU145 cells. Although there are some differences in 
the subset of EMT genes regulated by FZD8 in both cell lines, these results suggest that 
FZD8 is required for the expression of EMT genes in metastatic prostate cancer cells. 
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Figure 50. FZD8 regulates the expression of EMT markers at the mRNA level. Q-RT-PCR 
analysis showing expression levels of the indicated genes, normalized to 36B4, in PC-3M (A) and 
DU145 (B) cells, respectively silenced with control (siCtrl) or FZD8 siRNAs; error bars show SD 
for four independent experiments * p< 0.05 ** p< 0.001 by Student´s t test. 
Since the analysis by q-RT-PCR showed that FZD8 could be mediating the EMT 
process in metastatic prostate cancer cells, we decided to further analyze FZD8 effects 
on the expression of EMT markers at the protein level. With that purpose, western blot 
assays were carried out in PC-3M cells silenced for FZD8. Consistent with the mRNA 
data, there was a significant reduction in the protein levels of N-cadherin and Vimentin 
(mesenchymal markers) together with an increase in the epithelial marker Claudin 1 (Fig. 
51A). In order to investigate further the correlation between FZD8 and Wnt-11 with EMT 
marker expression, we carried out bioinformatics analysis using the MSKCC dataset 
from cBioPortal. As anticipated based on our results, both FZD8 and WNT11 expression 
correlated with expression of the mesenchymal genes SNAI1, SNAI3, TWIST1 and 
TWIST2, and negatively correlated with the expression of the epithelial markers CDH1 
and CTNNB1, further supporting the link between Wnt-11-FZD8 signaling and EMT (Fig. 
51B). 
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Figure 51. FZD8 regulates the expression of EMT markers at the protein level.  (A) Extracts 
from PC-3M silenced cells blotted for the indicated proteins; graph shows average relative protein 
levels, determined by densitometry analysis of blots from three independent experiments, 
normalized to HSP60 and relative to control siRNA. (B) Correlation analysis of FZD8 and WNT11 
mRNA expression with the indicated EMT genes in the MSKCC dataset calculated using 
cBioPortal; Pearson and Spearman coefficients were used to measure correlation. * p < 0.05 by 
Student´s t test. 
2.1.2.2 Regulation of WNT11 by FZD8: potential positive-
feedback loop 
   The fact that FZD8 is required for the EMT process in prostate cancer, together with 
reports describing WNT11 as an EMT gene in kidney epithelial cells (P. Zhang et al. 
2012; He et al. 2011) led us to analyze WNT11 expression in FZD8 silenced cells. FZD8 
silencing significantly reduced WNT11 expression both in PC-3M and DU145 cells (Fig. 
52A). Moreover, there was a positive correlation between FZD8 and WNT11 expression 
in the MSKCC dataset (Fig. 52B). These observations together suggest that there may 
be a positive-feedback loop in the pathway, in which FZD8 signaling increases 
expression of its ligand. However, further studies will be required to explore the 
mechanism of this regulation.  
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Figure 52. FZD8 regulates WNT11 expression. (A) Q-RT-PCR analysis showing expression 
levels of the indicated genes, normalized to 36B4, in PC-3M and DU145 cells silenced with control 
(siCtrl) or FZD8 siRNAs, error bars show SD for four independent experiments. (B) Correlation 
plot for FZD8 and WNT11 mRNA expression in the MSKCC prostate cancer dataset, generated 
using cBioPortal; * p < 0.05, ** p < 0.001 by Student´s t test. 
2.1.2.3 EMT in organotypic 3D cultures 
Since our observations demonstrate that FZD8 is involved in the regulation of EMT, 
we used 3D culture assays to examine organoid morphology, staining for laminin a1 and 
vimentin, to distinguish epithelial, and well-differentiated structures from mesenchymal, 
and undifferentiated ones. Confocal analysis at the endpoint of the 3D culture from both 
PC-3M and PC-3 cells silenced for FZD8 revealed that laminin a1, which was not 
detectable in control organoids, was clearly observed in FZD8-silenced organoids, 
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indicating the presence of a basal lamina characteristic of well-differentiated structures 
(Fig. 53). On the other hand, vimentin staining highlighted invasive cells migrating from 
control cell organoids but not from FZD8-silenced organoids, reflecting a reduction in 
invasive and mesenchymal properties of the latter (Fig. 53). Interestingly, a proportion 
of the FZD8-silenced organoids showed a total absence of vimentin staining, further 
supporting the importance of FZD8 for invasive behavior and EMT (Fig. 53, upper 
panel).  
 
Figure 53. Immunostaining of FZD8 silenced cells in organotypic 3D cultures. Confocal 
microscopy analysis of organoids derived from siCtrl and FZD8 silenced PC-3M (upper panel) 
and PC-3 (lower panel) cells at day 9 of growth in 3D culture; immunostaining for vimentin (Vim) 
is shown in green and for laminin-a1 (Lam) in red, blue staining shows cell nuclei (Draq5), scale 
bar 100 µm.  
2.2 Role of FZD8 in prostate pathogenesis: in vivo assays 
2.2.1  In vivo chicken chorioallantoic membrane (CAM) model 
Since our results highlight the malignant phenotype of FZD8 in prostate cancer, we 
decided to validate the functional role of FZD8 in vivo using the chorioallantoic 
membrane (CAM) model. This model is based on the properties of the CAM, which is a 
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highly vascular membrane found in chicken eggs that is easily accessible and that 
enables efficient tumor cell grafting and growth owing to the immunodeficient state of the 
chick embryo at this point in development. In this sense, the growth of tumor cells on the 
CAM mimics most of the characteristics of the carcinogenic process, including growth, 
invasion, angiogenesis and colonization of distant tissues (Deryugina & Quigley 2009) 
and also the cancer cell environment owing to its extracellular matrix protein content 
(Lokman et al. 2012). Control and FZD8-silenced PC-3 cells were grafted onto the 
exposed CAM of chicken embryos at developmental day 7 (EDD7) and allowed to grow 
for 3 days. At EDD10, tumors formed by FZD8-silenced PC-3 cells were significantly 
smaller than those formed by control cells (Fig. 54A-C), supporting the relevance of 
FZD8 in prostate cancer growth in vivo. Evaluation of the extent of FZD8 silencing at the 
moment of cell grafting onto the CAM and when tumors were excised indicated that 
silencing was maintained during the course of the assay (Fig. 54D).  
 
Figure 54. FZD8 is required for tumor growth in vivo in the CAM model. (A) Representative 
pictures of PC-3 derived tumors implanted on the CAM for 3 days. Left, overview of the egg; right, 
representative tumors from PC-3 cells silenced for FZD8; scale bars ~5 mm. (B) Average tumor 
size, as determined by ImageJ, relative to control tumors, error bars indicate SD from three 
independent experiments, each with 12-15 eggs per condition. (C) Boxplot of tumor size in a 
representative experiment. (D) FZD8 expression levels at day 0, when cells were implanted on 
the CAM and at the endpoint, when CAM tumors were excised from the egg; error bars indicate 
SD of three independent experiments * p < 0.05, ** p < 0.001 by Student´s t test. 
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As a way to study prostate cancer metastasis in this in vivo model, we analyzed the 
expression of vimentin, which contributes to prostate cancer invasiveness (Wei et al. 
2008; Y et al. 2008; Singh et al. 2003) in CAM tumors from control and siFZD8 PC-3 
cells. Immunohistochemical analysis of the CAM tumor sections allowed us to determine 
that tumors in which FZD8 was silenced exhibited lower levels of vimentin than control 
tumors, consistent with the role of FZD8 in prostate tumor cell invasion (Fig. 55). Of note, 
together with being a marker for invasiveness, immunostaining for vimentin distinguishes 
prostate cancer cells from CAM cells, which are negative for this marker (Fig. 55, 
arrows). 
 
Figure 55. Immunohistochemistry of FZD8 and vimentin in the CAM. Representative images 
of sections from CAM tumors silenced for FZD8; arrows show chick embryo cells, distinguished 
from PC-3 cells by the absence of vimentin staining, scale bar 50 µm. 
2.2.2 In vivo mouse model 
 Orthotopic mouse models are based on directly implantation of the human cell line of 
interest into their organ of origin. In our case, human PCa PC3-M cell line is directly 
implanted into the prostate of athymic mice. After 4-6 weeks, tumor size, presence of 
circulating tumor cells (CTCs), and metastasis to the lungs and lymph nodes can all be 
quantified (Pavese et al. 2013). Taking advantage of some sections from mice in which 
PC-3M cells were orthotopically implanted to generate prostate tumors, 
immunohistochemistry was used to determine the levels of FZD8 and Wnt-11 in lymph 
node metastases (Fig. 56). Consistent with a role for Wnt-11/FZD8 signaling in prostate 
cancer metastasis, both proteins were detected in lymph nodes from the mice. Vimentin 
staining was also used to distinguish prostate cancer cells from host cells.     
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Figure 56. Immunohistochemical staining of a lymph node metastasis from a PC-3 mouse 
xenograft. Sections were stained for FZD8, Wnt-11 and vimentin; scale bars in upper pictures 
50 µm; lower pictures show zoom areas from upper ones. 
2.3 Role of FZD8 in prostate tumorigenesis: analysis of patient 
samples  
The use of human samples in biomedical research has expanded our concept of cell 
biology and contributed to the evolution and progress of basic biomedical research. 
Based on the wide use of human samples to identify biomarkers that can predict prostate 
cancer progression, relapse, therapy response and survival, we explored the potential of 
FZD8 as a biomarker in prostate cancer using tissues form PCa patients. 
2.3.1 Bioinformatics analysis of prostate cancer datasets 
Aiming to corroborate our hypothesis of FZD8 being an indicator of prostate cancer 
progression, we performed a closer examination of FZD8 expression in prostate cancer 
datasets from the Oncomine database. The analysis showed that FZD8 mRNA was 
significantly upregulated in the highest number of datasets when comparing prostate 
carcinoma and benign prostate (Fig. 57A). Analysis of FZD8 mRNA expression in others 
datasets from the cBioPortal for Cancer Genomics (Cerami et al. 2012; Gao et al. 2013) 
also revealed elevated FZD8 mRNA expression (z-score threshold ±1.5) in 10% of 
tumors from the TGCA dataset (Abeshouse et al. 2015) as well as in 6% of tumors from 
the SU2C/PCF Metastatic Prostate Cancer dataset (Robinson et al. 2015). Interestingly, 
FZD8 mRNA expression correlated with the presence of the TMPRSS2-ERG gene fusion 
and ERG mRNA expression (Fig. 57B), which has been found in 50% of prostate tumors. 
Moreover, this observation was confirmed in a second dataset (Grasso; OncomineTM 
database, Fig. 57C).   
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Figure 57. FZD8 is upregulated in patient prostate tumors. (A) Analysis of FZD8 expression 
in four different datasets taken from OncomineTM: Tomlins (22 prostate glands and 30 prostate 
carcinomas), Arredouani (8 prostate glands and 13 prostate carcinomas), Varambally (6 prostate 
glands and 7 carcinomas) and Grasso (26 prostate glands and 59 carcinomas); prostate gland 
was defined as normal (N) and prostate carcinoma as tumor (T); only datasets with p < 0.05 and 
fold-change > 1.5 were considered. (B) Correlation of FZD8 and ERG mRNA expression in 
prostate cancer datasets from cBioPortal, SU2C/PCF Dream Team Metastatic Prostate Cancer 
dataset (Robinson et al., 2015) (left) and TGCA prostate cancer dataset (Cancer Genome Atlas 
Research Network, Cell, 2015) (right). (C) FZD8 expression in prostate tumors with (ERG+) and 
without (ERG-) ERG rearrangement from the Grasso dataset from OncomineTM. 
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The results from our studies in prostate cancer cell lines suggest a model in which 
FZD8 transduces Wnt-11 signals that promote EMT and prostate cancer cell invasion. 
In order to evaluate FZD8 and WNT11 gene expression during prostate cancer 
progression, we performed bioinformatics studies using the MSKCC dataset (Taylor et 
al. 2010). Importantly, the analysis revealed a clear upregulation of FZD8 in prostate 
cancer compared to normal prostate and in prostate cancer metastases compared to 
primary tumors. Both FZD8 and WNT11 were upregulated in high Gleason score tumors 
and in tumors that had spread to the lymph nodes (Fig. 58A). Moreover, expression of 
WNT11 correlated significantly (p = 0.014) and FZD8 showed a trend (p = 0.057) with 
increased biochemical recurrence (Fig. 58B). 
 
 
Figure 58. Correlation of FZD8 and WNT11 with prostate cancer relapse. (A) Bioinformatics 
analysis of FZD8 (left) and WNT11 (right) expression in prostate cancer using the MSKCC 
dataset. (B) Recurrence analysis based on FZD8 (left) and WNT11 (right) expression in the 
MSKCC dataset, determined using CamcAPP.  
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A deeper analysis of the MSKCC dataset also showed that elevated expression of 
both FZD8 and WNT11 was more prevalent in patients with recurrent disease, as 
compared to disease-free patients (p = 0.049, Fisher’s exact test, two-sided) (Fig. 59), 
which lends support to the relevance of the Wnt-11-FZD8 signaling pathway in prostate 
cancer progression. 
 
Figure 59. FZD8 and WNT11 expression and disease free status. Comparison of tumors with 
changes in FZD8 and WNT11 expression (up, red; down, blue) and disease-free status of 
patients, from cBioPortal. 
2.3.2  Analysis of FZD8 and Wnt-11 protein expression in prostate 
cancer patient TMAs 
To confirm these in silico data, we used a TMA comprising sections of benign and 
malignant prostate from 90 prostate cancer patients and performed 
immunohistochemistry to detect FZD8 and Wnt-11 protein expression. As expected, the 
evaluation of the staining revealed significantly higher levels of FZD8 and Wnt-11 in 
tumor cells compared to benign epithelium from the same patients (Fig. 60).  
 
Figure 60. FZD8 and Wnt-11 expression are increased in prostate cancer. 
Immunohistochemical staining of FZD8 and Wnt-11 in adjacent sections of prostate cancer 
(Gleason 4+3) and benign prostate from the same patient; scale bar 25 μm. 
Disease Free Status
FZD8
WNT11
Genetic Alteration
Disease Free Status
Heatmap
No alteration mRNA Upregulation mRNA Downregulation
N/A     Recurred Disease Free
N/A -3 3
69%
69%
WNT11
FZD8
Benign prostate
Prostate carcinoma
Wnt-11
Wnt-11
FZD8
FZD8
Results 
142 
 
Moreover, the previous observation was supported by the finding of a significant 
correlation in the levels of FZD8 and Wnt-11 in benign and tumor epithelia and stroma 
(Fig. 60, 61 and Table 18). 
 
Figure 61. FZD8 and Wnt-11 are expressed in disseminated tumor cells. 
Immunohistochemical staining of FZD8 and Wnt-11 in a section of prostate cancer (Gleason 4+3) 
from another patient; scale bar 25 μm. High magnification images for FZD8, Wnt-11, epithelial 
cytokeratins and H&E are also shown. Arrows show disseminated tumor cells positive for FZD8, 
Wnt-11 and epithelial cytokeratins. 
 
 Cancer vs Normal C.stroma vs N.stroma 
Correlation FZD8 Wnt-11 FZD8 Wnt-11 
Chi Pearson <0.001 <0.001 <0.001 <0.001 
Fisher Exact Two tails 1.13E-11 4.56E-09 7.27E-15 4.68E-12 
 
Table 18.  Correlation analysis of FZD8 and Wnt-11 protein expression in normal and 
cancer. Comparison of tumor and benign epithelium and cancer stroma and benign stroma.  
     Interestingly, it was observed that FZD8 and Wnt-11 were also both significantly lower 
in tumor stroma than in the benign stroma (Fig. 62 and Table 19), suggesting that 
elevated expression in cancer epithelial cells is accompanied by reduced expression in 
tumor-associated stroma, possibly reflecting a common mechanism of regulation of Wnt-
11 and FZD8.  
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Figure 62. Both FZD8 and Wnt-11 expression are increased in tumor epithelia and reduced 
in prostate cancer stroma. Stratification of FZD8 and Wnt-11 expression in cancer (T) and 
benign (N) epithelia and stroma. **p <0.001 with Chi-Squared test and Fisher´s exact test, two 
sided. 
 
 
Correlation FZD8 Wnt-11  Chi-square; Fisher Exact 
Cancer     
  Low High <0.0001; 0.000071 
 Low 17 5  
 High 18 46  
Benign     
  Low High No value;0.039 
 Low 61 8  
 High 14 7  
Cancer stroma     
  Low High 0.0063; 0.011 
 Low 46 17  
 High 10 14  
Benign stroma     
  Low High No value;0.027 
 Low 5 9  
 High 8 68  
 
Table 19. Correlation analysis of FZD8 and Wnt-11. Pearson Chi-square test with correction 
and Fisher´s exact test, two-sided were used. 
 
    
   Despite our observations showing that FZD8 and Wnt-11 levels were higher in prostate 
cancer than in benign prostatic epithelium, there was no significant correlation between 
high expression and Gleason score in this patient cohort (Table 20). In this regard, larger 
studies will be needed to clarify the role of Wnt-11/FZD8 as markers of prostate cancer 
progression and patient mortality.  
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Antigen Staining 
score Category n (%) Category n (%) 
Chi-Square; Fisher´s 
Exact 
FZD8       
 Benign Cancer <0.001; 1.13E-11 
Low 69 (76,7) 22 (25,6)  
High 21(23,3) 64 (74,4)  
 Gleason ≤ 3,4 Gleason  ≥4,3 NS 
Low 47 (52,8) 19 (12,3)  
High 21 (23,6) 2 (2,24)  
 pT2 pT3 NS 
Low 16 (17,9) 7 (7,8)  
High 33 (37,1) 33 (37,1)  
 PNI+ PNI- NS 
Low 7 (7,8) 16 (17,9)  
High 28 (31,4) 38 (42,7)  
Wnt-11       
 Benign Cancer <0.001; 4.56E-9 
Low 75 (83,3) 35 (40,7)  
High 15 (16,6) 51 (58,6)  
 Gleason ≤ 3,4 Gleason  ≥4,3 NS 
Low 36 (41,3) 15 (17,2)  
High 31 (35,6) 5(5,7)  
 pT2 pT3 NS 
Low 23 (26,4) 13 (14,9)  
High 25 (28,7) 26 (29,8)  
 PNI+ PNI- NS 
Low 12 (13,8) 24 (27,6)  
High 28 (32,2 23 (26,4)  
FZD8 stroma       
 Benign Cancer <0.001; 7.27E-15 
Low 14 (15,5) 63 (72,4)  
High 76 (84,4) 24 (27,6)  
 Gleason ≤ 3,4 Gleason  ≥4,3 NS 
Low 22 (24,7) 2 (2,2)  
High 46 (51,7) 19 (21,3)  
Wnt-11 stroma       
 Benign Cancer <0.001; 4.68E-12 
Low 13 (14,4) 56 (64,4)  
High 77 (85,5) 31 (35,6)  
 Gleason ≤ 3,4 Gleason  ≥4,3 NS 
Low 24 (27,3) 7 (7,9)  
High 44 (50) 13 (14,7)  
 
Table 20. Statistical analysis of FZD8 and Wnt-11 expression in TMAs. Staining was 
classified as low (score 0 or 1) or high (score 2 or 3). Entries are absolute numbers with % in 
parentheses. Statistical significance was determined using Chi-squared test, Pearson correction 
and Fisher´s exact test, two-sided; * p < 0.05  
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Chapter 3. Elucidation of the mechanism underlying the effects 
of FZD8 in prostate cancer pathogenesis 
Our results have revealed the contribution of FZD8 to prostate cancer pathogenesis, 
promoting migration and invasion abilities of tumor cells as well as EMT, which together 
may drive prostate cancer progression and metastasis. However, the mechanisms 
mediating this tumor promoter role of FZD8 in prostate cancer remain undetermined. 
Multiple studies have outlined the capability of Wnt signaling to activate other pathways 
in various types of cancer. Crosstalk between the Wnt pathway and the PI3K/AKT, Ras 
or mTOR pathways has been widely reported. Moreover, Wnt pathway crosstalk with 
growth factor signaling pathways such as EGF, VEGF, HGF, IGF, FGF or TGF- are 
fairly prevalent in the development and progression of cancer. In this regard, all these 
pathways could represent the mechanism driving FZD8 effects on prostate cancer. 
3.1 Involvement of FZD8 in TGF- signaling 
Among all the various signaling pathways, crosstalk between TGF-β and Wnt 
signaling is one of the best characterized and more extensively studied (Guo & Wang 
2009; Attisano & Wrana 2013). Moreover, by analyzing the expression levels of the major 
components of the TGF- signaling pathway, we observed high expression of TGF1, 
TGFRI, TGFRII, SMAD2 and SMAD3 in both metastatic prostate cancer cell lines PC-
3M and DU145 (Fig. 63).  
 
Figure 63. Expression of the major components of the TGF- signaling pathway. mRNA 
expression with Ct values of the indicated genes in PC-3M and DU145 cells. 36B4 Ct values were 
≈ 16 in all experiments); error bars show SD of three independent experiments. Of note, lower Ct 
indicates higher mRNA expression. 
In light of the fact that FZD8 is required for Wnt-11/ATF2 signaling, regulation of cell 
migration and invasion and expression of EMT-related genes, and based on the well 
reported implication of TGF- in these events and on the high expression of TGF- 
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components in PCa cell lines, we hypothesized that FZD8 could be mediating its effects 
by playing a direct role in regulating TGF-β signaling. To corroborate this hypothesis, the 
activation of TGF-β signaling was evaluated using gene reporter assays, analysis of 
TGF-β target gene expression and TGF-β dependent Smad phosphorylation, as well as 
through analysis of TGF-β dependent cell invasion and regulation of TGF-β dependent 
EMT. 
3.1.1 Analysis of TGF--dependent transcriptional activity 
In order to determine if FZD8 could regulate TGF-β signaling at the transcriptional 
level, we first evaluated activation of the CAGA reporter, a Smad-dependent gene 
reporter that contains 12 copies of the PAI-1 promoter (a TGF-β target gene). FZD8 
silencing in both PC-3M and DU145 cells significantly reduced TGF--dependent 
activation of the CAGA reporter (Fig. 64A and B). Moreover, this effect was also 
observed when FZD8 was silenced using an unrelated Dicer-substrate siRNA in PC-3M 
cells (Fig. 64C).   
   
Figure 64. FZD8 is required for TGF-β-dependent gene reporter activity. (A-C) CAGA12-
luciferase/renilla activity in PC-3M (A and C) and DU145 (B) cells, respectively, silenced with 
siFZD8 or dsiFZD8 and treated with -/+ 1-0,1 ng/mL TGF-β for 24 h; error bars show SD from 
three independent experiments. * p < 0.05, ** p < 0.001 by Student´s t test or ANOVA with Tukey 
post-hoc test where required. 
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3.1.2    Evaluation of target gene expression and Smad 
phosphorylation 
To further characterize the regulation of TGF- signaling by FZD8, we analyzed the 
expression of some TGF- target genes as well as the levels of Smad phosphorylation, 
which is considered to be a good indication of activation of the pathway. Consistent with 
our previous observations, FZD8 silencing was found to reduce the expression of the 
TGF- target genes MMP9 and PAI1, both in PC-3M and DU145 cells (Fig. 65A and B). 
Furthermore, through a deeper analysis of the pathway by western blotting, we also 
found that silencing of FZD8 reduced TGF-β-dependent Smad2 phosphorylation and 
Smad2/3 protein levels in both cell lines (Fig. 65C and D), further supporting the 
involvement of FZD8 in TGF-β/Smad-dependent signaling. 
 
Figure 65. FZD8 is required for expression of TGF-β target genes and TGF-β-dependent 
Smad phosphorylation. Relative mRNA expression of the indicated genes in PC-3M (A) and 
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DU145 (B) cells silenced for FZD8; error bars show SD of four independent experiments. Western 
blots of PC-3M (C) and DU145 (D) cells silenced for FZD8 and treated with 1 ng/mL of TGF-β for 
30 min. pSmad2, pSmad3, Smad2/3 and -tubulin were used for blotting; graph shows relative 
protein levels, as determined by densitometry analysis of bands from TGF-β-treated extracts, 
normalized to -tubulin and relative to control siRNA, from three independent experiments * p < 
0.05, ** p < 0.001 by Student´s t test. 
3.1.3 Analysis of TGF--dependent cell invasion 
Since TGF-β signaling has been shown to promote cell invasion and our results are 
consistent with a requirement for FZD8 in TGF-β signaling, we evaluated if FZD8 
silencing reduced invasion through its ability to inhibit TGF-β signaling. In fact, FZD8 
silencing significantly reduced TGF-β-induced cell invasion both in PC-3M (Fig. 66A, C 
and D) and DU145 cells (Fig. 66B, E and F) without affecting cell number (Fig. 67), 
supporting a role for FZD8 in regulating TGF-β signaling and its consequent effects.  
 
Figure 66. FZD8 is required for TGF-β-dependent cell invasion. Relative cell invasion of PC-
3M (A) and DU145 (B) cells silenced for FZD8 and treated with 5 ng/mL of TGF-β for 48 h; error 
bars represent SD of three independent experiments. (C-F) Relative cell invasion in a 
representative experiment and representative pictures of invading cells for PC-3M (C and D) and 
DU145 (E and F) cells. * p < 0.05 by Student´s t test. 
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Figure 67. Cell number analysis for invasion assays. (A) and (B) show cell number for PC-
3M and DU145 cells, respectively silenced for FZD8 and treated with 5 ng/mL of TGF-β for 48 h; 
error bars represent SD of three independent experiments. These data were used to normalize 
numbers of invading cells in Fig. 66. * p < 0.05, ** p < 0.001 by Student´s t test. 
3.1.4 Study of TGF--dependent-EMT regulation 
To extend our findings regarding FZD8 regulation of TGF- signaling, we determined 
if FZD8 silencing was also able to reduce EMT gene expression via inhibition of TGF-β 
signaling. To do this, the effects of TGF-β on the expression of EMT related genes were 
first examined. While TGF-β treatment increased MMP9 and PAI1 expression (Fig. 68A 
and B) in both PC-3M and DU145 cells, it did not affect expression of EMT-related genes 
in PC-3M cells, apart from a small increase in CDH2 and CDH1 (Fig. 68C), being the 
latter expected to decrease with TGF-β treatment (Cao & Kyprianou 2015; Papageorgis 
2015). In contrast, TGF-β treatment of DU145 cells increased VIM, SNAI1/2 and ZEB1 
expression and reduced expression of CDH1 (Fig. 68D). Not only that, TGF-β treatment 
also increased FZD8 and WNT11 expression (Fig. 68E), supporting the idea of a positive 
feedback loop in the regulation of EMT. These results suggest that although both cell 
lines are highly metastatic, they display different features regarding EMT gene 
expression, which makes DU145 cells more sensitive to TGF-β treatment than PC-3M 
cells. 
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Figure 68. Effects of TGF-β on EMT gene expression. (A-D) Q-RT-PCR analysis after 
treatment with 1 ng/mL TGF-β for 24 h of TGF-β target genes in PC-3M (A) and DU145 (B) cells 
as well as of EMT markers in PC-3M (C) and DU145 (D) cells. (E) Q-RT-PCR analysis of FZD8 
and WNT11 in DU145 cells after treatment with 1 ng/mL TGF-β for 24 h; in all cases error bars 
show SD for four independent experiments; * p < 0.05, ** p < 0.001 by Student´s t test. 
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   After evaluating the effects of TGF-β in both cell lines, we decided to use DU145 cells, 
where TGF-β effects were evident, aiming to determine if FZD8 silencing could affect 
TGF-β-dependent EMT gene expression. Examination of EMT-related genes upon TGF-
β treatment by q-RT-PCR revealed that FZD8 silencing inhibited TGF-β-induced 
expression of VIM, SNAI1/2, ZEB1, MMP9 and PAI-1 and increased expression of 
CLDN1 (Fig. 69A and B). Together, these results provide evidence for a functional role 
for FZD8 in regulating TGF-mediated EMT gene expression. 
 
 
Figure 69. FZD8 regulates TGF-β-dependent expression of EMT-related genes. Relative 
mRNA expression of the indicated EMT genes (A) as well as of the TGF-β target genes (B), 
relative to 36B4, in DU145 cells silenced for FZD8 and treated with 1 ng/mL TGF-β for 24 h; error 
bars show SD for four independent experiments. * p < 0.05, ** p < 0.001 by Student´s t test. 
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3.2 Mechanism of regulation of TGF- signaling by FZD8  
3.2.1 Regulation at the intracellular level  
      The observations found in this work indicate that FZD8 is involved in both Wnt-
11/ATF2 and TGF-β/Smad signaling. Interestingly, in addition to the traditional crosstalk 
between Wnt and TGF-β pathways observed at the level of Smad and -catenin, ATF2 
has also been reported to associate with Smad proteins (Sano et al. 1999). This suggests 
that Wnt-11/FZD8 signaling might regulate TGF-β/Smad via ATF2. In order to assess 
the contribution of ATF2 to TGF-β signaling, we evaluated the effects of a dominant-
negative form of ATF2, Δ-ATF2, which binds and inhibits the activities of ATF2 and its 
AP-1 family partners (Vinson et al. 2002). Gene reporter assays showed that Δ-ATF2 
significantly reduced TGF- activation of the Smad-dependent reporter CAGA-12 (Fig. 
70A), indicating that ATF2 and/or other AP-1 family members play a role in TGF-β/Smad 
signaling. An inhibitory effect of Δ-ATF2 was also observed when using the 3TP-lux 
reporter, which contains both Smad and AP-1 binding sites (Fig. 70B). Moreover, ∆-
ATF2 significantly reduced TGF-β-induced expression of VIM, SNAI2 and ZEB1 and 
increased the expression of CDH1 in DU145 cells (Fig. 71) indicating a requirement for 
ATF2 for the expression of a subset of TGF-β-regulated EMT genes. 
 
Figure 70. ATF2 is required for TGF-β-dependent gene reporter activity. Gene reporter 
assays of CAGA12-luciferase (A) or 3-TP-luciferase (B) activities in PC-3M cells transfected with 
empty vector CMV500 (V) or dominant-negative ATF2 (Δ-ATF2) and treated with 1 ng/mL TGF-
β for 24 h; error bars show SD for three independent experiments; * p < 0.05, ** p < 0.001 by 
ANOVA with Tukey post-hoc test. 
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Figure 71. ATF2 regulates TGF-β-dependent expression of EMT-related genes. Q-RT-PCR 
analysis showing mRNA expression of the indicated genes in DU145 cells transfected with empty 
vector CMV500 (V) or Δ-ATF2 and treated with 1 ng/mL TGF-β for 24 h; error bars show SD for 
four independent experiments; * p < 0.05 by Student´s t test. 
Since all these results together suggest that FZD8 may promote TGF-β/Smad-
dependent signaling via activation of ATF2, and given the reported association of ATF2 
with Smad2 and Smad3 (Sano et al. 1999), we wished to determine if this interaction 
was affected by FZD8 silencing. However, we were unable to detect a stable complex 
between ATF2 and Smad2 or Smad3 by immunoprecipitation in prostate cancer cells 
(Fig. 72), suggesting that signaling crosstalk takes place at some other point in the TGF-
β signaling pathway. 
 
Figure 72. ATF2 does not form a stable complex with Smad3. Western blots of anti-HA 
immunoprecipitates (IP) and extracts (inputs) from PC-3M cells transfected for 24 h with HA-
tagged ATF2 and c-JUN, and Smad3 plasmids were probed for ATF2 and c-JUN (HA) and Smad3 
(Flag); blots are representative of two independent experiments.   
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3.2.2 Regulation at the cell membrane 
3.2.2.1 FZD8 binds to TGF- receptors 
Based on our results excluding the regulation of TGF- signaling by FZD8 through 
Smad/ATF2 interaction, we next hypothesized that crosstalk between FZD8 and TGF-β 
signaling might take place at the cell membrane. TGF- signaling is initiated by ligand 
binding to two transmembrane receptor kinases (TGFRI and TGFRII), with binding of 
TGF- to TGFRII being a prerequisite for efficient ligand binding to TGFRI (Shi & 
Massagué 2003). To test if FZD8 associated with TGF receptors, PC-3M cells were 
transfected with plasmids expressing epitope-tagged FZD8, TGFRI and TGFRII and 
subjected to immunoprecipitation analysis. Interestingly, a stable interaction was 
observed between FZD8 and both TGFRI and TGFRII (Fig. 73A). In addition, 
immunofluorescence analysis also showed that FZD8 partially co-localized with both 
TGFRI and TGFRII in transfected cells, lending further support to our hypothesis (Fig. 
73B). 
            
Figure 73. FZD8 associates with TGF-β receptors. (A) Western blots of anti-1D4 
immunoprecipitates (IP) and extracts (inputs) from PC-3M cells transfected with indicated 
plasmids; anti- HA, Flag and 1D4 were used for blotting. Blots are representative of three 
independent experiments and the positions of molecular mass markers are indicated. (B) 
Immunofluorescence analysis of PC-3M cells transfected with 1D4-tagged FZD8 (red) and Flag-
tagged TGFRI or HA-tagged TGFRII (green) for 24 h; images are representative of three 
independent experiments, blue staining shows cell nuclei (DAPI); scale bar 25μm. 
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3.2.2.2 Analysis of interacting domains 
FZD8, as all members of the FZD family, contains an extracellular N-terminal 
cysteine-rich domain (CRD), which is very well characterized owing to its involvement in 
Wnt binding. To determine whether the FZD8 CRD was involved in the association of 
FZD8 with TGF receptors, a plasmid encoding the FZD8 CRD fused to the Fc domain 
of human IgG was used. This fusion protein associated with TGFRI but not with 
TGFRII (Fig. 74A) suggesting that FZD8 associates with TGFRI and that the observed 
interaction with TGFRII (Fig. 73A) is mediated by endogenous TGFRI. In contrast to 
FZD8 CRD IgG, the extracellular domain of LRP6 fused to the Fc domain of human IgG 
did not bind either TGFRI or TGFRII (Fig. 74A). Furthermore, a tagged form of the 
TGFRI extracellular domain (ΔTGFRI) readily associated with FZD8 CRD-IgG (Fig. 
74B), which is consistent with the interaction between FZD8 and TGFRI involving the 
extracellular domains of both proteins.  
 
Figure 74. FZD8 and TGFRI associate through their extracellular domains. (A) Western 
blots of Protein A/G-agarose immunoprecipitates (IP IgG) and extracts (inputs) from PC-3M cells 
transfected for 24 h with indicated plasmids; anti-HA, -Flag and -IgG were used for blotting. Blots 
are representative of three independent experiments and the positions of molecular mass 
markers are indicated. (B) Western blots of Protein A/G-agarose pull-downs (IP IgG) and extracts 
(inputs) from PC-3M cells transfected for 24 h with indicated plasmids; Anti-Flag and -IgG were 
used for blotting. Blots are representative of three independent experiments and the positions of 
molecular mass markers are indicated. 
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3.2.2.3 Effects of TGF- on the interaction 
 To determine if the interaction of FZD8 with TGFRI/RII was ligand-regulated, 
experiments were carried out using cells treated with or without exogenous TGF-. 
Western blotting for phosphorylated Smad3 indicated that transfection of TGFRI/II was 
sufficient to activate TGF- signaling and that this was not affected by exogenous TGF-
 (Fig. 75A). However, treatment with TGF- reduced the interaction between FZD8 and 
TGFRII, whereas there was no significant effect on its association with TGFRI (Fig. 
75B). These results are consistent with FZD8 interacting with TGFRII via TGFRI and 
TGF- treatment reducing binding of TGFRII to the FZD8-TGFRI complex.  
 
Figure 75. The FZD8-TGF-β receptor interaction is ligand-regulated. (A) Western blots of 
anti-1D4 immunoprecipitates (IP) and extracts (inputs) from PC-3M cells transfected for 24 h with 
plasmids encoding 1D4-tagged FZD8, Flag-tagged TGFRI and HA-tagged TGFRII, serum-
starved and treated -/+ 1 ng/mL TGF-β for 24 h. Anti-HA, Flag and 1D4 were used for blotting. 
Extracts were also probed for pSmad3 and GAPDH as a loading control. Blots are representative 
of three independent experiments and the positions of molecular mass markers are indicated. (B) 
Relative protein levels, as determined by densitometry analysis of bands from TGF-β-treated 
extracts, relative to control (Ctrl), from three independent experiments. 
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3.2.2.4 Implication of Wnt-11 in FZD8-TGFRI binding 
After demonstrating that the interaction between FZD8 and TGFRI/RII was TGF--
regulated, we wished to determine if Wnt-11 binding to FZD8 could prevent the FZD8-
TGFRI/RII complex or if on the contrary, FZD8 could be binding both Wnt-11 ligand and 
TGF- receptors at the same time. Unexpectedly, co-immunoprecipitation analysis of 
tagged forms of Wnt-11, FZD8 and TGFRs, indicated that Wnt-11 associated with FZD8 
even when it was bound to TGFRs (Fig. 76). Moreover, Wnt-11 also co-
immunoprecipitated with TGFRI, which may indicate binding mediated by endogenous 
FZD8 receptors (Fig. 76). 
 
Figure 76. Implication of Wnt-11 in FZD8-TGFRI binding. Western blots of anti-Flag 
immunoprecipitates (IP) and extracts (inputs) from PC-3M cells transfected for 24 h with plasmids 
encoding 1D4-tagged FZD8, Flag-tagged TGFRI and PA-tagged Wnt-11. Anti-PA, 1D4 and Flag 
were used for blotting. Blots are representative of three independent experiments and the 
positions of molecular mass markers are indicated. 
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In conclusion, our data lead us to stablish a model in which FZD8, by interacting both 
with Wnt-11 and TGFRI, is able to play a pivotal role in integrating Wnt and TGF- 
signals to drive EMT and invasion promoting prostate cancer progression and therefore, 
unveil FZD8 as an important target for the therapy of metastatic prostate cancer (Fig. 
77). 
 
 
Figure 77. Proposed model for FZD8 integration of Wnt-11 and TGF- signals. Regulation at 
the level of the receptors and transcription factors is shown. Dashed arrow indicates potential 
regulation of Smad2/3 by ATF2, based on other published studies (see text). 
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Prostate cancer is the second leading cause of death in men in industrialized 
countries. Owing to the crucial role of the androgen receptor in prostate carcinogenesis, 
androgen deprivation therapy is the main treatment option for prostate cancer patients. 
However, most patient tumors evolve to a castration resistant state in which tumor cells 
do not respond to hormonal therapy. Despite some recent therapies targeting AR and 
chemotherapy extend the life of prostate cancer patients, resistance to these treatments 
still appears, highlighting the urgent need for novel targets that do not rely on targeting 
the androgen receptor for the treatment of these patients. Interestingly, Wnt signaling 
has been shown to be altered at different stages of prostate cancer (Murillo-Garzón & 
Kypta 2017). Among these alterations, Wnt-11, a noncanonical Wnt ligand, has been 
shown to be upregulated in prostate tumors, particularly in metastasis (Zhu et al. 2004), 
as well as to promote prostate cancer cell migration and invasion and neuroendocrine-
like differentiation features of aggressive disease (Uysal-Onganer et al. 2010). Several 
reports in the literature have shown the importance of targeting Wnt receptors as a 
strategy to inhibit aberrant Wnt signaling. Monoclonal antibodies such as Vantictumab, 
which targets FZD receptors (FZD1, 2, 5, 7 and 8)(Gurney et al. 2012); OTSA101, which 
targets FZD10 (Nagayama et al. 2005; Fukukawa et al. 2008) and Cirmtuzumab, which 
targets the ROR1 Wnt coreceptor (Choi et al. 2015) are in clinical trials for different 
cancer types (Murillo-Garzón & Kypta 2017).  
Taking all this evidence into account and based on the requirement of Wnt ligands to 
activate their receptors and signal, we aimed to identify the receptors involved in Wnt-11 
signaling in order to use them as therapeutic targets to inhibit Wnt-11 signaling in 
prostate cancer. During the work described in this thesis, we found that FZD8 is highly 
expressed in metastatic prostate cancer cell lines as well as in prostate tumors, 
functioning as a major Wnt-11 receptor in metastatic prostate cancer. High FZD8 
expression was related to a tumor-promoting role in which it promotes prostate cancer 
cell migration, invasion and regulates EMT. Interestingly, we also found that this 
regulation is TGF--dependent suggesting that FZD8 mediates crosstalk between Wnt-
11 and TGF- signaling through binding to TGFRI. These findings support the fact that 
FZD8 could be a good therapeutic target for the treatment of metastatic prostate cancer. 
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Chapter 1. Identification and characterization of Wnt-11 
receptors in metastatic prostate cancer 
   The initial screen to identify Wnt receptors with increased expression in metastatic 
prostate cancer led us to select FZD2, FZD4 and FZD8 as the three main candidates for 
transducing Wnt-11 signals. Q-RT-PCR analysis of 23 Wnt receptors and coreceptors 
showed an increased expression of these receptors in PC-3M and VCaP cell lines, which 
are both highly metastatic and express the highest levels of WNT11.  
   The increasing expression of FZD2 from less metastatic to more metastatic PCa cell 
lines is consistent with studies showing FZD2 involvement in prostate cancer 
aggressiveness through mediation of Wnt-5a signaling and binding to the ROR2 Wnt 
coreceptor (Yamamoto et al. 2010; Sato et al. 2010). Of note, a recent study has also 
reported association of high FZD2 expression with metastasis and biochemical 
recurrence in prostate cancer (Sandsmark et al. 2017).  
   FZD4 was also upregulated in metastatic prostate cancer cell lines, however its 
expression was higher in VCaP cells. These observations suggest a role for this receptor 
in TMPRSS-ERG positive tumors. Indeed, an association between FZD4 and ERG has 
already been described (Gupta et al. 2010), where FZD4 was also found to be associated 
with EMT. Our analysis of Wnt receptor expression in prostate cancer datasets using the 
Oncomine database revealed that FZD4 was also upregulated when comparing normal 
versus prostate cancer tissues, lending further support for a role of this receptor in a 
subset of prostate tumors. 
   Together with FZD2 and FZD4, we found upregulation of FZD8 in metastatic prostate 
cancer cell lines. Moreover, and distinct to FZD2 and FZD4, this upregulation was 
supported by a strong colocalization between FZD8 and Wnt-11 found by 
immunofluorescence studies, suggesting a role for FZD8 as Wnt-11 receptor. Indeed, 
FZD8 has been reported to be a Wnt-11 receptor in the mouse, where Wnt-11 is required 
for the kidney development (Ye et al. 2011). Consistent with our finding of FZD8 being 
upregulated in VCaP cells (TMPRSS-ERG fusion positive cell line), this receptor has 
also been reported to be induced by ERG (Brase et al. 2011), which was also confirmed 
by our bioinformatics analysis in different datasets. Furthermore, a recent study has also 
described that the expression of FZD8 is directly correlated with ERG expression in PCa, 
showing that ERG directly targets and activates FZD8 by binding to its promoter 
(Chakravarthi et al. 2018). FZD8 expression was also found to be upregulated in a high 
number of prostate cancer datasets from the Oncomine and cBioPortal databases. In 
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addition, analysis of FZD8 protein expression in the ProteinAtlas also revealed its 
upregulation in PCa compared to normal prostate, consistent with studies showing 
increased expression of FZD8 in prostate tumor epithelial cells, as compared to luminal 
epithelial cells from benign prostate (Pascal et al. 2009). 
Interestingly, although our cell line data did not show a notable upregulation of any 
other Wnt receptor, our immunofluorescence assays also revealed a partial 
colocalization between Wnt-11 and FZD6 and Wnt-11 and FZD10. FZD6 has been 
reported to colocalize with Wnt-11 in breast cancer cell lines, where it activated 
noncanonical Wnt/PCP signaling and cell migration (Luga et al. 2012). Moreover, chip 
studies have shown an upregulation of FZD6 in a panel of 54 prostate cancer patients 
(Wissman et al. 2003), suggesting that further investigation to clarify the role of this 
receptor in metastatic prostate cancer could be fruitful. Our analysis also showed a 
partial colocalization between FZD10 and Wnt-11 but the expression of this receptor was 
restricted to VCaP cells, where its expression was not very high. These results may 
suggest a possible role for FZD10 in ERG positive tumors, although additional studies 
will be needed to explore this hypothesis.  
Despite its expression not being upregulated in highly metastatic prostate cancer cell 
lines, our q-RT-PCR analysis indicated that FZD7 expression was increased in C4-2B 
cells cultured under hormone-deprived conditions (CSS) to induce NED, which also 
upregulates WNT11 (Uysal-Onganer et al. 2010; Volante et al. 2016). Although FZD7 
did not colocalize with Wnt-11 in our immunofluorescence studies, it has been reported 
to colocalize with Wnt-11 at the apical adherens junction in Xenopus embryos, where it 
regulates convergent extension movements (Djiane et al. 2000; Yamanaka & Nishida 
2007; Kim et al. 2008). In addition, FZD7 mediates Wnt-11 signals during colon cancer 
cell invasion (Ueno et al., 2009). It would therefore be worthwhile investigating the 
possibility that FZD7 acts as a Wnt-11 receptor in neuroendocrine-like prostate cancer 
(for example, colocalization of Wnt-11 and FZD7 in CSS C4-2B cells). 
Since the interaction between Wnt ligands and FZD receptors is context-dependent 
(Niehrs 2012), it is possible that different FZD receptors can bind to Wnt-11 in different 
cell types or conditions, as has been reported (Djiane et al. 2000; Penzo-Mendèz et al. 
2003; Yamanaka & Nishida 2007; Cavodeassi et al. 2005; Witzel et al. 2006; Abdul-
Ghani et al. 2011; Ye et al. 2011), which supports the potential involvement of more than 
one FZD family member functioning as Wnt-11 receptor in prostate cancer. 
Regardless of the valuable information obtained through these approaches, the main 
limitation of this study is the lack of data based on Wnt receptor protein expression. Most 
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of the information deposited in available databases describes mRNA expression levels 
and it is more difficult to obtain information about protein expression. In addition, the fact 
that FZD receptors are cysteine-rich seven-pass-transmembrane domain proteins 
makes difficult to analyze them using western blotting because they readily form 
aggregates. However, when technically possible, specific antibodies for detecting Wnt 
receptors and coreceptors is essential to confirm that FZD protein expression levels 
reflect mRNA expression levels. 
    While the results described in this thesis are focused on FZD receptors, Wnt ligands 
also require binding to specific coreceptors in order to signal (Niehrs 2012). Our q-RT-
PCR analysis showed an upregulation of ROR1 in PC-3M prostate cancer cells, which 
is consistent with studies from Zhang et al. showing upregulation of this orphan tyrosine 
kinase receptor in 19 of 21 prostate tumors (S. Zhang et al. 2012). Even though there 
are few reports linking ROR1 to prostate cancer, several studies show that ROR1 is 
involved in other cancer types, such as leukemia, lung, breast and colon cancer (Kolb et 
al. 2016). Moreover, the closely related receptor ROR2 has been found to mediate Wnt-
11 signaling in zebrafish, regulating convergent extension movements (Bai et al. 2014). 
ROR2 has also been extensively studied in different types of cancer, including prostate 
cancer, where it binds Wnt-5a through FZD2, to promote tumor aggressiveness 
(Yamamoto et al. 2010). Our in silico analysis of prostate cancer datasets also 
highlighted the upregulation of PTK7 in several prostate cancer datasets, consistent with 
studies showing PTK7 as a predictor of lymph node metastasis and as a prognostic 
biomarker in prostate cancer (Zhang et al. 2014). Although not seen in our screen, other 
studies have shown the involvement of other Wnt coreceptors in Wnt-11 signaling, such 
as the tyrosine kinase receptor RYK in Xenopus models (Kim et al. 2008). These reports, 
together with our preliminary results for the study of coreceptors, highlight the 
requirement for further studies to identify those involved in Wnt-11 signaling in prostate 
cancer. 
According to the widely characterized implication of Wnt-11 in noncanonical pathways 
(Uysal-Onganer & Kypta 2012), our data show that several FZD receptors can transduce 
Wnt-11-ATF2 noncanonical signaling. Interestingly, only FZD8 and FZD10 were able to 
enhance the activation that Wnt-11 produces in PC-3M cells. It is important to bear in 
mind that besides being a mediator of noncanonical Wnt signaling, ATF2 is also involved 
in the stress response, for example after chemotherapeutic agents such as cisplatin, 
doxorubicin or paclitaxel (Lo Iacono et al. 2015; Li et al. 2016). Since transfection of FZD 
receptors, may also activate ATF2 by inducing cell stress, we tried to strengthen the case 
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for FZD8 functioning as a Wnt-11 receptor using a more physiological approach. In this 
regard, we showed that silencing of FZD8 significantly reduced Wnt-11 activation of the 
noncanonical ATF2 reporter, supporting the role of FZD8 as the major Wnt-11 receptor 
in metastatic prostate cancer. Importantly, immunoprecipitation assays confirmed that a 
stable interaction takes places between the ligand and the receptor, consistent with their 
strong colocalization in PC-3M cells. In light of the fact that FZD receptors can bind to 
different coreceptors (C. Li et al. 2008; Yamamoto et al. 2010; Carmon et al. 2012; 
Capurro et al. 2014) in order to signal, further studies will be needed  to determine 
whether this binding is direct or requires a Wnt coreceptor. Of note, when analyzing ATF2 
reporter activity, we observed FZD2 silencing also significantly reduced Wnt-11 
activation of ATF2. Although this effect was not as dramatic as that mediated by FZD8 
silencing, FZD2 has been described to promote tumorigenesis in prostate cancer through 
Wnt-5a signaling (Sato et al. 2010; Yamamoto et al. 2010; Sandsmark et al. 2017), 
encouraging additional studies to explore the role of FZD2 in Wnt-11 signaling.  
Several reports have demonstrated the importance of FZD8 in different cancer types 
via binding to distinct Wnt ligands. In lung cancer, FZD8 has been described as a Wnt-2 
receptor, activating the canonical pathway, with FZD8 silencing reducing cell 
proliferation, suppressing A549 xenograft growth and sensitizing cells to chemotherapy 
(Wang et al. 2012; Bravo et al. 2013). FZD8 canonical signaling has also been described 
in triple negative breast cancer, where it is involved in resistance to chemotherapy (Yin 
et al. 2013). In head and neck squamous carcinomas, FZD8 is required for c-Met 
mediated canonical Wnt signaling and its overexpression rescues c-Met shRNA-induced 
impairment of sphere formation, tumor incidence and orthotropic tumor growth (Sun et 
al. 2014). While these studies implicate FZD8 in canonical Wnt signaling, other reports 
suggest that FZD8 can function as a canonical or a noncanonical Wnt receptor.  Studies 
in renal cell carcinoma (RCC) have shown a dual role of FZD8, since its silencing reduces 
both canonical and noncanonical markers, including -catenin and c-MYC but also Rho, 
Rac, JNK and ATF2 (Yang et al. 2017). FZD8 has been described as a noncanonical 
Wnt-5a receptor in airway smooth muscle cells, where it mediates JNK noncanonical 
signaling and is required for TGF- dependent ECM1 production (Kumawat et al. 2013), 
confirmed in later studies on the role of FZD8 in profibrotic signaling (A. I. R. Spanjer et 
al. 2016).  In this project, we demonstrated that FZD8 functions as a Wnt-11 receptor in 
metastatic prostate cancer cells through the regulation of noncanonical Wnt signaling 
involving ATF2/AP-1 family of transcription factors. Moreover, FZD8 did not affect 
canonical Wnt signaling, as measured by a lack of effect on the TOP/FOP reporter and 
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expression of the -catenin/Tcf target gene, AXIN2. A recent study by Li et al. also 
reported the upregulation of FZD8 in prostate cancer, consistent with our results. 
However, they propose that FZD8 activates Wnt/-catenin signaling by increasing 
WNT3A expression. In contrast, our results indicate that Wnt/-catenin signaling is not 
affected by FZD8 silencing. Moreover, our data shows that Wnt/-catenin signaling 
activity remains low in prostate cancer, which is consistent with reports from Sandsmark 
et al. 2017, showing that there was no alteration in the expression levels of -catenin nor 
-catenin translocation to the nucleus when comparing normal versus cancer samples. 
Their studies also described an upregulation of AXIN2 or GSK3 in cancer samples 
compared to normal, which suggests an increased activity of the destruction complex in 
prostate cancer, emphasizing the low -catenin activity in prostate cancer cells 
(Sandsmark et al. 2017). How these contrasting mechanisms can be consolidated will 
require additional studies.  
Chapter 2. Implication of FZD8 in prostate cancer pathogenesis 
The processes leading to the malignant transformation of cells are very complex but 
the ability of cells to invade surrounding tissues and metastasize are key events in tumor 
progression (Martin et al. 2000; Martin et al. 2013; W. G. Jiang et al. 2015). In this sense, 
understanding the mechanisms involved in tumor cell invasion may allow us to find ways 
to limit tumor progression and, as a result, lead to a reduction in cancer patient mortality 
(Martin et al. 2000; Martin et al. 2013). 
In prostate cancer, previous studies by our group reported the involvement of Wnt-11 
in PCa cell migration and invasion (Uysal-Onganer et al. 2010). In this thesis work, after 
identifying FZD8 as major Wnt-11 receptor, we show that FZD8 is also required for 
prostate cancer cell migration and invasion. Our analysis of the effects of both transient 
and stable FZD8 silencing in different metastatic cell lines revealed it significantly 
reduced prostate cancer cell migration and invasion. Moreover, we were able to 
corroborate these 2D experiments using 3D organotypic cultures, showing that FZD8-
silenced cells mature into well-differentiated organoids that do not form invasive 
structures, unlike control cells. In this regard, both 2D and 3D experiments support the 
role of FZD8 in tumor progression through the regulation of migration and/or invasion 
activity in prostate cancer. It is important to highlight that the use of organotypic 3D 
cultures in our studies allowed us to overcome the limitations of 2D cultures, which 
despite being widely used in cancer research as a first approach to study different 
processes during tumor progression, usually represent more reductionist models that do 
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not into account the tumor microenvironment (TME) for tumor development and 
progression (Pampaloni et al. 2007; Härmä et al. 2010). In this regard, the use of 3D 
cultures allows one to address complex aspects of normal and malignant tissues, such 
as the extracellular matrix (ECM), basement membrane (BM), cell-cell and cell-matrix 
adhesion, tumor-stroma interactions, the formation of relevant tumor-like histology and 
more importantly in our case, to study tumor-cell invasion considering cell dynamics and 
tumor architecture (Härma et al. 2014).   
Consistent with our findings, several studies have reported the implication of FZD 
receptors, including FZD8, in cell migration and invasion. In colorectal cancer, it has been 
described that FZD8 acts as a Wnt-2 receptor in cancer associated fibroblast (CAFs) 
being associated with a pro-migratory and pro-invasive phenotype, since both WNT2 
and FZD8 knockdown reduced the migratory potential as well as the length of invasive 
sprouts of CAFs (Kramer et al. 2017). FZD8 knockdown has also been shown to reduce 
the number of spheres formed by head and neck squamous carcinoma cells (HNSCC) 
(Sun et al. 2014), reflecting the important role of cancer stem cells in invasion and 
metastasis (Li et al. 2007; Sampieri & Fodde 2012). A recent study by Li et al. (2017) 
also reported the involvement of FZD8 in prostate cancer migration, invasion and stem 
like phenotypes, supporting a model in which FZD8 promote prostate cancer progression 
through regulation of invasive capacities.  
The inhibition of Wnt signaling has traditionally relied on porcupine inhibitors which 
block Wnt secretion (Chen et al. 2009; Proffitt et al. 2013); tankyrase inhibitors, which 
inhibit -catenin-dependent Wnt signaling by stabilizing Axin2 (Chen et al. 2009) or drugs 
that target -catenin interactions with transcription factors (Anastas & Moon 2013). 
However, the elucidation of the structure of the XWnt-8-FZD8 CRD complex (Janda et 
al. 2012) has accelerated the development of drugs targeting the Wnt pathway at the 
receptor level (Gurney et al. 2012; Wei et al. 2011; Hojjat-Farsangi et al. 2013). Some 
years ago, a structure based study led to the identification of compounds that target the 
CRD domain of FZD receptors, preventing their binding to Wnt ligands (Lee et al. 2015). 
Our observation of the increased expression of FZD8 in metastatic prostate cancer cell 
lines and in a significant proportion of prostate tumors, together with the demonstrated 
inhibitory effect of FZD8 silencing on prostate cancer cell migration and invasion, 
suggests that inhibition of Wnt-FZD8 interactions may be a useful approach for the 
treatment of patients with metastatic prostate cancer. Here, we found that two of the 
small molecule inhibitors that target the Wnt binding site on FZD (Lee et al. 2015) were 
able to reduce prostate cancer cell migration, lending support to our suggestion of FZD8 
Discussion 
168 
 
as a good therapeutic target. Nevertheless, it is important to bear in mind that these 
compounds are not specific for FZD8 and that the observed effects might be also due to 
inhibition of binding between different Wnt ligands and FZD receptors (Lee et al. 2015). 
A different approach that target Wnt-FZD binding is based on using peptides that block 
the interaction between ligand and receptor. In this regard, Foxy-5, a formylated 
hexapeptide which mimics Wnt-5a, has been reported to inhibits breast cancer 
metastasis (Säfholm et al. 2006; Säfholm et al. 2008) and is also in clinical trials for 
metastatic breast, colon and prostate cancer (Murillo-Garzón & Kypta 2017). Taking this 
into account, specific peptides blocking Wnt-11/FZD8 binding would benefit this study as 
tools to mimic the effects of FZD8 silencing using a chemical approach.  
The acquisition of invasive and metastatic phenotypes during tumor progression is 
often provoked by aberrant activation of the embryonic program EMT (Thiery 2002; Nieto 
et al. 2016). In the last few years, many studies have demonstrated the presence of 
EMT-like states in PCa, suggesting its involvement in prostate cancer development and 
metastasis (Grant & Kyprianou 2013; Montanari et al. 2017). E-cadherin loss correlates 
with prostate tumor progression and Gleason grade (Gravdal et al. 2007) and elevated 
N-Cadherin has been shown to be a significant predictor of clinical recurrence in prostate 
cancer patients following radical prostatectomy, as well as an effective therapeutic target 
in CRPC (Tanaka et al. 2010). Among the EMT inducers, Wnt signaling has been 
described as one of the crucial activators of this phenotypic change (Lamouille et al. 
2014) and importantly, FZD receptors have been extensively related with the EMT 
program. In ERG positive prostate tumors, FZD4 has been shown to mediate loss of cell 
adhesion and EMT (Gupta et al. 2010). In addition, FZD2 was found to regulate EMT 
and metastasis in different cancer types, including breast, colon, hepatocellular 
carcinoma and lung cancer, where the expression of 75 EMT-associated genes were 
analyzed after FZD2 overexpression and depletion (Gujral et al. 2014). Moreover, a 
recent study has shown that activation of noncanonical Wnt signaling through Wnt-
5a/FZD2 is associated with increased expression of EMT markers and higher Gleason 
score (Sandsmark et al. 2017). Furthermore, FZD7 has been shown to promote EMT in 
cervical cancer where FZD7 knockdown inhibits invasion, metastasis, and EMT (Deng 
et al. 2015), and in oesophageal squamous cell carcinoma, where its high expression 
correlates with poor overall survival (Cao et al. 2017). In addition, FZD8 is involved in 
proliferation, migration and invasion of renal cell carcinoma, where it was able to induce 
the EMT program (Yang et al. 2017). Consistent with these studies, our work indicates 
that FZD8 regulates EMT in prostate cancer since its silencing reduces the expression 
of mesenchymal markers and increases the expression of epithelial markers, both at the 
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mRNA and protein levels.  Moreover, the involvement of Wnt-11/FZD8 signaling in EMT 
is also supported by our bioinformatics analysis, which shows a positive correlation 
between FZD8 and WNT11 with mesenchymal markers and a negative correlation with 
epithelial ones. Notably, the fact that a proportion of 3D spheroids from FZD8 silenced 
cells showed no vimentin staining also supports its role in EMT, although further staining 
experiments are needed to confirm that the organoids lacking vimentin are also negative 
for FZD8. Of particular interest, while FZD8 seems to regulate EMT favoring the 
mesenchymal phenotype in both PC-3M and DU145 cells, it is important to note that the 
EMT markers affected by FZD8 silencing were not exactly the same; for example, in PC-
3M cells, FZD8 silencing downregulated SNAI1 but not SNAI2 expression, while both 
were downregulated in DU145 cells. These distinctions might be attributed to the 
different extents of FZD8 silencing in the cell line, but it is also plausible that it reflects 
intrinsic differences between these cell lines. Although both are metastatic cell lines (the 
former to bone and the latter to brain) which do not express AR nor PSA and are 
androgen independent (Cunningham & You 2015), their different tumor origins make 
them display strong disparities. The more mesenchymal nature of PC-3M cells becomes 
evident when looking at the expression of EMT genes, such as CDH2, which is not 
expressed by DU145 cells but is highly expressed by PC-3M cells, and when treating 
the cells with TGF- which induces changes in EMT genes in DU145 cells but not in PC-
3M cells. In this way, it is possible that due to these distinctions, both cell lines may 
mediate the EMT process through regulation of different EMT-associated genes. The 
differences could also be explained by recent studies proposing that the EMT process is 
based on more dynamic changes characterized by cell fluidity and plasticity, in which 
different intermediate stages exist with induction of different EMT factors (Nieto et al. 
2016). In this regard, it is still possible to consider that FZD8 does not drive a full EMT 
and that our observations of the different EMT markers affected in both cell lines is due 
to partial EMT phenotypes in each line. 
Given all our observations suggesting that changes driven by FZD8 in the EMT 
program could be responsible for the observed effects in cell migration and invasion, we 
propose that FZD8 could therefore be involved in prostate cancer metastasis. Multiple 
studies during the last decade have shown that aberrant activation of one or more EMT-
TFs may make a cell more prone to undergo EMT, and this is a necessary and sufficient 
condition to drive the invasion–metastasis cascade (Thiery 2002; Nieto et al. 2016). 
However, the idea of EMT promoting metastasis and invasion was recently challenged 
by two studies in mouse models of pancreatic (Zheng et al. 2015) and breast cancer 
(Fischer et al. 2015) in which TWIST or SNAI1 knock-out or miR-200 overexpression 
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with the consequent suppression of ZEB1, respectively, did not affect the incidence of 
tumor metastasis. Although multiple interpretations were proposed, these new studies 
highlight the possibility of alternative mechanisms of cancer dissemination and 
metastasis that do not rely on aberrant overexpression of one or more EMT-TFs to alter 
cellular adhesion and invasion and drive metastasis (Nieto et al. 2016; Jolly et al. 2017). 
In this regard, our in vivo experiments using the CAM model highlight the importance of 
FZD8 in tumor growth and although we haven´t performed in vivo metastasis assays, 
recent studies by Lee et al. 2017 showed that downregulation of FZD8 greatly 
suppressed the incidence of PCa bone metastasis in vivo, which is consistent with our 
data and support our idea of FZD8 promoting EMT, subsequently regulating cell 
migration and invasion and therefore, driving prostate cancer metastasis.  
There has been a lot of progress in recent years improving cancer diagnostics, 
prognostics and treatment, thanks to the combination of already established clinico-
pathological features with the state-of-the-art –omics technologies, which together is 
defined as precision medicine (Shin et al. 2017). In the case of prostate cancer, precision 
medicine is distant from its application, since general parameters such as PSA, Gleason 
score or TNM grade are still mainly used to stratify patients. However, the extensive 
mutational landscape of metastatic CRPC lesions has pointed out the possibility of 
targeted therapies and precision medicine in CRPC (Mullane & Van Allen 2016). In this 
respect, the identification of the main players involved in cancer progression could 
contribute to a better stratification of the disease and consequently, to an improvement 
in the management of prostate cancer patients, through their use as biomarkers and 
therapeutic targets. In this project, we described that FZD8 is involved in prostate cancer 
cell migration, invasion and EMT as well as it is required in tumor growth. Therefore, we 
hypothesize that FZD8 may constitute a useful marker in prostate cancer progression. 
In fact, we demonstrate here that both FZD8 and Wnt-11 protein expression were 
upregulated in tissues from prostate cancer patients compared to benign tissues, which 
supports our hypothesis of FZD8 as a biomarker in prostate cancer. Unfortunately, we 
could not find a correlation of FZD8 with Gleason score. This could be explained by the 
low number of high Gleason samples in the TMA. Our bioinformatics analysis using the 
MSKCC dataset shows that FZD8 expression is increased in metastatic patients and 
correlates with high Gleason score samples as well as with abnormal lymph node 
metastasis, and that WNT11 expression positively correlates with patient survival and 
FZD8 expression also shows a trend for this. Analysis of a larger cohort of patients is 
required to provide strong evidence for a role of FZD8 as a prognostic factor in prostate 
cancer. 
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Chapter 3. Elucidation of the mechanism underlying the effects 
of FZD8 in prostate cancer pathogenesis 
In cancer, distinct pathways have predominant roles in the initiation and progression 
of EMT through the regulation of changes in morphology and gene expression that 
convert epithelial cells into motile mesenchymal cells which thereby stimulate tumor 
progression (Lamouille et al. 2014). The signals that cooperate to regulate EMT include 
TGF-β signaling, integrin cascades, several growth factors that act through receptor 
tyrosine kinases (RTKs), such as EGF, FGF, HGF and VEGF and also PI3K-AKT and 
MAPK signaling cascades, together with Wnt, Notch, Hedgehog, interleukin-6 (IL6) and 
HIF signaling (Wendt et al. 2009; Lamouille et al. 2014). Importantly, TGF-β signaling 
pathway is the best characterized inducer of the EMT process (Lamouille et al. 2014)  
In normal prostate and early stages of prostate cancer, TGF- serves as a tumor 
suppressor by inducing cell cycle arrest and apoptosis. However, in advanced prostate 
cancer, TGF- acts as a tumor promoter driving tumor invasion and metastasis (Jones 
et al. 2009). Indeed, elevated TGF-β levels in patient serum provide a significant 
prognostic value for highly aggressive metastatic disease and poor patient prognosis 
(Shariat et al. 2001). Moreover, dysfunctional TGF-β receptor signaling accelerates 
prostate cancer progression in a mouse model via EMT and cytoskeleton changes in the 
tumor microenvironment (Pu et al. 2009). It has also been reported that elevated TGF-β 
ligand levels correlate with increasing tumor grade in prostate cancer (Grant & Kyprianou 
2013) and that TGF-β1 is able to induce EMT in prostate tumor epithelial cells and in 
mouse models, upregulating matrix metalloproteinase-9 (MMP-9) and promoting tumor 
invasion (Cao & Kyprianou 2015). Since TGF-β is able to stimulate growth by its 
pleiotropic activities on both the cancer cell but also on the non-malignant stromal cell 
types of the tumor, it has also been shown that, particularly in prostate cancer, 
carcinoma-associated fibroblasts (CAF) derived from prostate tumors can stimulate 
tumor progression of non-transformed prostate epithelial cells (Jones et al. 2009).  
According to the well reported role of TGF- in regulating EMT and its crosstalk with 
Wnt signaling pathway (Guo & Wang 2009; Attisano & Wrana 2013), in this thesis work, 
we demonstrate that Wnt-11/FZD8 axis also regulates TGF-β signaling. Our analysis 
show that FZD8 is required for TGF-β-dependent transcription and Smad 
phosphorylation as well as for the expression of TGF-β target genes. In addition, we 
found that FZD8 also regulates TGF-β-dependent EMT gene expression as well as TGF-
β-dependent cell invasion. The fact that FZD8 silencing does not completely block the 
pathway may suggest that although FZD8 is involved in its regulation, it is not the only 
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factor and that TGF-β signaling in prostate cancer cells is also regulated by other signals. 
Importantly, our results are consistent with the reported crosstalk between Wnt and TGF-
β signaling (Guo & Wang 2009; Attisano & Wrana 2013; Carstens et al. 2014), as well 
as with studies from Spanjer et al., who demonstrated a role for FZD8 in TGF--induced 
profibrotic signaling through Wnt-5a, regulating collagen-a1, fibronectin, versican, a-
smooth muscle actin, and connective tissue growth factor (A. I. R. Spanjer et al. 2016). 
Our data also show that a dominant negative form of ATF2 is required for TGF-β 
dependent transcription, as well as for the regulation of a subset of TGF-β-dependent 
EMT genes. Although different reports have shown that Wnt-TGF-β crosstalk can be 
mediated by the interaction between Smad and ATF2 or other members of the AP-1 
family of transcription factors (Derynck et al. 1998; Sano et al. 1999; Hanafusa et al. 
1999; Massagué 2000), we were unable to detect a stable complex between Smad3 and 
ATF2 by co-immunoprecipitation. This might be explained by the specific conditions used 
in the immunoprecipitation. However, it would be also plausible that the crosstalk 
between both pathways involves other Smads, rather than Smad3 or other AP-1 
transcription factors, such as JUN, FOS, or MAF, highlighting the requirement of further 
studies to clarify this possible interaction. 
However, since both Wnt and TGF- are secreted factors that acts through binding to 
specific cell surface receptors, it is still possible that FZD8 regulation of TGF- signaling 
may take place at the cell membrane. In this thesis work, we found that FZD receptors 
can interact with TGFRs in the cell membrane and that this interaction is mediated 
through the FZD8-CRD and the extracellular domain of TGFRI. Moreover, we also 
found that this interaction was affected by exogenous TGF-since its addition reduced 
the binding of TGFRII to FZD8 and not TGFRI binding, supporting our observations of 
TGFRI mediating the interaction. Although other proteins have been found to interact 
with FZD receptors, including the recent described interaction with Clostridium 
difficile toxin B (Chen et al. 2018),  to our knowledge, this is the first work showing that 
FZD receptors can interact with TGFRs. The molecular events that take place 
subsequent to TGF- binding are complex: in the absence of ligand, TGFRI and 
TGFRII may occur as monomers, homodimers and heterodimers. TGFRII 
homodimers and heterodimers are stabilized by contacts between the receptor 
cytoplasmic domains, whereas TGFRI homodimers do not require the TGFRI 
cytoplasmic domain. TGF- binding to TGFRII homodimers, leads to the recruitment of 
TGFRI homodimers and the formation of a heterohexamer complex of TGF-, TGFRI 
and TGFRII dimers. TGFRII then phosphorylates and activates TGFRI, which 
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propagates the signal (Shi & Massagué 2003; Massagué 2012). Our results suggest that 
being part of this complex, FZD8 plays a role in signal transduction subsequent to 
TGFRII phosphorylation and activation of TGFRI, which enables the regulation of 
TGF- signaling. However, since our experiments used transfected receptors, the exact 
events that take place in the FZD8-TGFR complex will require detailed study of the 
endogenous receptors. Our results also show that Wnt-11 can still bind FZD8 while the 
latter is bound to TGFRI, suggesting that although both Wnt and TGFRI bind to FZD8 
through its CRD, different residues may be involved in the interaction. The novel model 
of Wnt-FZD signalosome, which shows that FZD receptors can dimerize through their 
CRD (DeBruine et al. 2017), increases the complexity of the interaction between FZD8 
and TGFRI. In this regard, elucidating the regions involved in FZD8 binding to TGFRI, 
as well as the resolution of the crystal structure of the complex would contribute to a 
better understanding of Wnt-FZD-TGFRI crosstalk in prostate cancer and therefore, to 
design better approaches to target this pathway in disease. Importantly, extrapolation of 
these findings to different systems would allow us to determine whether this interaction 
is specific of prostate cancer or on the contrary, is a common event that would benefit 
the treatment of other types of cancer and other diseases, such as fibrosis. 
In summary, we propose a model in which FZD8 can interact with Wnt-11 and 
TGFRI, integrating both Wnt and TGF- signaling pathways and thereby promoting 
EMT, cell migration and invasion, leading to prostate cancer metastasis. Hence, we 
believe that the role of FZD8 here described supports the potential of using this receptor 
as a therapeutic target in metastatic prostate cancer to block aberrant activation of both 
Wnt and TGF- signaling pathways.  
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In summary, the results obtained throughout this thesis confirm our hypothesis and 
demonstrate that the identification and characterization of the receptors that mediate 
Wnt-11 migration and invasion in prostate cancer cells could represent a potential 
therapeutic target to improve the treatment of prostate cancer patients.  
The results obtained lead to the following conclusions: 
1) FZD8 is highly expressed in more aggressive prostate cancer cell lines as well 
as in prostate cancer compared to benign tissues. 
2) FZD8 binds to Wnt-11 and acts as the main Wnt-11 receptor in metastatic 
prostate cancer, signaling through a noncanonical pathway. 
3) FZD8 is required for the main hallmarks of prostate cancer progression such as 
cell migration, invasion, invasion in organotypic 3D cultures, regulation of EMT 
and tumor growth in vivo. 
4) FZD8 and Wnt-11 expression correlate with prostate cancer progression. 
5) FZD8 integrates Wnt and TGF- signaling pathways through its association with 
TGFRI, which enables the subsequent regulation of TGF- signaling. 
6) FZD8 may constitute a therapeutic target in prostate cancer per se or in 
combination with TGF- inhibitors. 
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 Al Shareef Z, Kardooni H, Murillo-Garzón V, Domenici G, Stylianakis E, Steel 
JH, Rabano M, Gorroño-Etxebarria I, Zabalza I, Vivanco MDM, Waxman J, Kypta RM. 
Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and 
ECM-1. Oncogene. 2018 Jun 1. doi: 10.1038/s41388-018-0294-0. [Epub ahead of print] 
PubMed PMID: 29858602. 
Abstract 
Aberrant transforming growth factor-β (TGF-β) signaling is a hallmark of the stromal 
microenvironment in cancer. Dickkopf-3 (Dkk-3), shown to inhibit TGF-β signaling, is 
downregulated in prostate cancer and upregulated in the stroma in benign prostatic 
hyperplasia, but the function of stromal Dkk-3 is unclear. Here we show that DKK3 
silencing in WPMY-1 prostate stromal cells increases TGF-β signaling activity and that 
stromal cell-conditioned media inhibit prostate cancer cell invasion in a Dkk-3-dependent 
manner. DKK3 silencing increased the level of the cell-adhesion regulator TGF-β-
induced protein (TGFBI) in stromal and epithelial cell-conditioned media, and 
recombinant TGFBI increased prostate cancer cell invasion. Reduced expression of 
Dkk-3 in patient tumors was associated with increased expression of TGFBI. DKK3 
silencing reduced the level of extracellular matrix protein-1 (ECM-1) in prostate stromal 
cell-conditioned media but increased it in epithelial cell-conditioned media, and 
recombinant ECM-1 inhibited TGFBI-induced prostate cancer cell invasion. Increased 
ECM1 and DKK3 mRNA expression in prostate tumors was associated with increased 
relapse-free survival. These observations are consistent with a model in which the loss 
of Dkk-3 in prostate cancer leads to increased secretion of TGFBI and ECM-1, which 
have tumor-promoting and tumor-protective roles, respectively. Determining how the 
balance between the opposing roles of extracellular factors influences prostate 
carcinogenesis will be key to developing therapies that target the tumor 
microenvironment. 
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 Murillo-Garzón V, Gorroño-Etxebarria I, Åkerfelt M, Puustinen MC, Sistonen L, 
Nees M, Carton J, Waxman J, Kypta RM. Frizzled-8 integrates Wnt-11 and transforming 
growth factor-β signaling in prostate cancer. Nat Commun. 2018 May 1;9(1):1747. doi: 
10.1038/s41467-018-04042-w. PubMed PMID: 29717114; PubMed Central PMCID: 
PMC5931552. 
Abstract 
Wnt-11 promotes cancer cell migration and invasion independently of β-catenin but the 
receptors involved remain unknown. Here, we provide evidence that FZD8 is a major 
Wnt-11 receptor in prostate cancer that integrates Wnt-11 and TGF-β signals to promote 
EMT. FZD8 mRNA is upregulated in multiple prostate cancer datasets and in metastatic 
cancer cell lines in vitro and in vivo. Analysis of patient samples reveals increased levels 
of FZD8 in cancer, correlating with Wnt-11. FZD8 co-localizes and co-immunoprecipitates 
with Wnt-11 and potentiates Wnt-11 activation of ATF2-dependent transcription. FZD8 
silencing reduces prostate cancer cell migration, invasion, three-dimensional 
(3D) organotypic cell growth, expression of EMT-related genes, and TGF-β/Smad-
dependent signaling. Mechanistically, FZD8 forms a TGF-β-regulated complex with TGF-
β receptors that is mediated by the extracellular domains of FZD8 and TGFBR1. 
Targeting FZD8 may therefore inhibit aberrant activation of both Wnt and TGF-β signals 
in prostate cancer. 
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 Murillo-Garzón V, Kypta R. WNT signalling in prostate cancer. Nat Rev 
Urol.2017 Nov;14(11):683-696. doi: 10.1038/nrurol.2017.144. Epub 2017 Sep 12. 
Review. PubMed PMID: 28895566. 
Abstract 
Genome sequencing and gene expression analyses of prostate tumours have 
highlighted the potential importance of genetic and epigenetic changes observed in WNT 
signalling pathway components in prostate tumours - particularly in the development of 
castration-resistant prostate cancer. WNT signalling is also important in the prostate 
tumour microenvironment, in which WNT proteins secreted by the tumour stroma 
promote resistance to therapy, and in prostate cancer stem or progenitor cells, in which 
WNT-β-catenin signals promote self-renewal or expansion. Preclinical studies have 
demonstrated the potential of inhibitors that target WNT receptor complexes at the cell 
membrane or that block the interaction of β-catenin with lymphoid enhancer-binding 
factor 1 and the androgen receptor, in preventing prostate cancer progression. Some 
WNT signalling inhibitors are in phase I trials, but they have yet to be tested in patients 
with prostate cancer. 
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 Cautain B, de Pedro N, Murillo-Garzón V, Muñoz de Escalona M, González 
Menéndez V, Tormo JR, Martin J, El Aouad N, Reyes F, Asensio F, Genilloud O, Vicente 
F, Link W. High-content screening of natural products reveals novel nuclear export 
inhibitors. J Biomol Screen. 2014 Jan;19(1):57-65. doi: 10.1177/1087057113501389. 
Epub 2013 Sep 17. PubMed PMID: 24045581. 
Abstract 
Natural products are considered an extremely valuable source for the discovery of new 
drugs against diverse pathologies. As yet, we have only explored a fraction of the 
diversity of bioactive compounds, and opportunities for discovering new natural products 
leading to new drugs are huge. In the present study, U2nesRELOC, a previously 
established cell-based imaging assay, was employed to screen a collection of extracts 
of microbial origin for nuclear export inhibition activity. The fluorescent signal of untreated 
U2nesRELOC cells localizes predominantly to the cytoplasm. Upon treatment with the 
nuclear export inhibitor leptomycin B, the fluorescent-tagged reporter proteins appear as 
speckles in the nucleus. A proprietary collection of extracts from fungi, actinomycetes, 
and unicellular bacteria that covers an uncommonly broad chemical space was used to 
interrogate this nuclear export assay system. A two-step image-based analysis allowed 
us to identify 12 extracts with biological activities that are not associated with previously 
known active metabolites. The fractionation and structural elucidation of active 
compounds revealed several chemical structures with nuclear export inhibition activity. 
Here we show that substrates of the nuclear export receptor CRM1, such as Rev, 
FOXO3a and NF-κB, accumulate in the nucleus in the presence of the fungal metabolite 
MDN-0105 with an IC50 value of 3.4 µM. Many important processes in tumor formation 
and progression, as well as in many viral infections, critically depend on the 
nucleocytoplasmic trafficking of proteins and RNA molecules. Therefore, the disruption 
of nuclear export is emerging as a novel therapeutic approach with enormous clinical 
potential. Our work highlights the potential of applying high-throughput phenotypic 
imaging on natural product extracts to identify novel nuclear export inhibitors. 
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INTRODUCCIÓN 
 
En la actualidad, el cáncer de próstata representa en varones el tipo de cáncer más 
frecuentemente diagnosticado y la tercera causa más común de muerte en los países 
industrializados. Los principales factores de riesgo asociados a este tipo de cáncer 
son la edad y la raza, aunque otros factores como la herencia genética, la dieta o el 
consumo de alcohol se han visto asociados como un mayor riesgo. 
El cáncer de próstata tiene su origen en las neoplasias prostáticas intraepiteliales 
que normalmente progresan a neoplasias de alto grado dando lugar frecuentemente 
a carcinomas de próstata. Durante este proceso de transformación las células 
adquieren alteraciones a nivel molecular que determinan la progresión del cáncer 
hasta estadíos invasivos y metastáticos. 
Marcadores como el antígeno específico de próstata (PSA) se han empleado en el 
diagnóstico del cáncer de próstata lo que ha contribuido a una mejora en el diagnóstico 
de este tipo de tumores. Inicialmente, el tratamiento del cáncer de próstata se basa 
en el seguimiento y la vigilancia debido a la lenta progresión de dichos tumores. 
Posteriormente, cuando el tumor está localizado la principal terapia es la 
prostatectomía radical y/o la radioterapia. Cuando los tumores comienzan a 
metastatizar, la terapia de deprivación de andrógenos (ADT) es la opción más 
empleada debido al requerimiento de andrógenos de las células del cáncer de 
próstata para proliferar. Sin embargo, muchos pacientes desarrollan resistencia a esta 
terapia y aunque nuevos tratamientos están siendo desarrollados, no se han 
observado mejoras en la supervivencia, lo que estimula la investigación en los 
mecanismos que dan lugar a esta resistencia con el fin de identificar nuevas dianas 
que mejoren el tratamiento de esta enfermedad. 
La familia de proteínas de Wnt juega un papel fundamental en procesos como el 
desarrollo, la proliferación, la polaridad, la migración y la supervivencia de las células 
y por todo ello, alteraciones en los niveles de dichas proteínas se han visto implicados 
en enfermedades como el cáncer. Entre los miembros de esta familia, Wnt-11 
(miembro no canónico por señalizar independientemente de -catenina) se encuentra 
altamente expresado en líneas celulares de cáncer de próstata, así como en tumores 
de próstata.  Además, Wnt-11 promueve la migración y la invasión celular lo que 
sugiere su implicación en la progresión y la metástasis del cáncer de próstata.  
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En base a la implicación de Wnt-11 en el cáncer de próstata y a la necesidad que 
estas proteínas tienen de unirse a receptores de membrana para activar la 
señalización y mediar sus efectos, en esta tesis se plantea que la identificación y 
caracterización de los receptores de Wnt-11 puede representar una nueva diana 
terapéutica para inhibir los efectos de este ligando en la progresión del cáncer de 
próstata. Así, los objetivos principales de este trabajo consisten en identificar los 
receptores de Wnt-11 y caracterizar los efectos funcionales que ejercen en el cáncer 
de próstata, así como analizar los mecanismos moleculares que subyacen a esta ruta 
de señalización y evaluar el potencial de dichos receptores como biomarcadores y 
dianas terapéuticas en la progresión del cáncer de próstata. 
MATERIALES Y MÉTODOS 
En esta tesis se han llevado a cabo cultivos celulares tanto en 2D como en 3D y se 
han empleado diversas técnicas de biología molecular tales como extracción de RNA, 
PCR, western blotting e inmunoprecipitaciones. También se han llevado a cabo 
análisis de actividad reportera, microscopía de inmunoflurescencia, 
inmunohistoquímicas con muestras de pacientes y ensayos en modelos in vivo como 
la membrana corioalantoidea (CAM) del pollo. 
RESULTADOS 
Capítulo 1. Identificación y caracterización de los receptores de Wnt-11 en cáncer 
de próstata metastático 
Previos estudios demostraron una elevada expresión de Wnt-11 en líneas celulares 
de cáncer de próstata, así como en tumores de próstata, sobre todo, en metástasis. 
En base a esta implicación de Wnt-11 en el cáncer de próstata y al requerimiento de 
la unión entre las proteínas Wnt y sus receptores para señalizar y realizar su función, 
el objetivo inicial de esta tesis es la identificación de los receptores de Wnt que 
muestran una expresión elevada en cáncer de próstata y que, por ello, pueden jugar 
un papel fundamental en la progresión y la metástasis de este tipo de cáncer. 
Para ello, inicialmente, se llevó a cabo un análisis de la expresión de un amplio 
panel de receptores de Wnt incluyendo la familia de receptores Frizzled (FZD1-10), 
los receptores tirosina quinasa ROR1, ROR2, RYK, PTK7 and MuSK y otros 
coreceptores como LRP4-6, LGR4 and 5 and GPC4.  En primer lugar, se analizó la 
expresión de estos receptores en diferentes líneas celulares representando diferentes 
estadíos del cáncer de próstata mediante qRT-PCR. En este análisis, se observó que 
algunos receptores incluyendo FZD2, FZD4 y FZD8 se encuentran altamente 
expresados en las líneas celulares más agresivas. Además, el patrón de expresión de 
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estos receptores correlaciona con el patrón de Wnt-11, lo que sugiere que estos 
receptores pueden tener una implicación en la progresión del cáncer de próstata 
mediando la señalización de Wnt-11. La expresión de estos receptores también se 
evaluó mediante un análisis in silico usando bases de datos de pacientes con cáncer 
de próstata. De este modo, se observó que FZD4 y FZD8 y el correceptor PTK7 se 
encuentran altamente expresados en muestras de pacientes tumorales comparadas 
con tejido sano en diferentes bases de datos. Finalmente, el análisis conjunto de 
ambas estrategias de screening permitió la identificación de candidatos potenciales 
que se encuentran altamente expresados en cáncer de próstata y que, por tanto, 
pueden estar implicados en la patogénesis de esta enfermedad. 
Con el fin de evaluar cuál de los potenciales candidatos podía actuar como receptor 
de Wnt-11 en las células metastáticas de cáncer de próstata, se llevaron a cabo 
ensayos de colocalización por inmunofluorescencia entre los diez miembros de la 
familia de receptores FZD y Wnt-11. Este análisis permitió concluir que FZD8 es el 
receptor que mejor colocaliza con Wnt-11 aunque FZD6 y FZD10 también lo hacen 
parcialmente. 
Por último, para determinar qué receptor podía mediar la señalización de Wnt-11 
se emplearon ensayos de silenciamiento génico y actividad reportera. Estos 
experimentos permitieron concluir que FZD8 actúa como el receptor principal de Wnt-
11 en las células metástaticas del cáncer de próstata, ya que su silenciamiento génico 
reduce la activación que Wnt-11 ejerce sobre el reportero de ATF2 y de AP1 (ambos 
reporteros de la ruta no canónica de Wnt). Además, ensayos de inmunoprecipitación 
mostraron que FZD8 se une de forma estable a Wnt-11, lo que sostiene su papel como 
receptor principal de Wnt-11 en cáncer de próstata. 
Capítulo 2: Implicación de FZD8 en la patogénesis del cáncer de próstata 
Numerosos eventos se han visto implicados en la progresión tumoral incluyendo 
las capacidades de migración e invasión que las células adquieren durante el proceso 
metastático. Debido al papel de Wnt-11 en la migración e invasión celular, el siguiente 
objetivo de esta tesis se basa en estudiar el papel de su receptor, FZD8, en estas 
habilidades de las células metastáticas. 
En primer lugar, se llevaron a cabo ensayos de migración e invasión celular en 
cultivos en 2D usando canales Boyden. Estos experimentos permitieron concluir que 
el silenciamiento de FZD8 reduce la migración e invasión de las células de cáncer de 
próstata metastático. Estos efectos se corroboraron también con líneas celulares 
establemente silenciadas para FZD8 y con inhibidores químicos de la unión entre Wnt 
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y los receptores FZD. Además, los efectos de FZD8 sobre la invasión celular se 
estudiaron también mediante ensayos en 3D empleando cultivos organotípicos que 
simulan de una forma más fisiológica el comportamiento de las células en el 
organismo. Con estos estudios se comprobó que el silenciamiento de FZD8 reduce la 
invasión celular en 3D, reduciendo parámetros como el número y la longitud de los 
apéndices y aumentando la esfericidad de los organoides. 
Ya que uno de los eventos implicados en la adquisición de las capacidades de 
invasión y migración celular en los tumores es el proceso de transición epitelio-
mesénquima (EMT), se evaluó si FZD8 estaba implicado en este proceso. El análisis 
por PCR de diversos genes implicados en este proceso, así como a nivel proteico por 
western blot permitió determinar que el silenciamiento de FZD8 reduce la expresión 
de los factores mesenquimales y aumenta la expresión de los epiteliales apoyando el 
papel de FZD8 en el proceso de EMT. 
En segundo lugar, se trató de evaluar el papel de FZD8 en ensayos in vivo 
utilizando el modelo de la membrana corioalantoidea (CAM) del pollo que permite 
implantar células tumorales y evaluar el crecimiento tumoral. Así, tras implantar 
células de cáncer de próstata metastático silenciadas para FZD8 se pudo observar 
que éstas producían tumores de un menor tamaño que las controles, implicando a 
FZD8 en el crecimiento tumoral. 
Por último, se emplearon muestras de pacientes sanos y con cáncer de próstata 
contenidas en un array de tejido (TMA) para analizar la expresión de FZD8 y Wnt-11. 
El análisis por inmunohistoquímica de la expresión de ambos permitió observar que 
tanto FZD8 como Wnt-11 se encontraban altamente expresados en cáncer de próstata 
con respecto a los tejidos sanos. Aunque no se observó una correlación con el grado 
de Gleason de los pacientes, el análisis de la expresión en bases de datos mediante 
bioinformática sugiere que los pacientes con alta expresión de FZD8 y Wnt-11 tienen 
una menor tasa de supervivencia. 
Así, todos estos resultados sostienen la implicación de FZD8 en el proceso 
metastático del cáncer de próstata y su posible uso como biomarcadores y como 
dianas terapéuticas en esta enfermedad. 
Capítulo 3. Estudio del mecanismo que subyace a los efectos de FZD8 en la 
patogénesis del cáncer de próstata 
Los resultados obtenidos hasta este punto revelan la contribución de FZD8 en la 
patogénesis del cáncer de próstata promoviendo la migración e invasión celular y el 
proceso de EMT. Sin embargo, los mecanismos moleculares que median este proceso 
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se desconocen. La ruta de señalización de Wnt interacciona con otras muchas rutas 
durante la progresión del cáncer. Entre ellas, la ruta de señalización de TGF-, 
además de interaccionar con Wnt, se ha visto implicada en los eventos mediadores 
del proceso metastático como la migración e invasión celular y el proceso de EMT. 
Así, el último objetivo de esta tesis consistió en determinar si FZD8 media sus efectos 
regulando la señalización de TGF-
En primer lugar, se llevó a cabo un análisis de la actividad transcripcional de TGF-
 que permitió concluir que el silenciamiento de FZD8 reduce la ruta de TGF-
Además, el silenciamiento de FZD8 reduce la expresión de los genes diana de TGF-
 y los niveles de fosforilación de SMAD2 analizados mediante PCR y western blot, 
respectivamente lo que sostiene la implicación de FZD8 en la señalización de TGF-. 
Debido a la implicación de FZD8 en los procesos de migración e invasión celular y 
de EMT, se pretendió evaluar si FZD8 mediaba estos efectos a través de TGF-Así, 
el silenciamiento de TGF- redujo tanto la invasión como el proceso de EMT 
dependiente de TGF-.  
FZD8 está implicado en la ruta no canónica de Wnt activando ATF2 y, además, en 
la señalización de TGF-. En base a estos resultados, se analizó la posibilidad de que 
el requerimiento de FZD8 sobre TGF- estuviese mediado por ATF2. De este modo, 
el análisis de actividad reportera mostró que un dominante negativo de ATF2 es capaz 
de reducir el reportero de TGF- así como el proceso de EMT dependiente de TGF- 
indicando un posible requerimiento de ATF2 en esta ruta de señalización. 
Dado que diferentes estudios han mostrado que los factores de transcripción 
SMAD y ATF2 pueden interaccionar en el núcleo, en este trabajo se plateó que FZD8 
podría estar regulando esta interacción. Sin embargo, mediante análisis de 
inmunoprecipitación no se pudo detectar una unión estable entre los factores SMAD 
y ATF2 lo que llevó a descartar esta hipótesis. Posteriormente, se planteó que dado 
que ambas rutas, Wnt y TGF-, se activan por unión de los ligandos a receptores de 
membrana, podría ser posible que FZD8 estuviese interaccionando con los receptores 
de TGF- en la membrana celular. Inesperadamente, mediante ensayos de 
inmunoprecipitación e inmunofluorescencia, se observó que FZD8 interacciona con 
los receptores de TGF- (TGFRI y TGFRII). Además, se pudo comprobar que esta 
interacción está mediada por los dominios extracelulares de FZD8 y de TGFRI y que 
la unión entre FZD8 y los receptores de TGF- se ve afectada por la presencia de 
ligando (TGF-, el cuál disminuye la interacción entre FZD8 y TGFRII. Así mismo, 
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se pudo observar que en presencia de Wnt-11, FZD8 todavía puede unirse a los 
receptores de TGF- 
Todos estos resultados son consistentes con un modelo en el que FZD8 
integra ambas rutas de señalización, Wnt y TGF-β, y así promueve la migración 
e invasión celular además del proceso de EMT dando lugar a la metástasis del 
cáncer de próstata. Consecuentemente, FZD8 puede representar una óptima 
diana terapéutica en el cáncer de próstata metastático con el fin de bloquear 
los efectos de ambas rutas, Wnt y TGF-.  
CONCLUSIONES 
Los resultados de esta tesis permiten concluir que: 
- FZD8 se encuentra altamente expresado en las líneas celulares más agresivas 
de cáncer de próstata, además de en tejidos de cáncer de próstata y en 
metástasis con respecto a tejidos sanos. 
- FZD8 se une a Wnt-11 y actúa como receptor principal en cáncer de próstata 
metastático mediando una ruta no canónica de Wnt. 
- FZD8 está implicado en las principales características de la progresión tumoral 
tales como la migración, la invasión, la invasión en cultivos organotípicos en 
3D y el proceso de EMT. 
- FZD8 promueve el crecimiento tumoral in vivo. 
- La expresión de FZD8 y WNT11 correlaciona con la progresión del cáncer de 
próstata. 
- FZD8 integra las rutas de señalización de Wnt y TGF- a través de su 
asociación con TGFRI. 
- FZD8 puede constituir una diana terapéutica para el cáncer de próstata 
metastático per se o en combinación con inhibidores de la ruta de TGF-. 
   
 
